NZ613672B2 - Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals - Google Patents
Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals Download PDFInfo
- Publication number
- NZ613672B2 NZ613672B2 NZ613672A NZ61367212A NZ613672B2 NZ 613672 B2 NZ613672 B2 NZ 613672B2 NZ 613672 A NZ613672 A NZ 613672A NZ 61367212 A NZ61367212 A NZ 61367212A NZ 613672 B2 NZ613672 B2 NZ 613672B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- phenyl
- amino
- propionic acid
- pyridinecarbonyl
- tolyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 292
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 206010007554 Cardiac failure Diseases 0.000 claims abstract description 11
- 206010019280 Heart failure Diseases 0.000 claims abstract description 11
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 6
- 201000001320 atherosclerosis Diseases 0.000 claims abstract description 6
- -1 (S)[(5-Methoxyphenyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid (S)(2,4-Dichloro-phenyl)[(5-methoxyphenyl-pyridinecarbonyl)-amino]- propionic acid Chemical compound 0.000 claims description 571
- 125000001424 substituent group Chemical group 0.000 claims description 188
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 138
- 229910052736 halogen Inorganic materials 0.000 claims description 124
- 150000002367 halogens Chemical class 0.000 claims description 124
- 229910052739 hydrogen Inorganic materials 0.000 claims description 112
- 239000001257 hydrogen Substances 0.000 claims description 108
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 86
- 125000000217 alkyl group Chemical group 0.000 claims description 75
- 125000005842 heteroatoms Chemical group 0.000 claims description 73
- 229910052757 nitrogen Inorganic materials 0.000 claims description 73
- 239000011780 sodium chloride Substances 0.000 claims description 70
- 150000003839 salts Chemical class 0.000 claims description 67
- 125000000623 heterocyclic group Chemical group 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 55
- 229910052799 carbon Inorganic materials 0.000 claims description 54
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 50
- 229910052717 sulfur Inorganic materials 0.000 claims description 47
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 44
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 44
- 229910052760 oxygen Inorganic materials 0.000 claims description 44
- 125000004043 oxo group Chemical group O=* 0.000 claims description 43
- 239000001301 oxygen Substances 0.000 claims description 42
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 42
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 41
- 239000011593 sulfur Substances 0.000 claims description 41
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 239000012453 solvate Substances 0.000 claims description 37
- 150000002431 hydrogen Chemical class 0.000 claims description 36
- 125000001153 fluoro group Chemical group F* 0.000 claims description 29
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 150000002829 nitrogen Chemical group 0.000 claims description 26
- 239000011737 fluorine Substances 0.000 claims description 25
- 229910052731 fluorine Inorganic materials 0.000 claims description 25
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 25
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 21
- 125000004076 pyridyl group Chemical group 0.000 claims description 20
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- 208000010125 Myocardial Infarction Diseases 0.000 claims description 10
- 125000000524 functional group Chemical group 0.000 claims description 9
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 9
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 8
- 206010061255 Ischaemia Diseases 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 206010063837 Reperfusion injury Diseases 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 7
- 206010049694 Left ventricular dysfunction Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000006673 Asthma Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010038435 Renal failure Diseases 0.000 claims description 4
- 125000004429 atoms Chemical group 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 206010006451 Bronchitis Diseases 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 208000007451 Chronic Bronchitis Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000002249 Diabetes Complications Diseases 0.000 claims description 3
- 206010062585 Peripheral arterial occlusive disease Diseases 0.000 claims description 3
- 230000001396 anti-anti-diuretic Effects 0.000 claims description 3
- 201000003883 cystic fibrosis Diseases 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 208000005846 Cardiomyopathy Diseases 0.000 claims description 2
- 229940030606 DIURETICS Drugs 0.000 claims description 2
- 206010012655 Diabetic complications Diseases 0.000 claims description 2
- 208000002907 Heart Valve Disease Diseases 0.000 claims description 2
- 206010021425 Immune system disease Diseases 0.000 claims description 2
- 206010053643 Neurodegenerative disease Diseases 0.000 claims description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 201000008031 cardiomyopathy Diseases 0.000 claims description 2
- 201000006233 congestive heart failure Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003176 fibrotic Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 200000000008 restenosis Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical group [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 claims 1
- 230000001882 diuretic Effects 0.000 claims 1
- 108010059081 Cathepsin A Proteins 0.000 abstract description 37
- 230000002401 inhibitory effect Effects 0.000 abstract description 27
- 239000003112 inhibitor Substances 0.000 abstract description 17
- 206010038428 Renal disease Diseases 0.000 abstract description 5
- 201000009673 liver disease Diseases 0.000 abstract description 5
- 200000000018 inflammatory disease Diseases 0.000 abstract description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 913
- 235000019260 propionic acid Nutrition 0.000 description 229
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 200
- 125000003277 amino group Chemical group 0.000 description 146
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 125
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 100
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 92
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 58
- 235000002639 sodium chloride Nutrition 0.000 description 55
- 102100004315 CTSA Human genes 0.000 description 37
- 239000003480 eluent Substances 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- 230000002194 synthesizing Effects 0.000 description 22
- 238000001819 mass spectrum Methods 0.000 description 21
- 239000002253 acid Substances 0.000 description 20
- 238000000752 ionisation method Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000000132 electrospray ionisation Methods 0.000 description 17
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 239000003643 water by type Substances 0.000 description 14
- 239000000460 chlorine Substances 0.000 description 12
- 229910052801 chlorine Inorganic materials 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- 125000001544 thienyl group Chemical group 0.000 description 12
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 11
- 125000002843 carboxylic acid group Chemical group 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000001681 protective Effects 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 10
- 125000001207 fluorophenyl group Chemical compound 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 108060001001 BRK1 Proteins 0.000 description 9
- QXZGBUJJYSLZLT-FDISYFBBSA-N Bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 9
- 102100011311 KNG1 Human genes 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 230000035492 administration Effects 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 230000001808 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 125000004430 oxygen atoms Chemical group O* 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 125000003226 pyrazolyl group Chemical group 0.000 description 8
- 125000004434 sulfur atoms Chemical group 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 101710016816 CTSA Proteins 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
- MQHULLOCAJMXJU-UHFFFAOYSA-N 2-(2-methylphenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1C MQHULLOCAJMXJU-UHFFFAOYSA-N 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating Effects 0.000 description 6
- 150000001576 beta-amino acids Chemical class 0.000 description 6
- 210000004027 cells Anatomy 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 125000002541 furyl group Chemical group 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(Z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 125000002883 imidazolyl group Chemical group 0.000 description 5
- 230000000069 prophylaxis Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 235000011121 sodium hydroxide Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 4
- OFJWFSNDPCAWDK-UHFFFAOYSA-N 2-phenylbutyric acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1 OFJWFSNDPCAWDK-UHFFFAOYSA-N 0.000 description 4
- JIRKNEAMPYVPTD-UHFFFAOYSA-N 3-(2-methylphenyl)propanoic acid Chemical compound CC1=CC=CC=C1CCC(O)=O JIRKNEAMPYVPTD-UHFFFAOYSA-N 0.000 description 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 4
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 4
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 4
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical compound C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 208000000538 Diabetic Cardiomyopathy Diseases 0.000 description 4
- 208000007342 Diabetic Nephropathy Diseases 0.000 description 4
- 206010012647 Diabetic cardiomyopathy Diseases 0.000 description 4
- 206010061835 Diabetic nephropathy Diseases 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000003725 azepanyl group Chemical group 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 238000010192 crystallographic characterization Methods 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 230000000268 renotropic Effects 0.000 description 4
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000001984 thiazolidinyl group Chemical group 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- BLRHMMGNCXNXJL-UHFFFAOYSA-N 1-Methylindole Chemical compound C1=CC=C2N(C)C=CC2=C1 BLRHMMGNCXNXJL-UHFFFAOYSA-N 0.000 description 3
- LJUWHRPFXVSYNE-UHFFFAOYSA-N 2-methoxy-3-(2-methylphenyl)pyridine Chemical compound COC1=NC=CC=C1C1=CC=CC=C1C LJUWHRPFXVSYNE-UHFFFAOYSA-N 0.000 description 3
- IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 3
- VJHVLELNDFVKMS-UHFFFAOYSA-N 3-methoxy-2-phenylpyridine Chemical compound COC1=CC=CN=C1C1=CC=CC=C1 VJHVLELNDFVKMS-UHFFFAOYSA-N 0.000 description 3
- HJKGBRPNSJADMB-UHFFFAOYSA-N 3-phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=CN=C1 HJKGBRPNSJADMB-UHFFFAOYSA-N 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- GEKVKVCRBHQUFP-UHFFFAOYSA-N COC=1C(=NC=CC=1)C1=CC=CC=C1C Chemical compound COC=1C(=NC=CC=1)C1=CC=CC=C1C GEKVKVCRBHQUFP-UHFFFAOYSA-N 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 102000004172 Cathepsin L Human genes 0.000 description 3
- 108090000624 Cathepsin L Proteins 0.000 description 3
- UNBMQQNYLCPCHS-VYNDPHDASA-N Ebelactone B Chemical compound CC[C@@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)\C=C(/C)C[C@H](C)[C@@H]1OC(=O)[C@H]1CC UNBMQQNYLCPCHS-VYNDPHDASA-N 0.000 description 3
- 210000003734 Kidney Anatomy 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 208000009380 Neuraminidase deficiency with beta-galactosidase deficiency Diseases 0.000 description 3
- HXITXNWTGFUOAU-UHFFFAOYSA-N Phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001154 acute Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 230000003042 antagnostic Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 150000001721 carbon Chemical class 0.000 description 3
- 150000001728 carbonyl compounds Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 150000001793 charged compounds Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 3
- 125000000068 chlorophenyl group Chemical compound 0.000 description 3
- PMPVIKIVABFJJI-UHFFFAOYSA-N cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 229910000000 metal hydroxide Inorganic materials 0.000 description 3
- 150000004692 metal hydroxides Chemical class 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 125000003551 oxepanyl group Chemical group 0.000 description 3
- 235000011118 potassium hydroxide Nutrition 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 125000001680 trimethoxyphenyl group Chemical group 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N 1,2-dihydrobenzotriazol-4-one Chemical compound O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 2
- BSXPDVKSFWQFRT-UHFFFAOYSA-N 1-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CC=C2N(O)N=NC2=N1 BSXPDVKSFWQFRT-UHFFFAOYSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 2
- DNBIDYXUQOSGDT-UHFFFAOYSA-N 2-(2-chlorophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1Cl DNBIDYXUQOSGDT-UHFFFAOYSA-N 0.000 description 2
- SVAOECAKLGBAEW-UHFFFAOYSA-N 2-(2-fluorophenyl)pyridine Chemical compound FC1=CC=CC=C1C1=CC=CC=N1 SVAOECAKLGBAEW-UHFFFAOYSA-N 0.000 description 2
- KHEJPTNZSLUBNF-UHFFFAOYSA-N 2-(2-phenylphenyl)pyridine Chemical compound C1=CC=CC=C1C1=CC=CC=C1C1=CC=CC=N1 KHEJPTNZSLUBNF-UHFFFAOYSA-N 0.000 description 2
- DDSQXUWYUMIYRM-UHFFFAOYSA-N 2-(chloromethoxy)pyridine Chemical compound ClCOC1=CC=CC=N1 DDSQXUWYUMIYRM-UHFFFAOYSA-N 0.000 description 2
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-Chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- VEKIYFGCEAJDDT-UHFFFAOYSA-N 2-pyridin-3-ylpyridine Chemical group N1=CC=CC=C1C1=CC=CN=C1 VEKIYFGCEAJDDT-UHFFFAOYSA-N 0.000 description 2
- AZYTZQYCOBXDGY-UHFFFAOYSA-N 2-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=CC=N1 AZYTZQYCOBXDGY-UHFFFAOYSA-N 0.000 description 2
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 2
- BUMYLQQLSMCBPV-UHFFFAOYSA-N 3-methoxy-2-pyridin-3-ylpyridine Chemical compound COC1=CC=CN=C1C1=CC=CN=C1 BUMYLQQLSMCBPV-UHFFFAOYSA-N 0.000 description 2
- XTBDQNBYCVMUAH-UHFFFAOYSA-N 3-methoxy-2-pyridin-4-ylpyridine Chemical compound COC1=CC=CN=C1C1=CC=NC=C1 XTBDQNBYCVMUAH-UHFFFAOYSA-N 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 2
- DFLFESABTKVYOW-UHFFFAOYSA-N 4,6-dimethylpyridine Chemical compound CC1=C=C(C)N=C[CH]1 DFLFESABTKVYOW-UHFFFAOYSA-N 0.000 description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- XHPVOSNOIWGRQQ-UHFFFAOYSA-N 4-pyridin-2-ylmorpholine Chemical compound C1COCCN1C1=CC=CC=N1 XHPVOSNOIWGRQQ-UHFFFAOYSA-N 0.000 description 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 2
- JIADELSANNMYFC-UHFFFAOYSA-N 5-methoxypyrimidine Chemical compound COC1=CN=CN=C1 JIADELSANNMYFC-UHFFFAOYSA-N 0.000 description 2
- 102000017916 BDKRB1 Human genes 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 108010044231 Bradykinin B1 Receptor Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 208000008787 Cardiovascular Disease Diseases 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N Chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 101700062901 DPP Proteins 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 102100011343 GLB1 Human genes 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- 206010019641 Hepatic cirrhosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010024579 Lysosomal storage disease Diseases 0.000 description 2
- 210000003712 Lysosomes Anatomy 0.000 description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N N,N'-Diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- VGKOARVVEXZTPU-UHFFFAOYSA-N N-methylpyrazin-2-amine Chemical compound CNC1=CN=CC=N1 VGKOARVVEXZTPU-UHFFFAOYSA-N 0.000 description 2
- QROKOTBWFZITJZ-UHFFFAOYSA-N N-pyridin-2-ylacetamide Chemical compound CC(=O)NC1=CC=CC=N1 QROKOTBWFZITJZ-UHFFFAOYSA-N 0.000 description 2
- 208000004296 Neuralgia Diseases 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N Phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 2
- 206010057190 Respiratory tract infection Diseases 0.000 description 2
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 2
- FPQVGDGSRVMNMR-UHFFFAOYSA-N [[(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(C#N)=NOC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- CYKRMWNZYOIJCH-UHFFFAOYSA-N bromo(tripyrrolidin-1-yl)phosphanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(Br)N1CCCC1 CYKRMWNZYOIJCH-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 230000024881 catalytic activity Effects 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 150000002366 halogen compounds Chemical class 0.000 description 2
- 230000002140 halogenating Effects 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- KLGZELKXQMTEMM-UHFFFAOYSA-N hydride Chemical compound [H-] KLGZELKXQMTEMM-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 201000004044 liver cirrhosis Diseases 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000001868 lysosomic Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 125000004492 methyl ester group Chemical group 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229940113083 morpholine Drugs 0.000 description 2
- 230000002107 myocardial Effects 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000002902 organometallic compounds Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- VLYFRFHWUBBLRR-UHFFFAOYSA-L potassium;sodium;carbonate Chemical compound [Na+].[K+].[O-]C([O-])=O VLYFRFHWUBBLRR-UHFFFAOYSA-L 0.000 description 2
- 230000003449 preventive Effects 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 2
- 230000000707 stereoselective Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (-)-propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- ZYZHMSJNPCYUTB-CYBMUJFWSA-N (1R)-N-benzyl-1-phenylethanamine Chemical compound N([C@H](C)C=1C=CC=CC=1)CC1=CC=CC=C1 ZYZHMSJNPCYUTB-CYBMUJFWSA-N 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N (2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-y Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- FKTXDTWDCPTPHK-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical group FC(F)(F)[C](F)C(F)(F)F FKTXDTWDCPTPHK-UHFFFAOYSA-N 0.000 description 1
- LYVWJKRCILVKOI-UHFFFAOYSA-N 1,1,1-trifluorobutane Chemical group [CH2]CCC(F)(F)F LYVWJKRCILVKOI-UHFFFAOYSA-N 0.000 description 1
- GTIIVHODSNYECK-UHFFFAOYSA-N 1,1,1-trifluoropropane Chemical group [CH2]CC(F)(F)F GTIIVHODSNYECK-UHFFFAOYSA-N 0.000 description 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1,2,3-triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- FCDRINPELRTVHD-UHFFFAOYSA-N 1,2-oxazole Chemical compound C=1C=NOC=1.C=1C=NOC=1 FCDRINPELRTVHD-UHFFFAOYSA-N 0.000 description 1
- UGBLVKBJELNFPS-UHFFFAOYSA-N 1,2-thiazole Chemical compound C=1C=NSC=1.C=1C=NSC=1 UGBLVKBJELNFPS-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- ZBOWKDHBOFMERX-UHFFFAOYSA-N 1,3-diazepane Chemical compound C1CCNCNC1 ZBOWKDHBOFMERX-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 description 1
- OQFUNFPIPRUQAE-UHFFFAOYSA-N 1,4-thiazepane Chemical compound C1CNCCSC1 OQFUNFPIPRUQAE-UHFFFAOYSA-N 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 description 1
- SAIRZMWXVJEBMO-UHFFFAOYSA-N 1-bromo-3,3-dimethylbutan-2-one Chemical compound CC(C)(C)C(=O)CBr SAIRZMWXVJEBMO-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 125000006420 1-fluorocyclopropyl group Chemical group [H]C1([H])C([H])([H])C1(F)* 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- NLWCWEGVNJVLAX-UHFFFAOYSA-N 1-methoxy-2-phenylbenzene Chemical compound COC1=CC=CC=C1C1=CC=CC=C1 NLWCWEGVNJVLAX-UHFFFAOYSA-N 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- SFBMENHESNKIKS-UHFFFAOYSA-N 1-oxa-2,3-diazacyclopent-2-en-4-yne Chemical group O1N=NC#C1 SFBMENHESNKIKS-UHFFFAOYSA-N 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 1H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 1H-pyridin-4-one Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- PMCOWOCKUQWYRL-UHFFFAOYSA-N 2,4-dimethylpyrimidine Chemical compound CC1=CC=NC(C)=N1 PMCOWOCKUQWYRL-UHFFFAOYSA-N 0.000 description 1
- GCTFDMFLLBCLPF-UHFFFAOYSA-N 2,5-dichloropyridine Chemical compound ClC1=CC=C(Cl)N=C1 GCTFDMFLLBCLPF-UHFFFAOYSA-N 0.000 description 1
- XFAMUOYNXFXQTC-UHFFFAOYSA-N 2,5-difluoropyridine Chemical compound FC1=CC=C(F)N=C1 XFAMUOYNXFXQTC-UHFFFAOYSA-N 0.000 description 1
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 1
- SZXUTTGMFUSMCE-UHFFFAOYSA-N 2-(1H-imidazol-2-yl)pyridine Chemical compound C1=CNC(C=2N=CC=CC=2)=N1 SZXUTTGMFUSMCE-UHFFFAOYSA-N 0.000 description 1
- IJTIXYUWVKWMPA-UHFFFAOYSA-N 2-(2,3-dichlorophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC(Cl)=C1Cl IJTIXYUWVKWMPA-UHFFFAOYSA-N 0.000 description 1
- SPECGAQNAZRCGK-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(Cl)C=C1Cl SPECGAQNAZRCGK-UHFFFAOYSA-N 0.000 description 1
- KDYOFXPLHVSIHS-UHFFFAOYSA-N 2-(4-methylphenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(C)C=C1 KDYOFXPLHVSIHS-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholino)ethanesulfonic acid Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N 2-Imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-Methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-Methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- VQGHOUODWALEFC-UHFFFAOYSA-N 2-Phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=CC=N1 VQGHOUODWALEFC-UHFFFAOYSA-N 0.000 description 1
- ZNOVTXRBGFNYRX-UHFFFAOYSA-N 2-[[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- CAWHJQAVHZEVTJ-UHFFFAOYSA-N 2-methylpyrazine Chemical compound CC1=CN=CC=N1 CAWHJQAVHZEVTJ-UHFFFAOYSA-N 0.000 description 1
- MEAAWTRWNWSLPF-UHFFFAOYSA-N 2-phenoxypyridine Chemical compound C=1C=CC=NC=1OC1=CC=CC=C1 MEAAWTRWNWSLPF-UHFFFAOYSA-N 0.000 description 1
- MKSOZMCQINVWAZ-UHFFFAOYSA-N 2-pyridin-2-ylsulfanylpyrimidine Chemical compound N=1C=CC=NC=1SC1=CC=CC=N1 MKSOZMCQINVWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- UAVMXZQEEDWREU-UHFFFAOYSA-N 2H-benzotriazol-4-yloxy(tripyrrolidin-1-yl)phosphanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)OC1=CC=CC2=C1N=NN2 UAVMXZQEEDWREU-UHFFFAOYSA-N 0.000 description 1
- VUGRPJUREUOUIO-UHFFFAOYSA-N 2H-benzotriazol-4-yloxy-tris(dimethylamino)phosphanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)[P+](N(C)C)(N(C)C)OC1=CC=CC2=C1N=NN2 VUGRPJUREUOUIO-UHFFFAOYSA-N 0.000 description 1
- RINGWLLNBNVTMO-UHFFFAOYSA-N 3,6-dichloropyridine Chemical compound ClC1=C[C]=C(Cl)N=C1 RINGWLLNBNVTMO-UHFFFAOYSA-N 0.000 description 1
- HWWPLQGCHSVXQY-UHFFFAOYSA-N 3-(2-methoxyphenyl)pyridine Chemical compound COC1=CC=CC=C1C1=CC=CN=C1 HWWPLQGCHSVXQY-UHFFFAOYSA-N 0.000 description 1
- LDYGRLNSOKABMM-UHFFFAOYSA-N 3-(P-Tolyl)Propionic Acid Chemical compound CC1=CC=C(CCC(O)=O)C=C1 LDYGRLNSOKABMM-UHFFFAOYSA-N 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- CELKOWQJPVJKIL-UHFFFAOYSA-N 3-fluoropyridine Chemical compound FC1=CC=CN=C1 CELKOWQJPVJKIL-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N 3-methoxypyridine Chemical compound COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- YTEIHWVCQJZNEN-UHFFFAOYSA-N 3-pyridin-4-ylpyridine Chemical group C1=CN=CC(C=2C=CN=CC=2)=C1 YTEIHWVCQJZNEN-UHFFFAOYSA-N 0.000 description 1
- OAIVFOKDDZHMOU-UHFFFAOYSA-N 3-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=CN=C1 OAIVFOKDDZHMOU-UHFFFAOYSA-N 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 150000005240 3H-imidazo[4,5-b]pyridines Chemical compound 0.000 description 1
- LQLJNIMZZWZZLE-UHFFFAOYSA-N 4-(iminomethylideneamino)-N,N-dimethylpentan-1-amine;hydrochloride Chemical compound Cl.N=C=NC(C)CCCN(C)C LQLJNIMZZWZZLE-UHFFFAOYSA-N 0.000 description 1
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-Methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 1
- JVZRCNQLWOELDU-UHFFFAOYSA-N 4-Phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=NC=C1 JVZRCNQLWOELDU-UHFFFAOYSA-N 0.000 description 1
- VJXRKZJMGVSXPX-UHFFFAOYSA-N 4-ethylpyridine Chemical compound CCC1=CC=NC=C1 VJXRKZJMGVSXPX-UHFFFAOYSA-N 0.000 description 1
- SSSVNWQDTOQWPH-UHFFFAOYSA-N 4-phenyl-2-piperidin-1-ylpyrimidine Chemical compound C1CCCCN1C1=NC=CC(C=2C=CC=CC=2)=N1 SSSVNWQDTOQWPH-UHFFFAOYSA-N 0.000 description 1
- QJWQYVJVCXMTJP-UHFFFAOYSA-N 4-pyridin-4-ylmorpholine Chemical compound C1COCCN1C1=CC=NC=C1 QJWQYVJVCXMTJP-UHFFFAOYSA-N 0.000 description 1
- WJRKNLONLOMALV-UHFFFAOYSA-N 5-chloropyridine Chemical compound ClC1=C=NC=C[CH]1 WJRKNLONLOMALV-UHFFFAOYSA-N 0.000 description 1
- DVMILACIDBEACH-UHFFFAOYSA-N 6-fluoropyridine Chemical compound FC1=C=CC=C[N]1 DVMILACIDBEACH-UHFFFAOYSA-N 0.000 description 1
- MAQAGRJURDEYDQ-UHFFFAOYSA-N 6-methylpyridine Chemical compound CC1=C=CC=C[N]1 MAQAGRJURDEYDQ-UHFFFAOYSA-N 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 229940083712 Aldosterone antagonists Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N Amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 102400000346 Angiotensin 1-9 Human genes 0.000 description 1
- 101800000550 Angiotensin 1-9 Proteins 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N Angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 210000002376 Aorta, Thoracic Anatomy 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N Azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N Azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L Bis(triphenylphosphine)palladium(II) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- GCBNIIKPVIHBGR-UHFFFAOYSA-N C1=COC=N1.C1=COC=N1 Chemical compound C1=COC=N1.C1=COC=N1 GCBNIIKPVIHBGR-UHFFFAOYSA-N 0.000 description 1
- 102100014758 CPVL Human genes 0.000 description 1
- 101700061084 CPVL Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 210000001612 Chondrocytes Anatomy 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N Clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 Clopidogrel Drugs 0.000 description 1
- 208000008006 Collagen Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229940109239 Creatinine Drugs 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- 229960004486 Desoxycorticosterone acetate Drugs 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N Digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 102100004921 EDN1 Human genes 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 108010072834 Endothelin-1 Proteins 0.000 description 1
- 206010048653 Enzyme inhibition Diseases 0.000 description 1
- 102000003837 Epithelial Sodium Channels Human genes 0.000 description 1
- 108090000140 Epithelial Sodium Channels Proteins 0.000 description 1
- 210000004955 Epithelial membranes Anatomy 0.000 description 1
- 102100006624 F9 Human genes 0.000 description 1
- MEKWBVWGNBMLOX-UHFFFAOYSA-O F[B-](F)(F)F.F[B-](F)(F)F.ClC[N+]12C(C[NH+](CC1)CC2)F Chemical compound F[B-](F)(F)F.F[B-](F)(F)F.ClC[N+]12C(C[NH+](CC1)CC2)F MEKWBVWGNBMLOX-UHFFFAOYSA-O 0.000 description 1
- 108010029144 Factor IIa Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 229940012414 Factor VIIa Drugs 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 101710042131 GCG Proteins 0.000 description 1
- 102100003818 GCG Human genes 0.000 description 1
- 101710004110 GLP Proteins 0.000 description 1
- 201000008892 GM1 gangliosidosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229960002591 Hydroxyproline Drugs 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 210000001117 Keloid Anatomy 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 108010000851 Laminin Receptors Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 208000009856 Lung Disease Diseases 0.000 description 1
- 108009000252 Lung fibrosis Proteins 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 229960003105 Metformin Drugs 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- HGINADPHJQTSKN-UHFFFAOYSA-N Monoethyl malonic acid Chemical compound CCOC(=O)CC(O)=O HGINADPHJQTSKN-UHFFFAOYSA-N 0.000 description 1
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 1
- BXGTVNLGPMZLAZ-UHFFFAOYSA-N N'-ethylmethanediimine;hydrochloride Chemical compound Cl.CCN=C=N BXGTVNLGPMZLAZ-UHFFFAOYSA-N 0.000 description 1
- VMWJCFLUSKZZDX-UHFFFAOYSA-N N,N-dimethylmethanamine Chemical compound [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010029149 Nephropathy Diseases 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- 108009000118 Nuclear Receptors Proteins 0.000 description 1
- 101710008205 OXT Proteins 0.000 description 1
- 102100017240 OXT Human genes 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N Oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N Oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N Oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 Oxytocin Drugs 0.000 description 1
- 102100019727 P2RY1 Human genes 0.000 description 1
- 101700062635 P2RY1 Proteins 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 102100003647 PPARA Human genes 0.000 description 1
- 102100003341 PRSS8 Human genes 0.000 description 1
- 102000016387 Pancreatic Elastase Human genes 0.000 description 1
- 108010067372 Pancreatic Elastase Proteins 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N Phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N Phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- 229960005095 Pioglitazone Drugs 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000007232 Portal Hypertension Diseases 0.000 description 1
- 229960004063 Propylene glycol Drugs 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 206010037175 Psychiatric disease Diseases 0.000 description 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 description 1
- VIAFLMPQBHAMLI-UHFFFAOYSA-N PyBOP Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 VIAFLMPQBHAMLI-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- CLKZWXHKFXZIMA-UHFFFAOYSA-N Pyrinuron Chemical group C1=CC([N+](=O)[O-])=CC=C1NC(=O)NCC1=CC=CN=C1 CLKZWXHKFXZIMA-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038491 Renal papillary necrosis Diseases 0.000 description 1
- 229940086526 Renin-inhibitors Drugs 0.000 description 1
- 206010038683 Respiratory disease Diseases 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
- 102100016725 SCPEP1 Human genes 0.000 description 1
- 101710005494 SCPEP1 Proteins 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 102100019633 ST14 Human genes 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L Sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N Sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 208000008253 Systolic Heart Failure Diseases 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- 101700065588 TAC1 Proteins 0.000 description 1
- 102100002996 TAC1 Human genes 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N Tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N Thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N Thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N Thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 Triacetin Drugs 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 102100013671 ZHX2 Human genes 0.000 description 1
- SRUIBJVUBBOHHY-UHFFFAOYSA-N [2H-benzotriazol-4-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)C(=[N+](C)C)OC1=CC=CC2=C1N=NN2 SRUIBJVUBBOHHY-UHFFFAOYSA-N 0.000 description 1
- BIABKPAXSLKGLN-UHFFFAOYSA-N [dimethylamino(2H-triazolo[4,5-b]pyridin-7-yloxy)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)C(=[N+](C)C)OC1=CC=NC2=C1N=NN2 BIABKPAXSLKGLN-UHFFFAOYSA-N 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- RAFKCLFWELPONH-UHFFFAOYSA-N acetonitrile;dichloromethane Chemical compound CC#N.ClCCl RAFKCLFWELPONH-UHFFFAOYSA-N 0.000 description 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001339 alkali metal compounds Chemical class 0.000 description 1
- 150000001341 alkaline earth metal compounds Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated Effects 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000003288 anthiarrhythmic Effects 0.000 description 1
- 230000002236 anti-hypertrophic Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003144 bradykinin B1 receptor antagonist Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229940082638 cardiac stimulant Phosphodiesterase inhibitors Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- AVDNGGJZZVTQNA-UHFFFAOYSA-N di(pyrrol-1-yl)methanone Chemical class C1=CC=CN1C(=O)N1C=CC=C1 AVDNGGJZZVTQNA-UHFFFAOYSA-N 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;N,N-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- FXORZKOZOQWVMQ-UHFFFAOYSA-L dichloropalladium;triphenylphosphane Chemical compound Cl[Pd]Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 FXORZKOZOQWVMQ-UHFFFAOYSA-L 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 108010064033 elastin-binding proteins Proteins 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial Effects 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000000031 ethylamino group Chemical compound [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- FFLYUXVZEPLMCL-UHFFFAOYSA-N ethylchloranuidyl formate Chemical compound CC[Cl-]OC=O FFLYUXVZEPLMCL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960004222 factor IX Drugs 0.000 description 1
- 229940012426 factor X Drugs 0.000 description 1
- 229940012444 factor XIII Drugs 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003119 guanylate cyclase activator Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- RTIAQOLKVLAEAU-UHFFFAOYSA-N hexan-3-yl acetate Chemical compound CCCC(CC)OC(C)=O RTIAQOLKVLAEAU-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001631 hypertensive Effects 0.000 description 1
- 230000001077 hypotensive Effects 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000000415 inactivating Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical compound 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- NZTNZPDOBQDOSO-UHFFFAOYSA-N lithium;boron(1-) Chemical compound [Li+].[B-] NZTNZPDOBQDOSO-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 108010091175 matriptase Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- UGFPNFKMYRHGBG-UHFFFAOYSA-N methyl 6-bromo-3-hydroxypyridine-2-carboxylate Chemical compound COC(=O)C1=NC(Br)=CC=C1O UGFPNFKMYRHGBG-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000004027 organic amino compounds Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 101700057139 oxyT Proteins 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000005359 phenylpyridines Chemical compound 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000025627 positive regulation of urine volume Effects 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- NSETWVJZUWGCKE-UHFFFAOYSA-N propylphosphonic acid Chemical compound CCCP(O)(O)=O NSETWVJZUWGCKE-UHFFFAOYSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 108010031970 prostasin Proteins 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000005230 pyrazolo[3,4-b]pyridines Chemical compound 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000001084 renoprotective Effects 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 108010059841 serine carboxypeptidase Proteins 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- HVEFSVSCGJNJQK-UHFFFAOYSA-N tert-butyl 3-[benzyl(1-phenylethyl)amino]propanoate Chemical class C=1C=CC=CC=1C(C)N(CCC(=O)OC(C)(C)C)CC1=CC=CC=C1 HVEFSVSCGJNJQK-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N tetrahydro-2H-thiopyran Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 239000002536 vasopressin receptor antagonist Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N β-Propiolactone Chemical class O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
The disclosure relates to substituted 3-heteroaroylamino-propionic acid derivatives of formula (I), wherein the variables A, D, E, L, G, R10, R30, R40, R50 and R60 have the meanings indicated in the specification. These compounds are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The disclosure furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them. atment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The disclosure furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.
Description
Substituted 3-heteroaroylamino-propionic acid derivatives and their use as
pharmaceuticals
The present invention relates to compounds of the formula I,
30 40 50 60
wherein A, D, E, L, G, R , R , R , R and R have the meanings indicated
below, which are valuable pharmaceutical active compounds. They are inhibitors of
the protease cathepsin A, and are useful for the treatment of diseases such as
atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory
diseases, for example. The invention furthermore relates to processes for the
preparation of the compounds of the formula I, their use and pharmaceutical
compositions comprising them.
Cathepsin A (EC = 3.4.16.5; gene symbol CTSA) is a protease also known as
lysosomal carboxypeptidase A or protective protein. It belongs to a family of serine
carboxypeptidases which contains only two other mammalian representatives,
retinoid-inducible serine carboxypeptidase and vitellogenic carboxypeptidase-like
protein. Within the cell cathepsin A resides in lysosomes where it forms a high
molecular weight complex with beta-galactosidase and neuraminidase. The
interaction of cathepsin A with these glycosidases is essential for their correct
routing to the lysosome and protects them from intralysosomal proteolysis. A
deficiency of cathepsin A resulting from various mutations in the ctsa gene leads to
a secondary deficiency of beta-galactosidase and neuraminidase that is manifest as
the autosomal recessive lysosomal storage disorder galactosialidosis (cf. A. d'Azzo
et al., in "The Metabolic and Molecular Bases of Inherited Disease", vol. 2 (1995),
2835-2837). The majority of identified mutations in ctsa are missense mutations
affecting the folding or the stability of the protein. None of them was shown to occur
in the active site of the enzyme (G. Rudenko et al., Proc. Natl. Acad. Sci. USA 95
(1998), 621-625). Accordingly, the lysosomal storage disorder can be corrected with
catalytically inactive cathepsin A mutants (N. J. Galjart et al., J. Biol. Chem. 266
(1991), 14754-14762). The structural function of cathepsin A is therefore separable
from its catalytic activity. This is also underscored by the observation that in contrast
to mice deficient in the ctsa gene, mice carrying a catalytically inactivating mutation
in the ctsa gene do not develop signs of the human disease galactosialidosis (R. J.
Rottier et al., Hum. Mol. Genet. 7 (1998), 1787-1794; V. Seyrantepe et al.,
Circulation 117 (2008), 1973-1981).
Cathepsin A displays carboxypeptidase activity at acidic pH and deamidase and
esterase activities at neutral pH against various naturally occurring bioactive
peptides. In vitro studies have indicated that cathepsin A converts angiotensin I to
angiotensin 1-9 and bradykinin to bradykinin 1-8, which is the ligand for the
bradykinin B1 receptor. It hydrolyzes endothelin-1, neurokinin and oxytocin, and
deamidates substance P (cf. M. Hiraiwa, Cell. Mol. Life Sci. 56 (1999), 894-907).
High cathepsin A activity has been detected in urine, suggesting that it is
responsible for tubular bradykinin degradation (M. Saito et al., Int. J. Tiss. Reac. 17
(1995), 181-190). However, the enzyme can also be released from platelets and
lymphocytes and is expressed in antigen-presenting cells where it might be involved
in antigen processing (W. L. Hanna et al., J. Immunol. 153 (1994), 4663-4672; H.
Ostrowska, Thromb. Res. 86 (1997), 393-404; M. Reich et al., Immunol. Lett. (online
Nov. 30, 2009)). Immunohistochemistry of human organs revealed prominent
expression in renal tubular cells, bronchial epithelial cells, Leydig´s cells of the testis
and large neurons of the brain (O. Sohma et al., Pediatr. Neurol. 20 (1999), 210-
214). It is upregulated during differentiation of monocytes to macrophages (N. M.
Stamatos et al., FEBS J. 272 (2005), 2545-2556). Apart from structural and
enzymatic functions, cathepsin A has been shown to associate with neuraminidase
and an alternatively spliced beta-galactosidase to form the cell-surface laminin and
elastin receptor complex expressed on fibroblasts, smooth muscle cells,
chondroblasts, leukocytes and certain cancer cell types (A. Hinek, Biol. Chem. 377
(1996), 471-480).
The importance of cathepsin A for the regulation of local bradykinin levels has been
demonstrated in animal models of hypertension. Pharmacological inhibition of
cathepsin A activity increased renal bradykinin levels and prevented the
development of salt-induced hypertension (H. Ito et al., Br. J. Pharmacol. 126
(1999), 613-620). This could also be achieved by antisense oligonucleotides
suppressing the expression of cathepsin A (I. Hajashi et al., Br. J. Pharmacol. 131
(2000), 820-826). Besides in hypertension, beneficial effects of bradykinin have
been demonstrated in various further cardiovascular diseases and other diseases
(cf. J. Chao et al., Biol. Chem. 387 (2006), 665-75; P. Madeddu et al., Nat. Clin.
Pract. Nephrol. 3 (2007), 208-221). Key indications of cathepsin A inhibitors
therefore include atherosclerosis, heart failure, cardiac infarction, cardiac
hypertrophy, vascular hypertrophy, left ventricular dysfunction, in particular left
ventricular dysfunction after myocardial infarction, renal diseases such as renal
fibrosis, renal failure and kidney insufficiency; liver diseases such as liver fibrosis
and liver cirrhosis, diabetes complications such as nephropathy, as well as organ
protection of organs such as the heart and the kidney.
As indicated above, cathepsin A inhibitors can prevent the generation of the
bradykinin B1 receptor ligand bradykinin 1-8 (M. Saito et al., Int. J. Tiss. Reac. 17
(1995), 181-190). This offers the opportunity to use cathepsin A inhibitors for the
treatment of pain, in particular neuropathic pain, and inflammation, as has been
shown for bradykinin B1 receptor antagonists (cf. F. Marceau et al., Nat. Rev. Drug
Discov. 3 (2004), 845-852). Cathepsin A inhibitors can further be used as anti-
platelet agents as has been demonstrated for the cathepsin A inhibitor ebelactone
B, a propiolactone derivative, which suppresses platelet aggregation in hypertensive
animals (H. Ostrowska et al., J. Cardiovasc. Pharmacol. 45 (2005), 348-353).
Further, like other serine proteases such as prostasin, elastase or matriptase,
cathepsin A can stimulate the amiloride-sensitive epithelial sodium channel (ENaC)
and is thereby involved in the regulation of fluid volumes across epithelial
membranes (cf. C. Planes et al., Curr. Top. Dev. Biol. 78 (2007), 23-46). Thus,
respiratory diseases can be ameliorated by the use of cathepsin A inhibitors, such
as cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, asthma,
respiratory tract infections and lung carcinoma. Cathepsin A modulation in the
kidney could be used to promote diuresis and thereby induce a hypotensive effect.
Besides for the above-mentioned compound ebelactone B, an inhibitory effect on
cathepsin A has been found for certain dipeptidic phenylalanine derivatives which
are described in JP 2005/145839. There is a need for further compounds which
inhibit cathepsin A and offer an opportunity for the treatment of the mentioned
diseases and further diseases in which cathepsin A plays a role. The present
invention satisfies this need by providing the oxygen-substituted 3-
heteroaroylamino-propionic acid derivatives of the formula I defined below.
Certain compounds in which a 3-heteroaroylamino-propionic acid moiety can be
present, have already been described. For example, in amine
derivatives, which modulate the activity of steroid nuclear receptors, are described
which carry on the nitrogen atom of the amine function a heteroaroyl group and a
further group which is defined very broadly. In US 2004/0072802 broadly-defined
beta-amino acid derivatives are described which carry an acyl group on the beta-
amino group and are inhibitors of matrix metalloproteases and/or tumor necrosis
factor. In and , which relate to antagonists of the
platelet ADP receptor P2Y12 and inhibit platelet aggregation, pyrazoloylamino-
substituted carboxylic acid derivatives are described which, however, additionally
carry a carboxylic acid derivative group on the carbon atom carrying the
pyrazoloylamino group. Other pyrazoloylamino-substituted compounds, in which the
nitrogen atom of the amino group is connected to a ring system and which are
inhibitors of the blood clotting enzymes factor Xa and/or factor VIIa, are described in
A subject of the present invention is a compound of the formula I, in any of its
stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a
physiologically acceptable salt thereof, or a physiologically acceptable solvate of
any of them,
R10 R
wherein
A is chosen from the series consisting of C(R ) and N;
D is chosen from the series consisting of C(R ) and N;
E is chosen from the series consisting of C(R ) and N;
L is chosen from the series consisting of C(R ) and N;
where at least one and at most two of A, D, E or L is N;
71 72 73
G is chosen from the series consisting of R -O-C(O)-, R -N(R )-C(O)- and
tetrazolyl;
R is chosen from the series consisting of hydrogen, halogen, (C -C )-alkyl, HO-,
(C -C )-alkyl-O-, (C -C )-alkyl-S(O) - and NC-;
1 6 1 6 m
R is chosen from the series consisting of hydrogen, halogen, (C -C )-alkyl, (C -C )-
1 7 1 6
12 13 2,
alkyl-O-, (C -C )-alkyl-CO-, (C -C )-alkyl-CO-HN-, -NR R , Het (C -C )-cycloalkyl-
1 6 1 6 3 7
C H - and Ar-C H -, wherein s is an integer chosen from the series consisting of 0,
s 2s s 2s
1, 2 and 3;
R is chosen from the series consisting of hydrogen, halogen, (C -C )-alkyl, (C -C )-
1 6 1 6
4 12 13 2 11 12 13 2
alkyl-S(O) -, Het -(O) -, -NR R , Het , R -O-, R -N(R )-C(O)-O- and Het -C(O)-
O- and NC-, wherein s is an integer chosen from the series consisting of 0, 1, 2 and
3 and wherein t is an integer chosen from the series consisting of 0 and 1;
R is chosen from the series consisting of hydrogen, halogen, (C -C )-alkyl, (C -C )-
1 6 1 6
12 13 2
alkyl-O-, HO-, NR R , Het ;
R is chosen from the series consisting hydrogen, halogen, (C -C )-alkyl, (C -C )-
1 6 1 6
12 13 2
alkyl-O-, (C -C )-alkyl-S(O) -, HO-, -NR R , Het , phenyl-C H -(O) -, wherein s is
1 6 m s 2s t
an integer chosen from the series consisting of 0, 1, 2 and 3 and wherein t is an
integer chosen from the series consisting of 0 and 1;
1 2 2 3
or R and R or R and R or form pyridyl;
or R and R are –C((C -C )-alkyl)=N-N((C -C )-alkyl)-;
1 3 1 3
or R and R are –NH-CH=N-;
1 2 3 4 10
with the proviso that one of R , R , R , R or R is a cyclic substituent;
11 14
R is chosen from the series consisting of hydrogen, R , (C -C )-cycloalkyl, Ar and
Het ;
12 13
R and R are independently of each other chosen from the series consisting of
hydrogen and R ;
R is (C -C )-alkyl which is optionally substituted by one or more identical or
1 10
different substituents chosen from the series consisting of halogen, HO-, R -O-,
oxo, (C -C )-cycloalkyl, Ar, Het , Het , NC-, H N-C(O)-, (C -C )-alkyl-NH-C(O)-,
3 7 2 1 4
di((C -C )-alkyl)N-C(O)-, Het -C(O)-, (C -C )-alkyl-C(O)-NH- and (C -C )-alkyl-
1 4 1 4 1 4
S(O) -;
R is (C -C )-alkyl which is optionally substituted by one or more identical or
different substituents chosen from the series consisting halogen, HO- and (C -C )-
alkyl-O-;
R is (C -C )-alkyl which is optionally substituted by one or more identical or
different substituents chosen from the series consisting of HO-, (C -C )-alkyl-O- and
NC-;
31 32
R is chosen from the series consisting of R , (C -C )-cycloalkyl, R -C H - and
3 7 u 2u
Het -C H -, wherein u is an integer chosen from the series consisting of 0, 1, 2 and
u 2u
R is (C -C )-alkyl which is optionally substituted by one or more identical or
1 10
different substituents chosen from the series consisting of halogen, (C -C )-
cycloalkyl, HO-, (C -C )-alkyl-O-, (C -C )-alkyl-S(O) - and NC-;
1 6 1 6 m
R is chosen from the series consisting of phenyl and an aromatic 5-membered or
6-membered monocyclic heterocycle which comprises one, two or three identical or
different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and
sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle
all are optionally substituted by one or more identical or different substituents
chosen from the series consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, R ,
1 6 3 7
33 33
HO-, (C -C )-alkyl-O-, R -O-, R -(C -C )-alkyl-O-, -O-CH -O-, -O-CF -O-, (C -C )-
1 6 1 4 2 2 1 6
alkyl-S(O) -, H N-S(O) -, (C -C )-alkyl-NH-S(O) -, di((C -C )-alkyl)N-S(O) -, H N-,
m 2 2 1 4 2 1 4 2 2
(C -C )-alkyl-NH-, di((C -C )-alkyl)N-, Het , (C -C )-alkyl-C(O)-NH-, Ar-C(O)-NH-,
1 6 1 6 1 4
(C -C )-alkyl-S(O) -NH- and NC-;
1 4 2
R is chosen from the series consisting of phenyl and an aromatic 5-membered or
6-membered monocyclic heterocycle which comprises one, two or three identical or
different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and
sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle
all are optionally substituted by one or more identical or different substituents
chosen from the series consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, HO-,
1 6 3 7
(C -C )-alkyl-O-, (C -C )-alkyl-S(O) -, H N-S(O) -, (C -C )-alkyl-NH-S(O) -, di((C -
1 6 1 6 m 2 2 1 4 2 1
C )-alkyl)N-S(O) - and NC-;
R is chosen from the series consisting of hydrogen and (C -C )-alkyl;
40
or R and R together are (CH ) which is optionally substituted by one or more
identical or different (C -C )-alkyl substituents, wherein x is an integer chosen from
the series consisting of 2, 3, 4 and 5;
R is chosen from the series consisting of hydrogen, (C -C )-alkyl, HO- and (C -
1 6 1
C )-alkyl-O-;
R is chosen from the series consisting of hydrogen and (C -C )-alkyl;
50 60
or R and R together are (CH ) which is optionally substituted by one or more
identical or different (C -C )-alkyl substituents, wherein y is an integer chosen from
the series consisting of 2, 3, 4 and 5;
R is chosen from the series consisting of hydrogen and (C -C )-alkyl which is
optionally substituted by one or more identical or different substituents chosen from
the series consisting (C -C )-alkyl-O- and (C -C )-alkyl-C(O)-O-;
1 6 1 6
R is chosen from the series consisting of hydrogen, (C -C )-alkyl, (C -C )-
1 6 3 6
cycloalkyl, –CH -(CH ) -(C -C )-cycloalkyl, Het and -(CH ) -Het , where alkyl or
2 2 b 3 6 2 b
cycloalkyl is optionally substituted by one or more identical or different substituents
chosen from the series consisting of halogen, HO-, HOOC-, (C -C )-alkyl-O- and
(C -C )-alkyl-C(O)-O-, NC-, N((C -C )-alkyl) and b is 0, 1 or 2;
1 6 1 4 2
R is chosen from the series consisting of hydrogen, (C -C )-alkyl;
72 73
R and R together with the nitrogen atom to which they are bonded form a
saturated 4-membered to 7-membered monocyclic heterocycle, which contain
optionally one further ring heteroatom chosen from the series consisting of nitrogen,
oxygen and sulfur, which is optionally substituted by one or more identical or
different substituents chosen from the series consisting of halogen, (C -C )-alkyl,
HO- and (C -C )-alkyl-O-;
Ar, independently of each other group Ar, is chosen from the series consisting of
phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which
comprises one, two or three identical or different ring heteroatoms chosen from the
series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon
atom, wherein the phenyl and the heterocycle all are optionally substituted by one or
more identical or different substituents chosen from the series consisting of halogen,
(C -C )-alkyl, HO-(C -C )-alkyl, Het , -(CH ) -Phenyl, (C -C )-alkyl-O-, (C -C )-
1 6 1 6 2 x 1 6 3 7
12 13 2 12 13
cycloalkyl-(CH ) -O-, -CF , -CO-(C -C )-alkyl, -NR R , Het , -CO-NR R , CO-
2 x 3 1 6
Het , (C -C )-alkyl-S(O) -, H N-S(O) - and NC-;
1 6 m 2 2
and wherein phenyl may be substituted by -CH=CH-CH=CH-, -O-CH -O-, -O-CH -
CH -O-, -O-CF -O- or -N((C -C )-alkyl)-CH=CH-;
2 2 1 3
Het , independently of each other group Het , is a saturated or unsaturated 4-
membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen
atom via which Het is bonded and optionally one or two identical or different further
ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur,
which is optionally substituted by one or more identical or different substituents
chosen from the series consisting of halogen, (C -C )-alkyl, HO-, (C -C )-alkyl-O-,
1 4 1 4
oxo and NC-;
Het is a saturated 4-membered to 7-membered monocyclic heterocycle which
comprises a ring nitrogen atom via which Het is bonded and optionally one further
ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur,
which is optionally substituted by one or more identical or different substituents
chosen from the series consisting of halogen, (C -C )-alkyl, HO- and (C -C )-alkyl-
1 4 1 4
Het , independently of each other group Het , is a saturated 4-membered to 7-
membered monocyclic heterocycle which comprises one or two identical or different
ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur
and is bonded via a ring carbon atom, which is optionally substituted by one or more
identical or different substituents chosen from the series consisting of fluorine, (C
C )-alkyl and oxo;
Het , independently of each other group Het , is a saturated or unsaturated 4-
membered to 8-membered monocyclic heterocycle which comprises one to four ring
heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which
is optionally substituted by one or more identical or different substituents chosen
from the series consisting of halogen, (C -C )-alkyl, HO-, (C -C )-alkyl-O-, oxo and
1 4 1 4
NC-;
m, independently of each other number m, is an integer chosen from the series
consisting of 0, 1 and 2;
wherein all cycloalkyl groups, independently of each other, are optionally substituted
by one or more identical or different substituents chosen from the series consisting
of fluorine and (C -C )-alkyl;
wherein all alkyl, C H , C H , (CH ) and (CH ) groups, independently of each
s 2s u 2u 2 x 2 y
other, and independently of any other substituents, are optionally substituted by one
or more fluorine substituents.
If structural elements such as groups, substituents or numbers, for example, can
occur several times in the compounds of the formula I, they are all independent of
each other and can in each case have any of the indicated meanings, and they can
in each case be identical to or different from any other such element. In a
dialkylamino group, for example, the alkyl groups can be identical or different.
Alkyl groups, i.e. saturated hydrocarbon residues, can be linear (straight-chain) or
branched. This also applies if these groups are substituted or are part of another
group, for example an alkyl-O- group (alkyloxy group, alkoxy group) or an HO-
substituted alkyl group (hydroxyalkyl group). Depending on the respective definition,
the number of carbon atoms in an alkyl group can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, or
1, 2, 3, 4, 5, 6, 7 or 8, or 1, 2, 3, 4, 5 or 6, or 1, 2, 3 or 4, or 1, 2 or 3, or 1 or 2, or 1,
for example. In one embodiment of the invention, a (C -C )-alkyl group present in
1 10
the compounds of the formula I is a (C -C )-alkyl group, in another embodiment a
(C -C )-alkyl group, in another embodiment a (C -C )-alkyl group, in another
1 6 1 4
embodiment a (C -C )-alkyl group, in another embodiment a (C -C )-alkyl group, in
1 3 1 2
another embodiment a (C -C )-alkyl group, in another embodiment a methyl group.
In one embodiment of the invention, a (C -C )-alkyl group present in any position of
the compounds of the formula I is a (C -C )-alkyl group, in another embodiment a
(C -C )-alkyl group, in another embodiment a (C -C )-alkyl group, in another
1 4 1 3
embodiment a (C -C )-alkyl group, in another embodiment a (C -C )-alkyl group, in
1 2 2 3
another embodiment a methyl group, where any (C -C )-alkyl group present in the
compounds of the formula I can independently of each other (C -C )-alkyl group be
a group of any of these embodiments. In one embodiment of the invention, a (C -
C )-alkyl group present in any position of the compounds of the formula I is a (C -
C )-alkyl group, in another embodiment a (C -C )-alkyl group, in another
4 1 3
embodiment a (C -C )-alkyl group, in another embodiment a (C -C )-alkyl group, in
1 2 2 3
another embodiment a methyl group, where any (C -C )-alkyl group present in the
compounds of the formula I can independently of each other (C -C )-alkyl group be
a group of any of these embodiments. In one embodiment of the invention, a (C -
C )-alkyl group present in any position of the compounds of the formula I is a (C -
C )-alkyl group, in another embodiment a (C -C )-alkyl group, in another
3 1 2
embodiment a (C -C )-alkyl group, in another embodiment a methyl group, where
any (C -C )-alkyl group present in the compounds of the formula I can
independently of each other (C -C )-alkyl group be a group of any of these
embodiments. Examples of alkyl groups are methyl, ethyl, propyl groups including
propyl (i.e. n-propyl) and isopropyl, butyl groups including butyl (i.e. n-butyl), sec-
butyl, isobutyl and tert-butyl, pentyl groups including pentyl (i.e. n-pentyl), 1-
methylbutyl, isopentyl, neopentyl and tert-pentyl, hexyl groups including hexyl (i.e. n-
hexyl), 3,3-dimethylbutyl and isohexyl, heptyl groups including heptyl (i.e. n-heptyl),
octyl groups including octyl (i.e. n-octyl), nonyl groups including nonyl (i.e. n-nonyl),
and decyl groups including decyl (i.e. n-decyl). Examples of alkyl-O- groups are
methoxy, ethoxy, propoxy (i.e. n-propoxy), isopropoxy, butoxy (i.e. n-butoxy),
- are
isobutoxy, tert-butoxy, pentoxy (i.e. n-pentoxy). Examples of alkyl-S(O)
methylsulfanyl- (CH -S-), methanesulfinyl- (CH -S(O)-), methanesulfonyl
(CH -S(O) -), ethylsulfanyl- (CH -CH -S-), ethanesulfinyl- (CH -CH -S(O)-),
3 2 3 2 3 2
ethanesulfonyl (CH -CH -S(O) -), 1-methylethylsulfanyl- ((CH ) CH-S-), 1-
3 2 2 3 2
methylethanesulfinyl- ((CH ) CH-S(O)-), 1-methylethanesulfonyl ((CH ) CH-S(O) -).
3 2 3 2 2
In one embodiment of the invention the number m is chosen from 0 and 2, wherein
all numbers m are independent of each other and can be identical or different. In
another embodiment the number m in any of its occurrences is, independently of its
meaning in other occurrences, 0. In another embodiment the number m in any of its
occurrences is, independently of its meaning in other occurrences, 2.
A substituted alkyl group can be substituted in any positions, provided that the
respective compound is sufficiently stable and is suitable as a pharmaceutical active
compound. The prerequisite that a specific group and a compound of the formula I
are sufficiently stable and suitable as a pharmaceutical active compound, applies in
general with respect to the definitions of all groups in the compounds of the formula
I. In one embodiment of the invention, an individual carbon atom in any alkyl group
in the compounds of the formula I, as well as in other groups such as cycloalkyl
groups and heterocyclic groups, for example, independently of any other carbon
atom does not carry more than one substituent which is bonded via an oxygen
atom, nitrogen atom or sulfur atom, such as HO-, (C -C )-alkyl-O- or (C -C )-alkyl-
1 4 1 4
S(O) -substituents, for example. An alkyl group which is optionally substituted by
one or more fluorine substituents can be unsubstituted, i.e. not carry fluorine
substituents, or substituted, for example by one, two, three, four, five, six, seven,
eight, nine, ten or eleven fluorine substituents, or by one, two, three, four, five, six or
seven fluorine substituents, or by one, two, three, four or five fluorine substituents,
or by one, two or three fluorine substituents, which can be located in any positions.
For example, in a fluoro-substituted alkyl group one or more methyl groups can
carry three fluorine substituents each and be present as trifluoromethyl groups,
and/or one or more methylene groups (CH ) can carry two fluorine substituents
each and be present as difluoromethylene groups. The explanations with respect to
the substitution of a group by fluorine also apply if the group additionally carries
other substituents and/or is part of another group, for example of an alkyl-O- group.
Examples of fluoro-substituted alkyl groups are trifluoromethyl, 2-fluoroethyl, 1-
fluoroethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3,3,3-
trifluoropropyl, 2,2,3,3,3-pentafluoropropyl, 4,4,4-trifluorobutyl and
heptafluoroisopropyl. Examples of fluoro-substituted alkyl-O- groups are
trifluoromethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy and 3,3,3-trifluoropropoxy.
Examples of fluoro-substituted alkyl-S(O) - groups are trifluoromethylsulfanyl-
(CF -S-), trifluoromethanesulfinyl- (CF -S(O)-) and trifluoromethanesulfonyl
(CF -S(O) -).
The above explanations with respect to alkyl groups apply correspondingly to
alkanediyl groups (divalent alkyl groups) including the divalent groups C H , C H ,
s 2s u 2u
(CH ) and (CH ) . Also the alkyl part of a substituted alkyl group may be regarded
2 x 2 y
as an alkanediyl group. Thus, alkanediyl groups can also be linear or branched, the
bonds to the adjacent groups can be located in any positions and can start from the
same carbon atom or from different carbon atoms, and they can be substituted by
fluorine substituents. Examples of alkanediyl groups including the groups C H and
s 2s
C H and, as far they constitute polymethylene chains, the groups (CH ) are -CH -,
u 2u 2 x 2
-CH -CH -, -CH -CH -CH -, -CH -CH -CH -CH -, -CH -CH -CH -CH -CH -,
2 2 2 2 2 2 2 2 2 2 2 2 2 2
-CH(CH )-, -C(CH ) -, -CH(CH )-CH -, -CH -CH(CH )-, -C(CH ) -CH -,
3 3 2 3 2 2 3 3 2 2
-CH -C(CH ) -. Examples of fluoro-substituted alkanediyl groups, which can contain
2 3 2
one, two, three, four, five or six fluorine substituents, or one, two, three or four
fluorine substituents, or one or two fluorine substituents, for example, are -CHF-,
-CF - -CF -CH -, -CH -CF -, -CF -CF -, -CF(CH )-, -C(CF ) -, -C(CH ) -CF -,
2 2 2 2 2 2 2 3 3 2 3 2 2
-CF -C(CH ) -.
2 3 2
The number of ring carbon atoms in a (C -C )-cycloalkyl group can be 3, 4, 5, 6 or 7.
Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and
cycloheptyl. As regards the optional substitution of cycloalkyl groups by one or more
(C -C )-alkyl substituents, they be unsubstituted, i.e. not carry alkyl substituents, or
substituted, for example by one, two, three or four, or by one or two, identical or
different (C -C )-alkyl substituents, for example by methyl groups, which
substituents can be located in any positions. Examples of such alkyl-substituted
cycloalkyl groups are 1-methylcyclopropyl, 2,2-dimethylcyclopropyl, 1-
methylcyclopentyl, 2,3-dimethylcyclopentyl, 1-methylcyclohexyl, 4-methylcyclohexyl,
4-isopropylcyclohexyl, 4-tert-butylcyclohexyl and 3,3,5,5-tetramethylcyclohexyl. As
regards the optional substitution of cycloalkyl groups by one or more fluorine
substituents, they can be unsubstituted, i.e. not carry fluorine substituents, or
substituted, for example by one, two, three, four, five, six, seven, eight, nine, ten or
eleven fluorine substituents, or by one, two, three, four, five or six fluorine
substituents, or by one, two, three or four fluorine substituents, or by one or two
fluorine substituents. The fluorine substituents can be located in any positions of the
cycloalkyl group and can also be located in an alkyl substituent on the cycloalkyl
group. Examples of fluoro-substituted cycloalkyl groups are 1-fluorocyclopropyl, 2,2-
difluorocyclopropyl, 3,3-difluorocyclobutyl, 1-fluorocyclohexyl, 4,4-difluorocyclohexyl
and 3,3,4,4,5,5-hexafluorocyclohexyl. Cycloalkyl groups can also be substituted
simultaneously by fluorine and alkyl. Examples of (C -C )-cycloalkyl-substituted alkyl
11 30
groups, which can represent R or R , for example, are cyclopropylmethyl-,
cyclobutylmethyl-, cyclopentylmethyl-, cyclohexylmethyl-, cycloheptylmethyl-, 1-
cyclopropylethyl-, 2-cyclopropylethyl-, 1-cyclobutylethyl-, 2-cyclobutylethyl-, 1-
cyclopentylethyl-, 2-cyclopentylethyl-, 1-cyclohexylethyl-, 2-cyclohexylethyl-, 1-
cycloheptylethyl-, 2-cycloheptylethyl-. The explanations with respect cycloalkyl
groups apply correspondingly to divalent cycloalkyl groups (cycloalkanediyl groups),
40
which can occur in case the two groups R and R together are (CH ) or the two
50 60
groups R and R together are (CH ) . Also the cycloalkyl part of a substituted
cycloalkyl group may be regarded as a cycloalkanediyl group. Thus, for example,
the bonds through which a cycloalkanediyl group is connected to the adjacent
groups, can be located in any positions and can start from the same ring carbon
40
atom, as in the case of the cycloalkanediyl group which is present if R and R
50 60
together are (CH ) or the two groups R and R together are (CH ) , or from
2 x 2 y
different ring carbon atoms.
In substituted phenyl groups the substituents can be located in any positions. In the
case a the divalent substituents -O-CH -O- (methylenedioxy) and -O-CF -O-
(difluoromethylenedioxy) which can be present on phenyl groups and aromatic
heterocycles, the two oxygen atoms are bonded to adjacent ring carbon atoms of
the phenyl group or the aromatic heterocycle and replace two hydrogen atoms of
the parent system. In monosubstituted phenyl groups, the substituent can be
located in the 2-position, the 3-position or the 4-position. In disubstituted phenyl
groups, the substituents can be located in 2,3-position, 2,4-position, 2,5-position,
2,6-position, 3,4-position or 3,5-position. In trisubstituted phenyl groups, the
substituents can be located in 2,3,4-position, 2,3,5-position, 2,3,6-position, 2,4,5-
position, 2,4,6-position or 3,4,5-position. If a phenyl group carries four substituents,
some of which can be fluorine atoms, for example, the substituents can be located
in 2,3,4,5-position, 2,3,4,6-position or 2,3,5,6-position. If a polysubstituted phenyl
group carries different substituents, each substituent can be located in any suitable
position, and the present invention comprises all positional isomers. The number of
substituents in an optionally substituted phenyl group can be one, two, three, four or
five. In one embodiment of the invention, an optionally substituted phenyl group,
independently of any other optionally substituted phenyl group in a compound of the
formula I, carries one, two, three or four, in another embodiment one, two or three,
in another embodiment one or two, in another embodiment one, identical or different
substituents, and in another embodiment it is unsubstituted.
Likewise, in substituted heterocyclic groups, including aromatic 5-membered and 6-
32 33
membered monocyclic heterocycles which can represent R , R and Ar, saturated
and unsaturated 4-membered to 8-membered monocyclic heterocycles which can
represent Het , and saturated 4-membered to 7-membered monocyclic heterocycles
which can represent Het and Het , the substituents can be located in any positions
and can be present on ring carbon atoms and/or on suitable ring nitrogen atoms.
The present invention comprises all positional isomers. The number of substituents
which can be present on substituted heterocycles in the compounds of the formula I,
depends on the ring size, the number and type of the ring heteroatoms and the
degree of unsaturation. In one embodiment of the invention, the number of identical
or different substituents on any of the heterocyclic groups in the compounds of the
formula I, independently of the number of substituents in any other occurrence of
this group and the number of substituents in any other heterocyclic group in the
compounds of the formula I, is one, two, three, four or five, in another embodiment
one, two, three or four, in another embodiment one, two or three, in another
embodiment one or two, in another embodiment one. Ring nitrogen atoms which
optionally carry a substituent, include ring nitrogen atoms in saturated heterocyclic
rings other than those via which such a ring is bonded, and the ring nitrogen atom in
-membered aromatic heterocycles such as pyrrole, imidazole or triazole, which in
the parent heterocycle carry a hydrogen atom. In one embodiment of the invention,
the substituents on any such ring nitrogen atoms in heterocyclic groups are chosen
from those of the substituents specified in the definition of the respective group
which are bonded via a carbon atom, for example from the series consisting of (C -
C )-alkyl, (C -C )-cycloalkyl and R , in another embodiment from the series
6 3 7
consisting of (C -C )-alkyl and (C -C )-cycloalkyl, in the case of the aromatic
1 6 3 7
heterocycle which can represent R , from the series consisting of (C -C )-alkyl and
(C -C )-cycloalkyl in the case of the aromatic heterocycle which can represent R ,
and are (C -C )-alkyl in the case of the aromatic heterocycle which can represent Ar
1 2 3
and (C -C )-alkyl in the case of Het , Het and Het . Generally, besides optionally
carrying the substituents indicated in the definition of the respective group, suitable
ring nitrogen atoms in heterocyclic groups in the compounds of the formula I, in
particular aromatic heterocyclic groups such as the heterocyclic groups which can
32 33
represent R , R and Ar, for example the ring nitrogen atom in a pyridinyl group,
can also carry an oxido substituent -O and be present as an N-oxide.
The ring heteroatoms specified in the definitions of heterocyclic groups in the
compounds of the formula I, including the aromatic 5-membered and 6-membered
32 33
monocyclic heterocycles which can represent R , R and Ar and the heterocycles
1 2 3 4
which represent Het , Het , Het and Het can generally be present in any
combination and located in any suitable ring positions, provided that the resulting
group and the compound of the formula I are sufficiently stable and suitable as a
pharmaceutical active compound, as mentioned above. In one embodiment of the
invention, two oxygen atoms in any heterocyclic ring in the compounds of the
formula I cannot be present in adjacent ring positions. In another embodiment, two
ring heteroatoms in any non-aromatic heterocyclic ring in the compounds of the
formula I cannot be present in adjacent ring positions. In another embodiment, two
ring heteroatoms chosen from the series consisting of N atoms which carry a
hydrogen atom or a substituent and are bonded to the adjacent ring atoms by single
bonds, O atoms and S atoms in a non-aromatic heterocycle cannot be present in
adjacent ring positions. In an aromatic heterocycle the choice of ring heteroatoms
and their positions is limited by the prerequisite that the ring is aromatic, i.e., it
comprises a cyclic system of six delocalized pi electrons. Thus, for example, in an
aromatic monocyclic 6-membered heterocycle only nitrogen atoms can occur as ring
heteroatoms, and in an aromatic monocyclic 5-membered heterocycle only one ring
heteroatom chosen from the series consisting of O atoms, S atoms and N atoms
carrying a hydrogen atom or a substituent, can be present. An unsaturated
heterocycle which can represent Het , can be aromatic, for example in the case of a
pyrrolyl, imidazolyl or triazolyl group which is bonded via a ring nitrogen atom and
can represent Het , or non-aromatic and comprise one or two double bonds within
the ring which can be present in any positions. In one embodiment, a 4-membered
heterocycle representing Het cannot be unsaturated. A heterocyclic group can be
bonded via any ring carbon atom or via any suitable ring nitrogen atom,
respectively, as indicated in the definition of the respective group. The group Het
can be 4-membered, 5-membered, 6-membered or 7-membered or 8-membered.
The groups Het and Het can be 4-membered, 5-membered, 6-membered or 7-
membered.
Examples of aromatic heterocycles, from any one or more of which the aromatic 5-
32 33
membered and 6-membered monocyclic heterocycles which can represent R , R
and Ar and, as far as applicable, the group Het are chosen in one embodiment of
the invention, are pyrrole, furan, thiophene, imidazole, pyrazole, oxazole
([1,3]oxazole), isoxazole ([1,2]oxazole), thiazole ([1,3]thiazole), isothiazole
([1,2]thiazole), [1,2,3]triazole, [1,2,4]triazole, [1,3,4]oxadiazole, pyridine, pyridazine,
pyrimidine and pyrazine, which can all be bonded via any ring carbon atom or via
any suitable ring nitrogen atom, and which all are optionally substituted as indicated
with respect to the compounds of formula I in general or in any embodiment
specified above or below. Examples of specific residues of aromatic heterocycles,
from any one or more of which the aromatic, 5-membered or 6-membered
32 33
monocyclic heterocyclic residue which can represent R , R or Ar and, as far as
applicable, the group Het , are chosen in one embodiment of the invention, are
pyrrolyl, pyrrolyl, pyrrolyl, furanyl, furanyl, thiophenyl (2-thienyl),
thiophenyl (3-thienyl), imidazolyl, imidazolyl, imidazolyl, imidazolyl,
pyrazolyl, pyrazolyl, pyrazolyl, pyrazolyl, oxazolyl, oxazolyl, oxazol-
5-yl, isoxazolyl, isoxazolyl, isoxazolyl, thiazolyl, thiazolyl, thiazolyl,
isothiazolyl, isothiazolyl, isothiazolyl, [1,2,3]triazolyl, [1,2,3]triazolyl,
[1,2,3]triazolyl, [1,2,4]triazolyl, [1,2,4]triazolyl, [1,2,4]triazolyl,
[1,3,4]oxadiazolyl, pyridinyl (2-pyridyl), pyridinyl (3-pyridyl), pyridinyl (4-
pyridyl), pyridazinyl, pyridazinyl, pyrimidinyl, pyrimidinyl, and pyrazinyl,
which all are optionally substituted as indicated with respect to the compounds of
formula I in general or in any embodiment specified above or below.
Examples of saturated heterocycles and non-aromatic unsaturated heterocycles,
1 2 3 4
from any one or more of which the groups Het , Het , Het and Het are
independently of each other chosen in one embodiment of the invention, as far as
applicable with regard to the ring size and the degree of saturation, are azetidine,
oxetane, thietane, pyrrolidine, 2,5-dihydro-1H-pyrrole, tetrahydrofuran,
tetrahydrothiophene, pyrazolidine, imidazolidine, 4,5-dihydro-1H-imidazole,
[1,3]dioxolane, oxazolidine, thiazolidine, piperidine, 1,2,3,6-tetrahydropyridine,
tetrahydropyran, tetrahydrothiopyran, piperazine, [1,3]dioxane, [1,4]dioxane,
morpholine, thiomorpholine, azepane, oxepane, thiepane, [1,3]diazepane,
[1,4]diazepane, [1,4]oxazepane, [1,4]thiazepane and azocane, which all are
optionally substituted as indicated with respect to the compounds of formula I in
general or in any embodiment specified above or below. Examples of specific
residues of saturated and non-aromatic unsaturated heterocycles, from any one or
1 2 3 4
more of which the groups Het , Het , Het and Het are independently of each other
chosen in one embodiment of the invention, as far as applicable with regard to the
ring size, the degree of saturation and the kind of the atom via which the residue is
bonded are azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolidinyl,
pyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, tetrahydrofuranyl, tetrahydrofuranyl,
tetrahydrothiophenyl, tetrahydrothiophenyl, pyrazolidinyl, pyrazolidinyl,
imidazolidinyl, imidazolidinyl, imidazolidinyl, 4,5-dihydro-1H-imidazolyl,
1,3-dioxolanyl, 1,3-dioxolanyl, oxazolidinyl, oxazolidinyl, oxazolidinyl,
oxazolidinyl, thiazolidinyl, thiazolidinyl, thiazolidinyl, thiazolidinyl,
piperidinyl, piperidinyl, piperidinyl, piperidinyl, 1,2,3,6-tetrahydropyridin
yl, tetrahydropyranyl, tetrahydropyranyl, tetrahydropyranyl,
tetrahydrothiopyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl,
piperazinyl, piperazinyl, [1,3]dioxanyl, [1,3]dioxanyl, [1,3]dioxanyl,
[1,4]dioxanyl, morpholinyl, morpholinyl, morpholinyl, thiomorpholinyl,
thiomorpholinyl, thiomorpholinyl, azepanyl, azepanyl, azepanyl,
azepanyl, oxepanyl, oxepanyl, oxepanyl, [1,3]diazepanyl,
[1,4]diazepanyl, [1,4]oxazepanyl and [1,4]thiazepanyl, which all are
optionally substituted as indicated with respect to the compounds of formula I in
general or in any embodiment specified above or below.
Halogen is fluorine, chlorine, bromine or iodine. In one embodiment of the invention,
halogen in any occurrence in the compounds of the formula I, independently of all
other occurrences, is fluorine, chlorine or bromine, in another embodiment fluorine
or chlorine, in another embodiment fluorine.
An oxo substituent, i.e. an oxygen atom which is bonded via a double bond, when
bonded to a carbon atom, replaces two hydrogen atoms on the carbon atom of the
parent system to which it is bonded. Thus, if a CH group is substituted by oxo, it
becomes a carbonyl group (C(O), C=O). An oxo substituent cannot be present on a
carbon atom in an aromatic ring. Besides on carbon atoms, oxo substituents can
also be present on a ring sulfur atom in the group Het , in particular if the group Het
is saturated, and in the group Het , to give the ring member S(O) (S=O, i.e. a
sulfoxide group), if one oxo substituent is present on the sulfur atom, or the ring
member S(O) (S(=O) , i.e. a sulfone group), if two oxo substituents are present on
the sulfur atom. As examples of heterocycles which can represent Het and Het
and which carry oxo substituent a ring sulfur atom, 1,1-dioxo-tetrahydrothiophene,
1-oxo-thiomorpholine and 1,1-dioxo-thiomorpholine may be mentioned, which all are
optionally substituted by further substituents such as (C -C )-alkyl substituents as
indicated with respect to the compounds of formula I in general or in any
embodiment specified above or below.
The present invention comprises all stereoisomeric forms of the compounds of the
formula I, for example all enantiomers and diastereomers including cis/trans
isomers. The invention likewise comprises mixtures of two or more stereoisomeric
forms, for example mixtures of enantiomers and/or diastereomers including cis/trans
isomers, in all ratios. Asymmetric centers contained in the compounds of the
formula I, for example in unsubstituted or substituted alkyl groups, can all
independently of each other have the S configuration or the R configuration. The
invention relates to enantiomers, both the levorotatory and the dextrorotatory
antipode, in enantiomerically pure form and essentially enantiomerically pure form,
for example with a molar ratio of the two enantiomers of 99 : 1 or greater, and in the
form of racemates and in the form of mixtures of the two enantiomers in all ratios.
The invention likewise relates to diastereomers in the form of pure and essentially
pure diastereomers and in the form of mixtures of two or more diastereomers in all
ratios. The invention also comprises all cis/trans isomers of the compounds of the
formula I in pure form and essentially pure form, for example with a molar ratio of
the cis/trans isomers of 99 : 1 or greater, and in the form of mixtures of the cis
isomer and the trans isomer in all ratios. Cis/trans isomerism can occur in
substituted rings. The preparation of individual stereoisomers, if desired, can be
carried out by resolution of a mixture according to customary methods, for example,
by chromatography or crystallization, or by use of stereochemically uniform starting
compounds in the synthesis or by stereoselective reactions. Optionally, before a
separation of stereoisomers a derivatization can be carried out. The separation of a
mixture of stereoisomers can be carried out at the stage of the compound of the
formula I or at the stage of an intermediate in the course of the synthesis. The
invention also comprises all tautomeric forms of the compounds of the formula I.
Physiologically acceptable salts, including pharmaceutically utilizable salts, of the
compounds of the formula I generally comprise a nontoxic salt component. They
can contain inorganic or organic salt components. Such salts can be formed, for
example, from compounds of the formula I which contain an acidic group, for
example a carboxylic acid group (hydroxycarbonyl group, HO-C(O)-), and nontoxic
inorganic or organic bases. Suitable bases are, for example, alkali metal
compounds or alkaline earth metal compounds, such as sodium hydroxide,
potassium hydroxide, sodium carbonate or sodium hydrogencarbonate, or
ammonia, organic amino compounds and quaternary ammonium hydroxides.
Reactions of compounds of the formula I with bases for the preparation of the salts
are in general carried out according to customary procedures in a solvent or diluent.
Examples of salts of acidic groups thus are sodium, potassium, magnesium or
calcium salts or ammonium salts which can also carry one or more organic groups
on the nitrogen atom. Compounds of the formula I which contain a basic, i.e.
protonatable, group, for example an amino group or a basic heterocycle, can be
present in the form of their acid addition salts with physiologically acceptable acids,
for example as salt with hydrogen chloride, hydrogen bromide, phosphoric acid,
sulfuric acid, acetic acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid,
which in general can be prepared from the compounds of the formula I by reaction
with an acid in a solvent or diluent according to customary procedures. If the
compounds of the formula I simultaneously contain an acidic and a basic group in
the molecule, the invention also includes internal salts (betaines, zwitterions) in
addition to the salt forms mentioned. The present invention also comprises all salts
of the compounds of the formula I which, because of low physiological tolerability,
are not directly suitable for use as a pharmaceutical, but are suitable as
intermediates for chemical reactions or for the preparation of physiologically
acceptable salts, for example by means of anion exchange or cation exchange. The
present invention also comprises all solvates of the compounds of the formula I and
their salts, including physiologically acceptable solvates, such as hydrates, i.e.
adducts with water, and adducts with alcohols like (C -C )-alkanols.
In one embodiment of the invention, the group A is C(R ), in another embodiment A
is N, in one embodiment of the invention, the group D is chosen from the series
), in one
consisting of N, in another embodiment from the series consisting of C(R
embodiment of the invention, the group E is chosen from the series consisting of N,
in another embodiment from the series consisting of C(R ), in one embodiment of
the invention, the group L is chosen from the series consisting of N, in another
embodiment from the series consisting of C(R ), with the proviso that one or two of
the groups A, D, E, L is N.
In another embodiment of the invention, the group A is N and the groups D, E and L
2 3 4
are C(R ), C(R ) and C(R ).
In another embodiment of the invention, the group D is N and the groups A, E and L
1 3 4
are C(R ), C(R ) and C(R ).
In another embodiment of the invention, the group E is N and the groups A, D and L
1 2 4
are C(R ), C(R ) and C(R ).
In another embodiment of the invention, the group L is N and the groups A, D and E
1 2 3
are C(R ), C(R ) and C(R ).
In another embodiment of the invention, the groups A and D are N and the groups E
and L are C(R ) and C(R ).
In another embodiment of the invention, the group A and E is N and the groups D
and L are C(R ) and C(R ).
In another embodiment of the invention, the group A and L is N and the groups D
and E are C(R ) and C(R ).
In another embodiment of the invention, the group D and E is N and the groups A
and L are C(R ) and C(R ).
In another embodiment of the invention, the group D and L is N and the groups A
and E are C(R ) and C(R ).
In another embodiment of the invention, the group E and L is N and the groups A
and D are C(R ) and C(R ).
In terms of formulae resulting from formula I by incorporation of meanings of A, D, E
or L, in one embodiment of the invention a compound of the formula I is a
compound of any one or more of formulae I-1 to I-7, for example a compound of
formula I-1, or a compound of formula I-2, or a compound of formula I-3, or a
compound of formula I-4, or a compound of formula I-5, or a compound of formula I-
6, or a compound of formula I-7 in any of its stereoisomeric forms or a mixture of
stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a
physiologically acceptable solvate of any of them, wherein in the compounds of
1 2 3 10 30 40 50 60
formulae I-1 to I-7 the groups A, D, E, G, R , R , R , R , R , R , R and R are
defined as in the compounds of formula I in general or in any embodiment specified
above or below.
R10 R4
R 30
40 O
R10 R
N 60
R2 R1
I-1 I-2
30
R10 R10
40 40
60 60
50 50
R2 R2
I-4 I-5
R10 40
60 50
R3 H R
R1 R2
I-6 I-7
In one embodiment of the invention, the group G is chosen from the series
71 72 73
consisting of R -O-C(O)-, R -N(R )-C(O)- and tetrazolyl, in another
71 72 73
embodiment from the series consisting of R -O-C(O)- and R -N(R )-C(O)-, in
71 72 73
another embodiment G is R -O-C(O)-, and in another embodiment G is R -N(R )-
C(O)-.
In one embodiment of the invention, the group R is chosen from the series
consisting of hydrogen, halogen, (C -C )-alkyl, HO-, (C -C )-alkyl-O-, and NC-, in
1 6 1 6
another embodiment from the series consisting of hydrogen, halogen, (C -C )-alkyl,
(C -C )-alkyl-O- and NC-, in another embodiment from the series consisting of
hydrogen, halogen, (C -C )-alkyl and NC-, in another embodiment from the series
consisting of hydrogen, halogen, (C -C )-alkyl, HO- and (C -C )-alkyl-O-, in another
1 6 1 6
embodiment from the series consisting of hydrogen, halogen, (C -C )-alkyl and (C -
1 6 1
C )-alkyl-O-, in another embodiment from the series consisting of hydrogen, halogen
and (C -C )-alkyl, in another embodiment from the series consisting of hydrogen
and halogen, in another embodiment from the series consisting of hydrogen, fluorine
and chlorine, and in another embodiment R is hydrogen. In one embodiment of the
invention, a (C -C )-alkyl group occurring in R is a (C -C )-alkyl group, in another
1 6 1 4
embodiment a (C -C )-alkyl group, in another embodiment it is methyl.
In one embodiment of the invention, the group R is chosen from the series
consisting of (C -C )-alkyl and (C -C )-cycloalkyl-C H -, in another embodiment
1 7 3 7 s 2s
from the series consisting of (C -C )-cycloalkyl-C H - and Ar-C H -, in another
3 7 s 2s s 2s
embodiment R is (C -C )-alkyl, in another embodiment R is (C -C )-cycloalkyl-
1 7 3 7
C H -, and in another embodiment R is Ar-C H -. In one embodiment, s is an
s 2s s 2s
integer chosen from the series consisting of 0, 1 and 2, in another embodiment from
the series consisting of 0 and 1, in another embodiment from the series consisting of
1 and 2, in another embodiment s is 0, and in another embodiment s is 1. In one
embodiment of the invention, R is Ar-C H - and s is 0, i.e., R is the group Ar and
s 2s
the group D thus is the group N(Ar). In one embodiment, the divalent alkanediyl
group C H is a linear group. In one embodiment, a (C -C )-alkyl group
s 2s 1 7
representing R is a (C -C )-alkyl group, in another embodiment a (C -C )-alkyl
3 7 3 6
group. In one embodiment, a (C -C )-cycloalkyl group occurring in R is a (C -C )-
3 7 3 6
cycloalkyl group, in another embodiment a (C -C )-cycloalkyl group, in another
embodiment a cyclopropyl group. In one embodiment, a group Ar occurring in R is
chosen from the series consisting of phenyl and an aromatic 5-membered or 6-
membered heterocycle which comprises one or two identical or different ring
heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which
is bonded via a ring carbon atom, in another embodiment from the series consisting
of phenyl and an aromatic 6-membered heterocycle which comprises one or two
nitrogen atoms as ring heteroatoms, in another embodiment from the series
consisting of phenyl, thiophenyl, pyridinyl and pyrimidinyl, in another embodiment
from the series consisting of phenyl and thiophenyl, in another embodiment from the
series consisting of phenyl, pyridinyl and pyrimidinyl, in another embodiment from
the series consisting of phenyl and pyridinyl, and in another embodiment a group Ar
occurring in R is phenyl, which groups all are optionally substituted as indicated
with respect to the compounds of formula I in general or in any embodiment
specified above or below. In one embodiment, a group Ar occurring in R is
optionally substituted by one, two or three identical or different substituents, in
another embodiment it is optionally substituted by one or two identical or different
substituents, in another embodiment it is optionally substituted by one substituent, in
another embodiment it is substituted by one, two or three identical or different
substituents, in another embodiment it is substituted by one or two identical or
different substituents, and in another embodiment it is substituted by one
substituent. In one embodiment, the substituents which are optionally present on a
group Ar occurring in R , are chosen from the series consisting of halogen, (C -C )-
alkyl, (C -C )-alkyl-O-, (C -C )-alkyl-S(O) - and NC-, in another embodiment from
1 6 1 6 m
the series consisting of halogen, (C -C )-alkyl, (C -C )-alkyl-O- and (C -C )-alkyl-
1 6 1 6 1 6
S(O) -, in another embodiment from the series consisting of halogen, (C -C )-alkyl
m 1 6
and (C -C )-alkyl-S(O) -, in another embodiment from the series consisting of
1 6 m
halogen and (C -C )-alkyl, in another embodiment from the series consisting of
halogen, in another embodiment from the series consisting of fluorine and chlorine,
in another embodiment from the series consisting of fluorine, chlorine and methyl. In
one embodiment of the invention, a (C -C )-alkyl group occurring in R is a (C -C )-
1 6 1 4
alkyl group, in another embodiment a (C -C )-alkyl group, in another embodiment it
is methyl.
Examples of groups Ar which can occur in R , and from any one or more of which a
group Ar occurring in R is chosen in one embodiment of the invention, are phenyl,
2-fluoro-phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 2-chloro-phenyl, 3-chloro-phenyl,
4-chloro-phenyl, 3-bromo-phenyl, 4-bromo-phenyl, 2,3-dichloro-phenyl, 2,4-dichloro-
phenyl, 2,5-dichloro-phenyl, 2,6-dichloro-phenyl, 3,4-dichloro-phenyl, 2,3-difluoro-
phenyl, 2,4-difluoro-phenyl, 2,5-difluoro-phenyl, 2,6-difluoro-phenyl, 3,4-difluoro-
phenyl, 2-chlorofluoro-phenyl, 3,4,5-trifluoro-phenyl, 2-methyl-phenyl (o-tolyl), 3-
methyl-phenyl (m-tolyl), 4-methyl-phenyl (p-tolyl), 2,3-dimethyl-phenyl, 2,4-dimethyl-
phenyl, 2,5-dimethyl-phenyl, 2,6-dimethyl-phenyl, 3,4-dimethyl-phenyl, 2-ethyl-
phenyl, 3-ethyl-phenyl, 4-ethyl-phenyl, 3-isopropyl-phenyl, 3-tert-butyl-phenyl, 4-tert-
butyl-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 2-fluoromethyl-
phenyl, 3-chloromethyl-phenyl, 5-chloromethyl-phenyl, 5-chlorofluoro
methyl-phenyl, 2-fluorotrifluoromethyl-phenyl, 2-fluorotrifluoromethyl-phenyl, 4-
fluorotrifluoromethyl-phenyl, 5-fluorotrifluoromethyl-phenyl, 3-chloro
trifluoromethyl-phenyl, 5-chlorotrifluoromethyl-phenyl, 5-chlorotrifluoromethyl-
phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3-ethoxy-phenyl,
3-propoxy-phenyl, 3-isopropoxy-phenyl, 4-tert-butoxy-phenyl, 3-trifluoromethoxy-
phenyl, 4-trifluoromethoxy-phenyl, 3-(2,2,2-trifluoroethoxy)-phenyl, 5-chloro
methoxy-phenyl, 3-chloromethoxy-phenyl, 5-fluoroisopropoxy-phenyl, 2-fluoro-
3-trifluoromethoxy-phenyl, 4-methoxy-3,5-dimethyl-phenyl, 3-methoxy
trifluoromethyl-phenyl, 2,3-methylenedioxy-phenyl, 2,3-difluoromethylenedioxy-
phenyl, 3,4-methylenedioxy-phenyl, 3,4-difluoromethylenedioxy-phenyl, 3-
methylsulfanyl-phenyl, 3-ethylsulfanyl-phenyl, 3-trifluoromethylsulfanyl-phenyl, 3-
methanesulfonyl-phenyl, 3-ethanesulfonyl-phenyl, 3-sulfamoyl-phenyl, 2-cyano-
phenyl, 3-cyano-phenyl, 4-cyano-phenyl, thiophenyl, thiophenyl, 3-chloro-
thiophenyl, 4-chloro-thiophenyl, 5-chloro-thiophenyl, 4,5-dichloro-thiophen-
2-yl, 5-chloro-thiophenyl, 2,5-dichloro-thiophenyl, 4-methyl-thiophenyl, 5-
methyl-thiophenyl, 4,5-dimethyl-thiophenyl, pyridinyl, pyridinyl, pyridin
yl, 2-chloro-pyridinyl, 5-chloro-pyridinyl, 6-chloro-pyridinyl, 2-chloro-pyridin-
4-yl, 2,6-dichloro-pyridinyl, 6-methoxy-pyridinyl, 2-chloromethoxy-pyridin
In one embodiment of the invention, the group R is chosen from the series
consisting of hydrogen, halogen, (C -C )-alkyl, (C -C )-alkyl-O-, and NC-, in another
1 6 1 6
embodiment from the series consisting of hydrogen, halogen, (C -C )-alkyl and NC-,
in another embodiment from the series consisting of hydrogen, halogen, (C -C )-
alkyl and (C -C )-alkyl-O-, in another embodiment from the series consisting of
hydrogen, halogen and (C -C )-alkyl, in another embodiment from the series
consisting of hydrogen and halogen, in another embodiment from the series
consisting of hydrogen and (C -C )-alkyl, in another embodiment from the series
consisting of hydrogen, fluorine and chlorine, in another embodiment R is
hydrogen, and in another embodiment R is (C -C )-alkyl. In one embodiment of the
invention, a (C -C )-alkyl group occurring in R is a (C -C )-alkyl group, in another
1 6 1 4
embodiment a (C -C )-alkyl group, in another embodiment it is methyl.
In one embodiment of the invention, the group R is chosen from the series
11 12 13
consisting of R -O- and R -N(R )-C(O)-O-, in another embodiment from the series
12 13 2 10
consisting of R -N(R )-C(O)-O- and Het -C(O)-O-, and in another embodiment R
is R -O-.
2 2 3 4 10
In one embodiment, the group Het which can occur in the group R , R , R or R ,
is a saturated 4-membered to 6-membered, in another embodiment a 5-membered
or 6-membered, in another embodiment a 5-membered, monocyclic heterocycle
which, besides the ring nitrogen via which Het is bonded, optionally comprises one
further ring heteroatom chosen from the series nitrogen, oxygen and sulfur. In one
2 2 3 4 10
embodiment, the group Het which can occur in the group R , R , R or R , does
not comprise a further ring heteroatom besides the ring nitrogen atom via which
2 2 2
Het is bonded. In one embodiment, the group Het which can occur in the group R ,
3 4 10
R , R or R is selected from the series pyrrolidine, piperidine and morpholine.
In one embodiment, the number of substituents which are optionally present on a
2 2 3 4 10
group Het which can occur in group R , R , R or R , is one, two, three or four, in
another embodiment one, two or three, in another embodiment one or two, in
another embodiment one, and in another embodiment such a group Het is
unsubstituted. In one embodiment, the substituents which are optionally present on
2 2 3 4 10
a group Het which can occur in the group R , R , R or R , are chosen from the
series consisting of fluorine, (C -C )-alkyl, HO- and (C -C )-alkyl-O-, in another
1 4 1 4
embodiment from the series consisting of (C -C )-alkyl, HO- and (C -C )-alkyl-O-, in
1 4 1 4
another embodiment from the series consisting of (C -C )-alkyl and HO- and (C -
1 4 1
C )-alkyl-O-, in another embodiment they are (C -C )-alkyl substituents, and in
4 1 4
another embodiment they are HO- substituents.
In one embodiment of the invention, the group R is chosen from the series
14 3
consisting of hydrogen, R , (C -C )-cycloalkyl and Het , in another embodiment
from the series consisting of hydrogen and R , in another embodiment from the
series consisting of hydrogen, R and (C -C )-cycloalkyl, in another embodiment
from the series consisting of (C -C )-cycloalkyl, Ar and Het , in another embodiment
3 11
from the series consisting of (C -C )-cycloalkyl and Het , in another embodiment R
11 14 11
is hydrogen, in another embodiment R is R , and in another embodiment R is
Ar. In one embodiment, a group Ar representing R is phenyl which is optionally
substituted as indicated with respect to the compounds of formula I in general or in
any embodiment specified above or below. In one embodiment, a group Ar
representing R is optionally substituted by one, two or three identical or different
substituents, in another embodiment it is optionally substituted by one or two
identical or different substituents, in another embodiment it is optionally substituted
by one substituent. In one embodiment, the substituents which are optionally
present on a group Ar representing R , are chosen from the series consisting of
halogen, (C -C )-alkyl, (C -C )-alkyl-O- and NC-, in another embodiment from the
1 4 1 4
series consisting of halogen, (C -C )-alkyl and (C -C )-alkyl-O-, in another
1 4 1 4
embodiment from the series consisting of halogen and (C -C )-alkyl. In one
embodiment, a (C -C )-cycloalkyl group representing R is a (C -C )-cycloalkyl
3 7 3 6
3 11
group. In one embodiment, a group Het representing R is a saturated 4-
membered to 6-membered monocyclic heterocycle which comprises one or two
identical or different ring heteroatoms, in another embodiment one ring heteroatom,
which are chosen from the series consisting of nitrogen, oxygen and sulfur, in
another embodiment it comprises one ring heteroatom chosen from the series
consisting of nitrogen and oxygen, in another embodiment one ring heteroatom
chosen from the series consisting of oxygen and sulfur, and in another embodiment
it comprises one oxygen atom as ring heteroatom, wherein the heterocycle is
bonded via a ring carbon atom and is optionally substituted by one, two, three or
four, in another embodiment by one or two, identical or different substituents chosen
from the series consisting of fluorine, (C -C )-alkyl and oxo, in another embodiment
from the series consisting of fluorine and (C -C )-alkyl.
12 13
In one embodiment of the invention, the groups R and R are independently of
each other chosen from the series consisting of hydrogen and R , in another
embodiment from the series consisting of R and Ar, and in another embodiment
12
they are identical or different groups R . In one embodiment, one of the groups R
13 15
and R is chosen from the series consisting of R and Ar, and the other is a group
12 13
R . In one embodiment, a group Ar representing R or R is phenyl which is
optionally substituted by one or two, in another embodiment by one, identical or
different substituents chosen from the series consisting of halogen and (C -C )-alkyl,
and in another embodiment it is unsubstituted phenyl.
In one embodiment of the invention, the (C -C )-alkyl group representing the group
1 10
R is a (C -C )-alkyl group, in another embodiment a (C -C )-alkyl group, in another
1 8 1 7
embodiment a (C -C )-alkyl group, in another embodiment a (C -C )-alkyl group, in
1 4 1 3
another embodiment a (C -C )-alkyl group, in another embodiment a methyl group,
in another embodiment a (C -C )-alkyl group, in another embodiment a (C -C )-alkyl
4 8 4 7
group, in another embodiment a (C -C )-alkyl group, in another embodiment a C -
7 6
alkyl group, wherein all these alkyl groups are linear or branched as applies to alkyl
groups in the compounds of the formula I in general, and are optionally substituted
by one or more identical or different substituents as indicated with respect to the
compounds of formula I in general or in any embodiment specified above or below.
In one embodiment of the invention, the number of optional substituents in an alkyl
group representing R is one, two, three or four, in another embodiment one, two or
three, in another embodiment one or two, in another embodiment one. In one
embodiment, an alkyl group representing R is unsubstituted, and in another
embodiment it is substituted by one, two, three or four, in another embodiment by
one, two or three, in another embodiment by one or two, in another embodiment by
one substituent as indicated.
In one embodiment, a (C -C )-cycloalkyl group occurring as a substituent on an alkyl
group representing R is a (C -C )-cycloalkyl group, in another embodiment it is a
cyclopropyl group. In one embodiment, a group Ar occurring as a substituent on an
alkyl group representing R is phenyl or an aromatic 5-membered or 6-membered
monocyclic heterocycle which comprises one or two identical or different ring
heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, and
in another embodiment comprises one nitrogen atom as ring heteroatom and in the
case of a 5-membered heterocycle one additional ring heteroatom chosen from the
series consisting of nitrogen, oxygen and sulfur, and in another embodiment a group
Ar occurring as a substituent in an alkyl group representing R is chosen from
phenyl, pyrazolyl, isoxazolyl and thiazolyl, wherein all these groups Ar are optionally
substituted by one or more identical or different substituents as indicated with
respect to the compounds of formula I in general or in any embodiment specified
above or below. In one embodiment, the number of optional substituents on a group
Ar occurring as a substituent in an alkyl group representing R is one, two or three,
in another embodiment one or two, in another embodiment one. In one embodiment,
the substituents which are optionally present on a group Ar occurring as a
substituent in an alkyl group representing R , are chosen from the series consisting
of halogen, (C -C )-alkyl, (C -C )-alkyl-O- and NC-, in another embodiment from the
1 4 1 4
series consisting of halogen, (C -C )-alkyl and (C -C )-alkyl-O-, in another
1 4 1 4
embodiment from the series consisting of halogen and (C -C )-alkyl, and in another
embodiment they are (C -C )-alkyl groups.
In one embodiment, a group Het occurring as a substituent on an alkyl group
representing R is a saturated or unsaturated 4-membered to 6-membered
heterocycle, in another embodiment a 5-membered or 6-membered heterocycle,
which comprises a ring nitrogen atom via which Het is bonded and optionally one
further ring heteroatom chosen from the series consisting of nitrogen, oxygen and
sulfur, which is optionally substituted as indicated with respect to the compounds of
formula I in general or in any embodiment specified above or below. In one
embodiment, a group Het occurring as a substituent on an alkyl group representing
R does not comprise any further ring heteroatom besides the ring nitrogen atom
via which Het is bonded. In one embodiment, a group Het occurring as a
substituent on an alkyl group representing R is saturated, in another embodiment it
is unsaturated. In one embodiment, the number of substituents which are optionally
present on a group Het occurring as a substituent on an alkyl group representing
R is one, two, three or four, in another embodiment one, two or three, in another
embodiment one or two, in another embodiment one. In one embodiment, the
substituents which are optionally present on a group Het occurring as a substituent
on an alkyl group representing R are chosen from the series consisting of halogen,
(C -C )-alkyl, HO-, (C -C )-alkyl-O- and oxo, in another embodiment from the series
1 4 1 4
consisting of fluorine, (C -C )-alkyl, HO- and oxo, in another embodiment from the
series consisting of fluorine, (C -C )-alkyl and oxo, in another embodiment from the
series consisting of (C -C )-alkyl and oxo, and in another embodiment they are oxo
substituents. In one embodiment, the number of oxo substituents which are
occurring as a substituent on an alkyl group
optionally present on a group Het
representing R , is not greater than two, and in another embodiment it is not
greater than one.
In one embodiment, a group Het occurring in the substituent Het -C(O)- on an alkyl
group representing R is a 4-membered to 6-membered heterocycle, in another
embodiment a 5-membered or 6-membered heterocycle, which is saturated or
unsaturated and comprises a ring nitrogen atom via which Het is bonded and
optionally one further ring heteroatom chosen from the series consisting of nitrogen,
oxygen and sulfur, and which is optionally substituted as indicated with respect to
the compounds of formula I in general or in any embodiment specified above or
below. In one embodiment, a group Het occurring in the substituent Het -C(O)- on
an alkyl group representing R does not comprise any further ring heteroatom
besides the ring nitrogen atom via which Het is bonded. In one embodiment, a
group Het occurring in the substituent Het -C(O)- on an alkyl group representing
R is saturated or comprises one double bond within the ring, and in another
embodiment it is saturated. In one embodiment, the number of substituents which
are optionally present on a group Het occurring in the substituent Het -C(O)- on an
alkyl group representing R is one, two, three or four, in another embodiment one,
two or three, in another embodiment one or two, in another embodiment one. In one
embodiment, the substituents which are optionally present on a group Het
1 14
occurring in the substituent Het -C(O)- on an alkyl group representing R are
chosen from the series consisting of halogen, (C -C )-alkyl, HO-, (C -C )-alkyl-O-
1 4 1 4
and oxo, in another embodiment from the series consisting of fluorine, (C -C )-alkyl,
HO- and oxo, in another embodiment from the series consisting of fluorine, (C -C )-
alkyl and oxo, in another embodiment from (C -C )-alkyl and oxo, in another
embodiment they are oxo substituents, and in another embodiment they are (C -C )-
alkyl substituents. In one embodiment, the number of oxo substituents which are
optionally present on a group Het occurring in the substituent Het -C(O)- on an
alkyl group representing R , is not greater than two, and in another embodiment it
is not greater than one, and in another embodiment no oxo substituents are present
on such a group Het .
In one embodiment, a group Het occurring as a substituent on an alkyl group
representing R is a saturated 4-membered to 6-membered monocyclic heterocycle
which comprises one or two identical or different ring heteroatoms, and in another
embodiment comprises one ring heteroatom, which are chosen from the series
consisting of nitrogen, oxygen and sulfur, and is bonded via a ring carbon atom and
is optionally substituted as indicated with respect to the compounds of formula I in
general or in any embodiment specified above or below. In one embodiment, the
ring heteroatoms in a group Het occurring as a substituent on an alkyl group
representing R are chosen from the series consisting of nitrogen and oxygen, in
another embodiment from the series consisting of oxygen and sulfur, in another
embodiment they are nitrogen atoms, and in another embodiment they are oxygen
atoms. In one embodiment, the number of substituents which are optionally present
3 14
on a group Het occurring as a substituent on an alkyl group representing R is
one, two, three or four, in another embodiment one, two or three, in another
embodiment one or two, in another embodiment one. In one embodiment, the
substituents which are optionally present on a group Het occurring as a substituent
on an alkyl group representing R are chosen from the series consisting of fluorine
and (C -C )-alkyl, in another embodiment from the series consisting of (C -C )-alkyl
1 4 1 4
and oxo, in another embodiment they are (C -C )-alkyl substituents, and in another
embodiment they are oxo substituents. In one embodiment, the number of oxo
substituents which are optionally present on a group Het occurring as a substituent
on an alkyl group representing R , is not greater than two, and in another
embodiment it is not greater than one.
In one embodiment, the substituents which are optionally present on an alkyl group
14 16
representing R are chosen from the series consisting of halogen, HO-, R -O-,
oxo, (C -C )-cycloalkyl, Ar, Het , Het , H N-C(O)-, (C -C )-alkyl-NH-C(O)-, di((C -
3 7 2 1 4 1
C )-alkyl)N-C(O)- and Het -C(O)-, in another embodiment from the series consisting
16 1 3
of halogen, HO-, R -O-, oxo, (C -C )-cycloalkyl, Het , Het , H N-C(O)-, (C -C )-
3 7 2 1 4
alkyl-NH-C(O)-, di((C -C )-alkyl)N-C(O)- and Het -C(O)-, in another embodiment
16 1
from the series consisting of halogen, HO-, R -O-, oxo, (C -C )-cycloalkyl, Het ,
Het , di((C -C )-alkyl)N-C(O)- and Het -C(O)-, in another embodiment from the
16 1 3
series consisting of halogen, HO-, R -O-, oxo, (C -C )-cycloalkyl, Het and Het , in
another embodiment from the series consisting of halogen, HO-, R -O-, oxo, (C -
C )-cycloalkyl, Ar, Het and Het , in another embodiment from the series consisting
16 1 1
of HO-, R -O-, oxo, (C -C )-cycloalkyl, Ar, Het , di((C -C )-alkyl)N-C(O)- and Het -
3 7 1 4
C(O)-, in another embodiment from the series consisting of HO-, R -O-, oxo, (C -
C )-cycloalkyl, Ar, di((C -C )-alkyl)N-C(O)- and Het -C(O)-, in another embodiment
7 1 4
from the series consisting of HO-, R -O-, oxo, (C -C )-cycloalkyl and Ar, in another
embodiment from the series consisting of HO-, R -O-, oxo, (C -C )-cycloalkyl,
di((C -C )-alkyl)N-C(O)- and Het -C(O)-, in another embodiment from the series
16 1 3
consisting of HO-, R -O-, oxo, (C -C )-cycloalkyl, Het and Het , in another
embodiment from the series consisting of HO-, R -O-, oxo, (C -C )-cycloalkyl and
Het , in another embodiment from the series consisting of HO-, oxo, (C -C )-
cycloalkyl and Het , in another embodiment from the series consisting of HO-, oxo
and (C -C )-cycloalkyl, in another embodiment from the series consisting of HO-,
oxo and Het , in another embodiment from the series consisting of HO- and oxo, in
another embodiment from the series consisting of HO-, R -O-, (C -C )-cycloalkyl
and Het , in another embodiment from the series consisting of HO-, (C -C )-
cycloalkyl and Het , in another embodiment from the series consisting of HO- and
(C -C )-cycloalkyl, in another embodiment from the series consisting of HO- and
Het , in another embodiment they are HO- substituents, and in another embodiment
they are oxo substituents. In one embodiment, the number of oxo substituents which
are optionally present on an alkyl group representing R , is not greater than two,
and in another embodiment it is not greater than one. In one embodiment, halogen
atoms occurring as substituents on an alkyl group representing R , are chosen from
the series consisting of fluorine and chlorine atoms, and in another embodiment
they are fluorine atoms and, besides being substituted by an other substituents, in
this latter embodiment an alkyl group representing R is thus optionally substituted
by fluorine substituents as applies to alkyl groups in the compounds of the formula I
in general.
Examples of groups which can represent R , and from any one or more of which
R is chosen in one embodiment of the invention, are methyl, ethyl, propyl,
isopropyl, butyl, isobutyl, cyclopropylmethyl, benzyl, 2-hydroxy-ethyl, 2-hydroxy-
propyl, 2-hydroxy-butyl, 2-hydroxymethyl-propyl, 2-hydroxymethyl-butyl, 2-
hydroxymethyl-butyl, 2-hydroxy-2,3-dimethyl-butyl, 2-hydroxy-3,3-dimethyl-butyl,
2-ethylhydroxy-butyl, 2-hydroxy-2,3,3-trimethyl-butyl, 2-ethylhydroxymethyl-
butyl, 2-ethylhydroxy-3,3-dimethyl-butyl, 2-cyclopropylhydroxy-ethyl, 2-
cyclopropylhydroxy-propyl, 2-cyclopropylhydroxy-butyl, 2-oxo-propyl, 2-oxo-
butyl, 3-methyloxo-butyl, 3,3-dimethyloxo-butyl, 2-cyclopropyloxo-ethyl.
In case the optionally substituted alkyl group representing R , including the
examples of groups listed afore which can represent R , contains a chiral carbon
atom, the compound of the formula I can be present with respect to this carbon
atom in any of it stereoisomeric forms, i.e. in R configuration or in S configuration, or
in the form of a mixture of the stereoisomeric forms in any ratio, for example as a
mixture of the two stereoisomeric forms in a molar ratio of 1 : 1, as applies to all
chiral carbon atoms in the compounds of the formula I. In one embodiment of the
invention, the compound of the formula I has at a chiral carbon atom in R pure
stereochemical configuration, either R configuration or S configuration, or essentially
pure stereochemical configuration, for example with a molar ratio of the two
configurations of 99 : 1 or greater.
In one embodiment of the invention, the (C -C )-alkyl group representing the group
R is a (C -C )-alkyl group, in another embodiment a (C -C )-alkyl group, in another
1 4 1 2
embodiment a methyl group, wherein all these alkyl groups are optionally
substituted by one or more identical or different substituents as indicated with
respect to the compounds of formula I in general or in any embodiment specified
above or below. In one embodiment of the invention, the number of optional
substituents in an alkyl group representing R is one or two, in another embodiment
one. In one embodiment, the alkyl group representing R is unsubstituted. In one
embodiment, the substituents which are optionally present on an alkyl group
representing R are chosen from the series consisting of HO- and (C -C )-alkyl-O-.
In one embodiment of the invention, the (C -C )-alkyl group representing the group
R is a (C -C )-alkyl group, in another embodiment a (C -C )-alkyl group, in another
1 4 1 3
embodiment a (C -C )-alkyl group, in another embodiment an ethyl group, in
another embodiment a methyl group, wherein all these alkyl groups are optionally
substituted by one or more identical or different substituents as indicated with
respect to the compounds of formula I in general or in any embodiment specified
above or below. In one embodiment of the invention, the number of optional
substituents in an alkyl group representing R is one or two, in another embodiment
one. In one embodiment, an alkyl group representing R is unsubstituted, in
another embodiment it is substituted by one or two identical or different substituents,
in another embodiment it is substituted by one substituent. In one embodiment, the
substituents which are optionally present on an alkyl group representing R are
chosen from the series consisting of HO- and (C -C )-alkyl-O-, in another
embodiment they are HO- substituents, in another embodiment they are (C -C )-
alkyl-O- substituents, and in another embodiment they are (C -C )-alkyl-O-
substituents.
In one embodiment of the invention, the group R is chosen from the series
31 3
consisting of R , (C -C )-cycloalkyl and Het -C H -, in another embodiment from
3 7 u 2u
32 3
the series consisting of (C -C )-cycloalkyl, R -C H - and Het -C H -, in another
3 7 u 2u u 2u
32 3
embodiment from the series consisting of R -C H - and Het -C H -, in another
u 2u u 2u
32 30 31
embodiment R is R -C H -, and in another embodiment R is R . In one
u 2u
embodiment, u is an integer chosen from the series consisting of 0, 1 and 2, in
another embodiment from the series consisting of 0 and 1, in another embodiment
from the series consisting of 1 and 2, in another embodiment u is 0, and in another
32
embodiment u is 1. In one embodiment, R is R -C H - and u is 0, i.e., in this
u 2u
embodiment R is chosen from the series consisting of phenyl and an aromatic 5-
membered or 6-membered monocyclic heterocycle which comprises one, two or
three identical or different ring heteroatoms chosen from the series consisting of
nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the
phenyl and the heterocycle all are optionally substituted as indicated with respect to
the compounds of formula I in general or in any embodiment specified above or
below. In one embodiment, the divalent alkanediyl group C H is a linear group.
u 2u
In one embodiment, the (C -C )-cycloalkyl group representing R is a (C -C )-
3 7 3 6
cycloalkyl group, in another embodiment a (C -C )-cycloalkyl group, in another
3 30
embodiment a cyclopropyl group. In one embodiment, a group Het occurring in R
is a saturated 4-membered to 6-membered monocyclic heterocycle, in another
embodiment a saturated 5-membered or 6-membered heterocycle, in another
embodiment a saturated 6-membered heterocycle, which comprises one or two
identical or different ring heteroatoms, and in another embodiment comprises one
ring heteroatom, which are chosen from the series consisting of nitrogen, oxygen
and sulfur, and is bonded via a ring carbon atom and is optionally substituted as
indicated with respect to the compounds of formula I in general or in any
embodiment specified above or below. In one embodiment, the ring heteroatoms in
3 30
a group Het occurring in R are chosen from the series consisting of nitrogen and
oxygen, in another embodiment from the series consisting of oxygen and sulfur, in
another embodiment they are nitrogen atoms, and in another embodiment they are
oxygen atoms. In one embodiment, the number of substituents which are optionally
3 30
present on a group Het occurring in R is one, two, three or four, in another
embodiment one, two or three, in another embodiment one or two, in another
3 30
embodiment one, and in another embodiment a group Het occurring in R is
unsubstituted. In one embodiment, the substituents which are optionally present on
3 30
a group Het occurring in R are chosen from the series consisting of fluorine and
(C -C )-alkyl, in another embodiment they are (C -C )-alkyl substituents.
1 4 1 4
In one embodiment of the invention, the (C -C )-alkyl group representing R is a
1 10
(C -C )-alkyl group, in another embodiment a (C -C )-alkyl group, in another
1 8 1 4
embodiment a (C -C )-alkyl group, in another embodiment a (C -C )-alkyl group, in
1 3 1 2
another embodiment a methyl group, in another embodiment a (C -C )-alkyl group,
in another embodiment a (C -C )-alkyl group, wherein all these alkyl groups are
optionally substituted by one or more identical or different substituents as indicated
with respect to the compounds of formula I in general or in any embodiment
specified above or below. In one embodiment of the invention, the number of
optional substituents in an alkyl group representing R is one, two or three, in
another embodiment one or two, in another embodiment one. In one embodiment,
an alkyl group representing R is unsubstituted, and in another embodiment it is
substituted by one, two or three, in another embodiment by one or two, in another
embodiment by one substituent as indicated. In one embodiment, the optional
substituents on an alkyl group representing R are chosen from the series
consisting of halogen, (C -C )-cycloalkyl, (C -C )-alkyl-O- and NC-, in another
3 7 1 6
embodiment from the series consisting of halogen, (C -C )-cycloalkyl and (C -C )-
3 7 1 6
alkyl-O-, in another embodiment from the series consisting of halogen and (C -C )-
cycloalkyl, and in another embodiment they are (C -C )-cycloalkyl substituents. In
one embodiment, halogen atoms occurring as substituents on an alkyl group
representing R , are chosen from the series consisting of fluorine and chlorine
atoms, and in another embodiment they are fluorine atoms and, besides being
substituted by an other substituents, in this latter embodiment an alkyl group
representing R is thus optionally substituted by fluorine substituents as applies to
alkyl groups in the compounds of the formula I in general. In one embodiment, a
(C -C )-cycloalkyl group occurring as a substituent on an alkyl group representing
R is a (C -C )-cycloalkyl group, in another embodiment a (C -C )-cycloalkyl group,
3 6 5 6
in another embodiment a cyclopropyl group.
In one embodiment of the invention, the group R is chosen from the series
consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic
heterocycle which comprises one or two identical or different ring heteroatoms, in
another embodiment one ring heteroatom, which are chosen from the series
consisting of nitrogen, oxygen and sulfur, and is bonded via a ring carbon atom, in
another embodiment from the series consisting of phenyl and an aromatic 6-
membered monocyclic heterocycle which comprises one or two nitrogen atoms as
ring heteroatoms, wherein the phenyl and the heterocycle all are optionally
substituted by one or more identical or different substituents as indicated with
respect to the compounds of formula I in general or in any embodiment specified
above or below. In one embodiment, the ring heteroatoms in an aromatic
are chosen from the series consisting of nitrogen and
heterocycle representing R
sulfur, in another embodiment they are nitrogen atoms. In one embodiment, R is
chosen from the series consisting of phenyl and an aromatic 6-membered
heterocycle as defined, in another embodiment R is a 6-membered monocyclic
heterocycle as defined, in another embodiment R is chosen from the series
consisting of phenyl, thiophenyl and pyridinyl, in another embodiment from the
series consisting of phenyl and pyridinyl, in another embodiment R is phenyl, and
in another embodiment R is pyridinyl, all of which are optionally substituted by one
or more identical or different substituents as indicated with respect to the
compounds of formula I in general or in any embodiment specified above or below.
In one embodiment, the number of substituents which are optionally present on a
phenyl group and an aromatic heterocycle representing R is one, two, three or
four, in another embodiment one, two or three, in another embodiment one or two,
in another embodiment one.
In one embodiment, the substituents which are optionally present on a phenyl group
and an aromatic heterocycle representing R , in particular on a phenyl group, are
chosen from the series the series consisting of from halogen, (C -C )-alkyl, (C -C )-
1 6 3 7
33 33 33
cycloalkyl, R , (C -C )-alkyl-O-, R -O-, R -(C -C )-alkyl-O-, -O-CH -O-, -O-CF -O-,
1 6 1 4 2 2
(C -C )-alkyl-S(O) -, H N-S(O) -, (C -C )-alkyl-NH-S(O) -, di((C -C )-alkyl)N-S(O) -,
1 6 m 2 2 1 4 2 1 4 2
(C -C )-alkyl-NH-, di((C -C )-alkyl)N-, Het , (C -C )-alkyl-C(O)-NH-, Ar-C(O)-NH-,
1 6 1 6 1 4
(C -C )-alkyl-S(O) -NH- and NC-, in another embodiment from the series consisting
1 4 2
33 33 33
of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, R , (C -C )-alkyl-O-, R -O-, R -(C -
1 6 3 7 1 6 1
C )-alkyl-O-, -O-CH -O-, -O-CF -O-, (C -C )-alkyl-S(O) -, H N-S(O) -, (C -C )-alkyl-
4 2 2 1 6 m 2 2 1 4
NH-S(O) -, di((C -C )-alkyl)N-S(O) -, (C -C )-alkyl-NH-, di((C -C )-alkyl)N-, Het and
2 1 4 2 1 6 1 6
NC-, in another embodiment from the series consisting of halogen, (C -C )-alkyl,
33 33 33
(C -C )-cycloalkyl, R , (C -C )-alkyl-O-, R -O-, R -(C -C )-alkyl-O-, -O-CH -O-, -
3 7 1 6 1 4 2
O-CF -O-, (C -C )-alkyl-S(O) -, (C -C )-alkyl-NH-, di((C -C )-alkyl)N-, Het and NC-,
2 1 6 m 1 6 1 6
in another embodiment from the series consisting of halogen, (C -C )-alkyl, R , (C -
1 6 1
33 1
C )-alkyl-O-, R -O-, -O-CH -O-, -O-CF -O-, (C -C )-alkyl-S(O) -, Het and NC-, in
6 2 2 1 6 m
another embodiment from the series consisting of halogen, (C -C )-alkyl, R , (C -
1 6 1
C )-alkyl-O-, R -O-, -O-CH -O-, -O-CF -O- and NC-, in another embodiment from
6 2 2
33 33
the series consisting of halogen, (C -C )-alkyl, R , (C -C )-alkyl-O-, R -O- and NC-
1 6 1 6
in another embodiment from the series consisting of halogen, (C -C )-alkyl, (C -C )-
1 6 3 7
33 33 33
cycloalkyl, R , (C -C )-alkyl-O-, R -O-, R -(C -C )-alkyl-O-, -O-CH -O-, -O-CF -O-,
1 6 1 4 2 2
(C -C )-alkyl-S(O) -, di((C -C )-alkyl)N-S(O) -, H N-, di((C -C )-alkyl)N-, Het , (C -
1 6 m 1 4 2 2 1 6 1
C )-alkyl-C(O)-NH-, Ar-C(O)-NH- and NC-, in another embodiment from the series
33 33
consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, R , (C -C )-alkyl-O-, R -O-,
1 6 3 7 1 6
R -(C -C )-alkyl-O-, -O-CH -O-, -O-CF -O-, (C -C )-alkyl-S(O) -, di((C -C )-alkyl)N-
1 4 2 2 1 6 m 1 4
S(O) -, H N-, di((C -C )-alkyl)N-, Het and NC-, in another embodiment from the
2 2 1 6
series consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, R , (C -C )-alkyl-O-,
1 6 3 7 1 6
33 33
R -O-, R -(C -C )-alkyl-O-, -O-CH -O-, -O-CF -O-, (C -C )-alkyl-S(O) -, di((C -C )-
1 4 2 2 1 6 m 1 4
alkyl)N-S(O) -, di((C -C )-alkyl)N-, Het and NC-, in another embodiment from the
2 1 6
series consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, R , (C -C )-alkyl-O-,
1 6 3 7 1 6
33 33
R -O-, R -(C -C )-alkyl-O-, (C -C )-alkyl-S(O) -, di((C -C )-alkyl)N-S(O) -, di((C -
1 4 1 6 m 1 4 2 1
C )-alkyl)N-, Het and NC-, in another embodiment from the series consisting of
33 33
halogen, (C -C )-alkyl, R , (C -C )-alkyl-O- and R -O-, in another embodiment
1 6 1 6
from the series consisting of halogen, (C -C )-alkyl, R and (C -C )-alkyl-O-, in
1 6 1 6
another embodiment from the series consisting of halogen, (C -C )-alkyl and R , in
another embodiment from the series consisting of halogen and (C -C )-alkyl. In one
embodiment, in case that substituents from the series consisting of (C -C )-
33 33 33 1
cycloalkyl, R , R -O-, R -(C -C )-alkyl-O-, -O-CH -O-, -O-CF -O-, Het and
1 4 2 2
Ar-C(O)-NH- are present on a phenyl group and an aromatic heterocycle
representing R , not more than two such substituents, in another embodiment not
more than one such substituent, are present, either without any other substituents or
together with any other substituents.
In one embodiment, a (C -C )-alkyl group occurring in a substituent on a phenyl
group and an aromatic heterocycle representing R is a (C -C )-alkyl group, in
another embodiment a (C -C )-alkyl group, in another embodiment a (C -C )-alkyl
1 3 1 2
group, in another embodiment a methyl group. In one embodiment, a (C -C )-
cycloalkyl group occurring as a substituent on a phenyl group and an aromatic
heterocycle representing R is a (C -C )-cycloalkyl group, in another embodiment a
(C -C )-cycloalkyl group, in another embodiment a (C -C )-cycloalkyl group, in
3 5 3 4
another embodiment it is a cyclopropyl group. In one embodiment, a group Ar
occurring in a substituent on a phenyl group and an aromatic heterocycle
representing R is chosen from the series consisting of phenyl and an aromatic 5-
membered or 6-membered heterocycle which comprises one or two identical or
different ring heteroatoms, in another embodiment one ring heteroatom, chosen
from the series consisting of nitrogen, oxygen and sulfur, which is bonded via a ring
carbon atom, and in another embodiment it is a phenyl group, which groups all are
optionally substituted as indicated with respect to the compounds of formula I in
general or in any embodiment specified above or below. In one embodiment, the
number of optional substituents on a group Ar occurring in a substituent on a phenyl
group and an aromatic heterocycle representing R is one or two, in another
embodiment one, and the optional substituents are chosen from the series
consisting of halogen, (C -C )-alkyl, (C -C )-alkyl-O-, (C -C )-alkyl-S(O) - and NC-,
1 4 1 4 1 4 m
in another embodiment from the series consisting of halogen, (C -C )-alkyl and (C -
1 4 1
C )-alkyl-O-, in another embodiment from the series consisting of halogen and (C -
C )-alkyl, and in another embodiment such a group Ar is unsubstituted.
In one embodiment, a group Het occurring as a substituent on a phenyl group or an
aromatic heterocycle representing R is a saturated or unsaturated 4-membered to
6-membered monocyclic heterocycle, in another embodiment a 5-membered or 6-
membered heterocycle, which comprises a ring nitrogen atom via which Het is
bonded and optionally one or two further ring heteroatoms, in another embodiment
one further ring heteroatom, which are chosen from the series consisting of
nitrogen, oxygen and sulfur, which is optionally substituted as indicated with respect
to the compounds of formula I in general or in any embodiment specified above or
below. In one embodiment, a group Het occurring as a substituent on a phenyl
group or an aromatic heterocycle representing R does not comprise any further
ring heteroatom besides the ring nitrogen atom via which Het is bonded. In one
embodiment, a group Het occurring as a substituent on a phenyl group or an
aromatic heterocycle representing R is saturated, in another embodiment it is
unsaturated. In one embodiment, the number of substituents which are optionally
occurring as a substituent on a phenyl group or an aromatic
present on a group Het
heterocycle representing R is one, two, three or four, in another embodiment one,
two or three, in another embodiment one or two, in another embodiment one, and in
another embodiment such a group Het is unsubstituted. In one embodiment, the
substituents which are optionally present on a group Het occurring as a substituent
on a phenyl group or an aromatic heterocycle representing R are chosen from the
series consisting of halogen, (C -C )-alkyl, HO-, (C -C )-alkyl-O- and oxo, in another
1 4 1 4
embodiment from the series consisting of fluorine, (C -C )-alkyl, HO- and oxo, in
another embodiment from the series consisting of fluorine, (C -C )-alkyl and oxo,
and in another embodiment they are (C -C )-alkyl substituents.
32 32
Examples of groups R from any one or more of which R is chosen in one
embodiment of the invention, are phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, 4-fluoro-
phenyl, 2-chloro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 3-bromo-phenyl, 4-
bromo-phenyl, 2,3-dichloro-phenyl, 2,4-dichloro-phenyl, 2,5-dichloro-phenyl, 2,6-
dichloro-phenyl, 3,4-dichloro-phenyl, 2,3-difluoro-phenyl, 2,4-difluoro-phenyl, 2,5-
difluoro-phenyl, 2,6-difluoro-phenyl, 3,4-difluoro-phenyl, 2-chlorofluoro-phenyl,
3,4,5-trifluoro-phenyl, 2-methyl-phenyl (o-tolyl), 3-methyl-phenyl (m-tolyl), 4-methyl-
phenyl (p-tolyl), 2,3-dimethyl-phenyl, 2,4-dimethyl-phenyl, 2,5-dimethyl-phenyl, 2,6-
dimethyl-phenyl, 3,4-dimethyl-phenyl, 2-ethyl-phenyl, 3-ethyl-phenyl, 4-ethyl-phenyl,
3-isopropyl-phenyl, 3-tert-butyl-phenyl, 4-tert-butyl-phenyl, 3-trifluoromethyl-phenyl,
4-trifluoromethyl-phenyl, 2-fluoromethyl-phenyl, 3-chloromethyl-phenyl, 5-
chloromethyl-phenyl, 5-chlorofluoromethyl-phenyl, 2-fluorotrifluoromethyl-
phenyl, 2-fluorotrifluoromethyl-phenyl, 4-fluorotrifluoromethyl-phenyl, 5-fluoro-
3-trifluoromethyl-phenyl, 3-chlorotrifluoromethyl-phenyl, 5-chloro
trifluoromethyl-phenyl, 5-chlorotrifluoromethyl-phenyl, 2-methoxy-phenyl, 3-
methoxy-phenyl, 4-methoxy-phenyl, 3-ethoxy-phenyl, 3-propoxy-phenyl, 3-
isopropoxy-phenyl, 4-tert-butoxy-phenyl, 3-trifluoromethoxy-phenyl, 4-
trifluoromethoxy-phenyl, 3-(2,2,2-trifluoroethoxy)-phenyl, 5-chloromethoxy-
phenyl, 3-chloromethoxy-phenyl, 5-fluoroisopropoxy-phenyl, 2-fluoro
trifluoromethoxy-phenyl, 4-methoxy-3,5-dimethyl-phenyl, 3-methoxy
trifluoromethyl-phenyl, 2,3-methylenedioxy-phenyl, 2,3-difluoromethylenedioxy-
phenyl, 3,4-methylenedioxy-phenyl, 3,4-difluoromethylenedioxy-phenyl, 3-
methylsulfanyl-phenyl, 3-ethylsulfanyl-phenyl, 3-trifluoromethylsulfanyl-phenyl, 3-
methanesulfonyl-phenyl, 3-ethanesulfonyl-phenyl, 3-sulfamoyl-phenyl, 2-cyano-
phenyl, 3-cyano-phenyl, 4-cyano-phenyl, thiophenyl, thiophenyl, 3-chloro-
thiophenyl, 4-chloro-thiophenyl, 5-chloro-thiophenyl, 4,5-dichloro-thiophen-
2-yl, 5-chloro-thiophenyl, 2,5-dichloro-thiophenyl, 4-methyl-thiophenyl, 5-
methyl-thiophenyl, 4,5-dimethyl-thiophenyl, pyridinyl, pyridinyl, pyridin
yl, 2-chloro-pyridinyl, 5-chloro-pyridinyl, 6-chloro-pyridinyl, 2-chloro-pyridin-
4-yl, 2,6-dichloro-pyridinyl, 6-methoxy-pyridinyl, 2-chloromethoxy-pyridin
In one embodiment of the invention, the group R is chosen from the series
consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic
heterocycle which comprises one or two identical or different ring heteroatoms, in
another embodiment one ring heteroatom, which is chosen from the series
consisting of nitrogen, oxygen and sulfur, and is bonded via a ring carbon atom,
wherein the phenyl and the heterocycle all are optionally substituted by one or more
identical or different substituents as indicated with respect to the compounds of
formula I in general or in any embodiment specified above or below. In one
embodiment, the ring heteroatoms in an aromatic heterocycle representing R are
chosen from the series consisting of nitrogen and sulfur, in another embodiment
they are nitrogen atoms. In one embodiment, R is chosen from the series
consisting of phenyl and an aromatic 6-membered heterocycle as defined, in
another embodiment from the series consisting of phenyl and an aromatic 6-
membered heterocycle which comprises one or two nitrogen atoms as ring
heteroatoms, in another embodiment R is a 6-membered monocyclic heterocycle
as defined, in another embodiment it is an aromatic 6-membered heterocycle which
comprises one or two nitrogen atoms as ring heteroatoms, in another embodiment
R is chosen from the series consisting of phenyl, thiophenyl and pyridinyl, in
another embodiment from the series consisting of phenyl and pyridinyl, in another
33 33
embodiment R is phenyl, and in another embodiment R is pyridinyl, all of which
are optionally substituted by one or more identical or different substituents as
indicated with respect to the compounds of formula I in general or in any
embodiment specified above or below. In one embodiment, the number of
substituents which are optionally present on a phenyl group and an aromatic
heterocycle representing R is one, two or three, in another embodiment one or
two, in another embodiment one.
In one embodiment, the substituents which are optionally present on a phenyl group
and an aromatic heterocycle representing R , are chosen from the series consisting
of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, HO-, (C -C )-alkyl-O-, (C -C )-alkyl-
1 6 3 7 1 6 1 6
S(O) -, H N-S(O) -, di((C -C )-alkyl)N-S(O) - and NC-, in another embodiment from
m 2 2 1 4 2
the series consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, HO-, (C -C )-alkyl-
1 6 3 7 1 6
O-, H N-S(O) -, di((C -C )-alkyl)N-S(O) - and NC-, in another embodiment from the
2 2 1 4 2
series consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, HO-, (C -C )-alkyl-O-
1 6 3 7 1 6
and NC-, are chosen from the series the series consisting of halogen, (C -C )-alkyl,
(C -C )-alkyl-O-, (C -C )-alkyl-S(O) - and NC-, in another embodiment from the
1 4 1 4 m
series consisting of halogen, (C -C )-alkyl, (C -C )-alkyl-O- and NC-, in another
1 4 1 4
embodiment from the series consisting of halogen, (C -C )-alkyl and (C -C )-alkyl-
1 4 1 4
O-, in another embodiment from the series consisting of halogen and (C -C )-alkyl.
In one embodiment, a (C -C )-alkyl group occurring in a substituent on a phenyl
group and an aromatic heterocycle representing R is a (C -C )-alkyl group, in
another embodiment a (C -C )-alkyl group, in another embodiment a (C -C )-alkyl
1 3 1 2
group, in another embodiment a methyl group. In one embodiment, a (C -C )-
cycloalkyl group occurring as a substituent on a phenyl group and an aromatic
heterocycle representing R is a (C -C )-cycloalkyl group, in another embodiment a
(C -C )-cycloalkyl group, in another embodiment a (C -C )-cycloalkyl group, in
3 5 3 4
another embodiment it is a cyclopropyl group.
In one embodiment of the invention, the group R is chosen from the series
consisting of hydrogen and (C -C )-alkyl, in another embodiment from the series
consisting of hydrogen and methyl, and in another embodiment R is hydrogen. In
40 30 40
case R and R are different and the carbon atom carrying R and R thus is
chiral, in one embodiment of the invention the compound of the formula I has at this
carbon atom pure stereochemical configuration, either R configuration or S
configuration, or essentially pure stereochemical configuration, for example with a
32
molar ratio of the two configurations of 99 : 1 or greater. In case R is R -C H -
u 2u
40
and u is 0, i.e. R is phenyl or an aromatic heterocycle as defined, R is hydrogen
and R is hydrogen, in one embodiment of the invention the compound of the
40
formula I has at the carbon atom carrying R and R pure S configuration, or
essentially pure S configuration, for example with a molar ratio of S configuration to
R configuration of 99 : 1 or greater.
40 30
In case R and R together are a divalent group (CH ) , the two groups R and
R together with the carbon atom carrying them form a cycloalkane ring chosen
from cyclopropane, cyclobutane, cyclopentane and cyclohexane, which carries the
50 60
moieties -C(O)-NH and -C(R )(R )-G depicted in formula I on the same ring carbon
atom. In one embodiment of the invention, the number of (C -C )-alkyl substituents
which are optionally present on the group (CH ) , is one, two, three or four, in
another embodiment one or two, and in another embodiment no alkyl substituents
are present on the group (CH ) . In one embodiment, a (C -C )-alkyl group occurring
2 x 1 4
as a substituent on the group (CH ) is a methyl group. In one embodiment, the
integer x is chosen from the series consisting of 2, 4 and 5, in another embodiment
from 4 and 5, in another embodiment x is 2, and in another embodiment x is 4. In
40
one embodiment of the invention, R and R together cannot be (CH ) , and in this
40
embodiment R and R thus only have their other meanings as defined.
In one embodiment of the invention, the group R is chosen from the series
consisting of hydrogen, (C -C )-alkyl and HO-, in another embodiment from the
series consisting of hydrogen and (C -C )-alkyl, in another embodiment from the
series consisting of hydrogen and (C -C )-alkyl, in another embodiment from the
series consisting of hydrogen and methyl, in another embodiment from the series
consisting of hydrogen and HO-, and in another embodiment R is hydrogen.
In one embodiment of the invention, the group R is chosen from the series
consisting of hydrogen and (C -C )-alkyl, in another embodiment from the series
consisting of hydrogen and (C -C )-alkyl, in another embodiment from the series
consisting of hydrogen and (C -C )-alkyl, in another embodiment from the series
consisting of hydrogen and methyl, and in another embodiment R is hydrogen. In
50 60 50
one embodiment of the invention, R and R both are hydrogen. In case R and
60 50 60
R are different and the carbon atom carrying R and R thus is chiral, in one
embodiment of the invention the compound of the formula I has at this carbon atom
pure stereochemical configuration, either R configuration or S configuration, or
essentially pure stereochemical configuration, for example with a molar ratio of the
two configurations of 99 : 1 or greater.
50 60 50
In case R and R together are a divalent group (CH ) , the two groups R and
R together with the carbon atom carrying them form a cycloalkane ring chosen
from cyclopropane, cyclobutane, cyclopentane and cyclohexane, which carries the
40
moieties -C(R )(R )- and G depicted in formula I on the same ring carbon atom. In
one embodiment of the invention, the number of (C -C )-alkyl substituents which are
optionally present on the group (CH ) , is one, two, three or four, in another
embodiment one or two, and in another embodiment no alkyl substituents are
present on the group (CH ) . In one embodiment, a (C -C )-alkyl group occurring as
2 y 1 4
a substituent on the group (CH ) is a methyl group. In one embodiment, the integer
y is chosen from the series consisting of 2, 4 and 5, in another embodiment from 4
and 5, in another embodiment y is 2, and in another embodiment y is 4. In one
50 60
embodiment of the invention, R and R together cannot be (CH ) , and in this
50 60
embodiment R and R thus only have their other meanings as defined. In one
50 60
embodiment of the invention, R and R together cannot be (CH ) if
40
simultaneously R and R together are (CH ) .
In one embodiment of the invention, the group R is chosen from the series
consisting of hydrogen and (C -C )-alkyl, in another embodiment from the series
consisting of hydrogen and (C -C )-alkyl, in another embodiment from the series
consisting of hydrogen and (C -C )-alkyl, in another embodiment from the series
consisting of hydrogen and (C -C )-alkyl, in another embodiment R is hydrogen, in
71 71
another embodiment R is (C -C )-alkyl, in another embodiment R is (C -C )-alkyl,
1 6 1 4
71 71
in another embodiment R is (C -C )-alkyl, and in another embodiment R is (C -
1 3 1
C )-alkyl, wherein all these alkyl groups are optionally substituted as indicated with
respect to the compounds of formula I in general or in any embodiment specified
above or below. In one embodiment, the number of substituents which are optionally
present on an alkyl group representing R is one or two, in another embodiment it is
one, in another embodiment an alkyl group representing R is unsubstituted. In one
embodiment, substituents which are optionally present on an alkyl group
representing R are (C -C )-alkyl-O- substituents, in another embodiment (C -C )-
1 6 1 4
alkyl-O- substituents, in another embodiment (C -C )-alkyl-O- substituents, in
another embodiment (C -C )-alkyl-C(O)-O- substituents, in another embodiment
(C -C )-alkyl-C(O)-O- substituents, in another embodiment (C -C )-alkyl-C(O)-O-
1 4 1 3
substituents.
In one embodiment the group R is chosen from the series consisting of hydrogen,
(C -C )-alkyl, (C -C )-cycloalkyl –CH -(CH ) -(C -C )-cycloalkyl and -(CH ) -Het ,
1 6 3 6 2 2 b 3 6 2 b
where alkyl or cycloalkyl is optionally substituted by one or more identical or
different substituents chosen from the series consisting of halogen, HO-, HOOC-,
(C -C )-alkyl-O- and (C -C )-alkyl-C(O)-O-, NC-, N((C -C )-alkyl) and b is 0, 1 or 2
1 6 1 6 1 4 2
and the group R is chosen from the series consisting hydrogen, (C -C )-alkyl.
72 73
In another embodiment the groups R and R together with the nitrogen atom to
which they are bonded form a saturated 4-membered to 7-membered monocyclic
heterocycle, which contain optionally one further ring heteroatom chosen from the
series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by
one or more identical or different substituents chosen from the series consisting of
halogen, (C -C )-alkyl, HO- and (C -C )-alkyl-O-.
1 4 1 4
In another embodiment the group R is chosen from the series consisting of
hydrogen, (C -C )-alkyl, (C -C )-cycloalkyl, Het and –CH -Het , where alkyl or
1 6 3 6 2
cycloalkyl is optionally substituted by one or more identical or different substituents
chosen from the series consisting of halogen, HO-, HOOC-, (C -C )-alkyl-O- and
(C -C )-alkyl-C(O)-O-, NC-, N((C -C )-alkyl) and the group R is chosen from the
1 6 1 4 2
series consisting hydrogen, (C -C )-alkyl.
72 73
In another embodiment the groups R and R together with the nitrogen atom to
which they are bonded form a saturated 5-membered to 6-membered monocyclic
heterocycle, which contain optionally one further ring heteroatom chosen from the
series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by
one or more identical or different substituents chosen from the series consisting of
halogen, (C -C )-alkyl, HO- and (C -C )-alkyl-O-.
1 4 1 4
In one embodiment the group R is chosen from the series consisting of hydrogen,
(C -C )-alkyl, (C -C )-cycloalkyl and –CH -Het , where alkyl or cycloalkyl is
1 6 3 6 2
optionally substituted by one or more identical or different substituents chosen from
the series consisting of halogen, HO-, HOOC-, (C -C )-alkyl-O- and (C -C )-alkyl-
1 6 1 6
C(O)-O-, NC-, N((C -C )-alkyl) and the group R is chosen from the series
1 4 2
consisting hydrogen and (C -C )-alkyl.
72 73
In another embodiment the groups R and R together with the nitrogen atom to
which they are bonded form a saturated 5-membered to 6-membered monocyclic
heterocycle, which contain no further ring heteroatoms, which is optionally
substituted by one or more identical or different substituents chosen from the series
consisting of halogen, (C -C )-alkyl, HO- and (C -C )-alkyl-O-.
1 4 1 4
In one embodiment the group R is chosen from the series consisting of hydrogen,
2, 2-dimethyl-butane-3yl, 2, 2-dimethyl-propane-3yl, pentan-3yl, propane-2yl, 2-
methyl-propane-2yl, butane-1yl, butane-2yl, 2-methyl-butane-3yl, 2-methyl-butane-
2-yl, -CH CHF , -CHCF , CH CN, -CH CH OCH , -CH(CH OH)CH(CH ) , -
2 2 3 2 2 2 3 2 3 2
CH C(CH ) -CH OH, CH(C H )CH OCH , CH CH CH N(CH ) , cyclopropane,
2 3 2 2 2 5 2 3 2 2 2 3 2
4 73
cyclobutane, cyclopentane, cyclohexane and –CH -Het and the group R is
hydrogen.
72 73
In another embodiment the groups R and R together with the nitrogen atom to
which they are bonded form pyrrolidine, which is optionally substituted by HO-.
In another embodiment the group R is chosen from the series consisting of
hydrogen, (C -C )-alkyl, where alkyl is substituted by one or more times by HO- and
the group R is hydrogen.
72 73
In one embodiment of the invention, the groups R and R are independently of
each other chosen from the series consisting of hydrogen and (C -C )-alkyl, in
another embodiment from the series consisting of hydrogen and methyl. In one
72 73
embodiment, one of the groups R and R is hydrogen and the other is chosen
from the series consisting of hydrogen and (C -C )-alkyl, in another embodiment
from the series consisting of hydrogen and (C -C )-alkyl, in another embodiment
from the series consisting of hydrogen an methyl, and in another embodiment both
72 73
groups R and R are hydrogen.
In one embodiment of the invention the group Het , independently of each other
group Het , is a saturated or unsaturated 4-membered to 8-membered monocyclic
heterocycle which comprises one to four ring heteroatoms chosen from the series
consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or
more identical or different substituents chosen from the series consisting of halogen,
(C -C )-alkyl, HO-, (C -C )-alkyl-O-, oxo and NC-;
1 4 1 4
In another embodiment the group Het , independently of each other group Het , is a
saturated or unsaturated 5-membered to 6-membered monocyclic heterocycle
which comprises one to four ring heteroatoms chosen from the series consisting of
nitrogen, oxygen and sulfur which is optionally substituted by one or more identical
or different substituents chosen from the series consisting of halogen, (C -C )-alkyl,
HO-, (C -C )-alkyl-O-, oxo and NC-;
In another embodiment the group Het , independently of each other group Het , is a
unsaturated 5-membered to 6-membered monocyclic heterocycle which comprises
one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen
and sulfur which is optionally substituted by one or more identical or different
substituents chosen from the series consisting of halogen, (C -C )-alkyl, HO-, (C -
1 4 1
C )-alkyl-O- and NC-;
In another embodiment the group Het , independently of each other group Het , is
selected from 1, 2-oxadiazolyl, tetrazlolyl, pyrazolyl, furanyl, pyridinyl, pyriminyl,
which is optionally substituted by methyl.
In one embodiment of the invention, a group Ar in any occurrence in the compounds
of the formula I, independently of each other group Ar, is chosen from the series
consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic
heterocycle which comprises one or two identical or different ring heteroatoms, in
another embodiment one ring heteroatom, which is chosen from the series
consisting of nitrogen, oxygen and sulfur, and which is bonded via a ring carbon
atom, in another embodiment Ar is chosen from the series consisting of phenyl and
an aromatic 6-membered heterocycle which comprises one or two nitrogen atoms
as ring heteroatoms, in another embodiment Ar is chosen from the series consisting
of phenyl, thiophenyl and pyridinyl, in another embodiment from the series
consisting of phenyl and thiophenyl, in another embodiment from the series
consisting of phenyl and pyridinyl, in another embodiment a group Ar is phenyl, and
in another embodiment a group Ar is pyridinyl, wherein the phenyl and all
heterocycles are optionally substituted as indicated with respect to the compounds
of formula I in general or in any embodiment specified above or below. In one
embodiment, the number of substituents which are optionally present on a group Ar,
independently of each other group Ar, is one, two, three or four, in another
embodiment one, two or three, in another embodiment one or two, in another
embodiment one, and in another embodiment a group Ar is unsubstituted.
In one embodiment, in case that substituents from the series consisting of –CH=CH-
CH=CH-, -O-CH -CH -O-, -N((C -C )-alkyl)-CH=CH-, -O-CH -O- and -O-CF -O- are
2 2 1 3 2 2
present on a group Ar which is phenyl, not more than two such substituents, in
another embodiment not more than one such substituent, are present, either without
any other substituents or together with any other substituents. In one embodiment,
the substituents which are optionally present on a group Ar, independently of each
other group Ar, are chosen from the series consisting of halogen, (C -C )-alkyl, HO-
(C -C )-alkyl, Het4, -(CH ) -phenyl, (C -C )-alkyl-O-, (C -C )-cycloalkyl-(CH ) -O-, -
1 6 2 x 1 6 3 7 2 x
12 13 2 12 13 2
CF , -CO-(C -C )-alkyl, -NR R , Het , -CO-NR R , CO-Het , (C -C )-alkyl-S(O) -
3 1 6 1 6 m
, H N-S(O) - and NC-;
in another embodiment from the series consisting of halogen, (C -C )-alkyl, (C -C )-
1 6 1 6
alkyl-O-, (C -C )-alkyl-S(O) - and NC-, in another embodiment from the series
1 6 m
consisting of halogen, (C -C )-alkyl, (C -C )-alkyl-O- and NC-, in another
1 6 1 6
embodiment from the series consisting of halogen, (C -C )-alkyl and (C -C )-alkyl-
1 6 1 6
O-, in another embodiment from the series consisting of halogen, (C -C )-alkyl and
(C -C )-alkyl-O-, in another embodiment from the series consisting of halogen and
(C -C )-alkyl.
A subject of the invention are all compounds of the formula I wherein any one or
more structural elements such as groups, substituents and numbers are defined as
in any of the specified embodiments or definitions of the elements or have one or
more of the specific meanings which are mentioned herein as examples of
elements, wherein all combinations of one or more specified embodiments and/or
definitions and/or specific meanings of the elements are a subject of the present
invention. Also with respect to all such compounds of the formula I, all their
stereoisomeric forms and mixtures of stereoisomeric forms in any ratios, and their
physiologically acceptable salts, and the physiologically acceptable solvates of any
of them, are a subject of the present invention.
As an example of compounds of the invention which with respect to any structural
elements are defined as in specified embodiments of the invention or definitions of
such elements, compounds of the formula I may be mentioned wherein
71 72 73
G is chosen from the series consisting of R -O-C(O)- and R -N(R )-C(O)-;
32
R is R -C H -, wherein u is an integer chosen from the series consisting of 0 and
u 2u
R is chosen from the series consisting of phenyl and an aromatic 6-membered
monocyclic heterocycle which comprises one or two nitrogen atoms as ring
heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted
by one or more identical or different substituents chosen from the series consisting
33 33 33
of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, R , HO-, (C -C )-alkyl-O-, R -O-, R -
1 6 3 7 1 6
(C -C )-alkyl-O-, -O-CH -O-, -O-CF -O-, (C -C )-alkyl-S(O) -, di((C -C )-alkyl)N-
1 4 2 2 1 6 m 1 4
S(O) -, H N-, di((C -C )-alkyl)N-, Het , (C -C )-alkyl-C(O)-NH-, Ar-C(O)-NH- and
2 2 1 6 1 4
NC-;
R is chosen from the series consisting of phenyl and an aromatic 6-membered
monocyclic heterocycle which comprises one or two nitrogen atoms as ring
heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted
by one or more identical or different substituents chosen from the series consisting
of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, HO-, (C -C )-alkyl-O-, (C -C )-alkyl-
1 6 3 7 1 6 1 6
S(O) -, H N-S(O) -, di((C -C )-alkyl)N-S(O) - and NC-;
m 2 2 1 4 2
R is hydrogen.
As another such example of compounds of the invention which with respect to any
structural elements are defined as in specified embodiments of the invention or
definitions of such elements, compounds of the formula I may be mentioned wherein
G is R -O-C(O)-;
32
R is R -C H -, wherein u is 0;
u 2u
R is chosen from the series consisting of phenyl, wherein the phenyl is optionally
substituted by one or more identical or different substituents chosen from the series
consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, R , HO-, (C -C )-alkyl-O-,
1 6 3 7 1 6
33 33
R -O-, R -(C -C )-alkyl-O-, -O-CH -O-, -O-CF -O-, (C -C )-alkyl-S(O) -, di((C -C )-
1 4 2 2 1 6 m 1 4
alkyl)N-S(O) -, H N-, di((C -C )-alkyl)N-, Het , (C -C )-alkyl-C(O)-NH-, Ar-C(O)-NH-
2 2 1 6 1 4
and NC-;
R is chosen from the series consisting of phenyl, wherein the phenyl is optionally
substituted by one or more identical or different substituents chosen from the series
consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, HO-, (C -C )-alkyl-O-, (C -
1 6 3 7 1 6 1
C )-alkyl-S(O) -, H N-S(O) -, di((C -C )-alkyl)N-S(O) - and NC-;
6 m 2 2 1 4 2
R is hydrogen.
As another such example of compounds of the invention which with respect to any
structural elements are defined as in specified embodiments of the invention or
definitions of such elements, compounds of the formula I may be mentioned wherein
R is hydrogen;
R is hydrogen.
As another such example of compounds of the invention which with respect to any
structural elements are defined as in specified embodiments of the invention or
definitions of such elements, compounds of the formula I may be mentioned wherein
formula I is selected from the series of subformulae I-1 to I-7
R10 R4
R 30
R10 R
N 60
R2 R1
I-1 I-2
30
R10 R10
40 40
60 60
R 50
R2 R2
I-4 I-5
R10 40
60 50
R3 H
R1 R2
I-6 I-7 .
As another such example of compounds of the invention which with respect to any
structural elements are defined as in specified embodiments of the invention or
definitions of such elements, compounds of the formula I-1
I-1
wherein
R is Ar-C H -, wherein s is an integer chosen from the series consisting of 0;
s 2s
3 11
R is chosen from the series consisting of hydrogen, halogen, R -O-, HO-, (C -C )-
alkyl and (C -C )-alkyl-O-; preferred HO- and(C -C )-alkyl
1 6 1 6
R is hydrogen;
R is hydrogen;
As another such example of compounds of the invention which with respect to any
structural elements are defined as in specified embodiments of the invention or
definitions of such elements, compounds of the formula I-1
R10 R
wherein
R is hydrogen;
R is chosen from the series consisting of hydrogen, halogen, (C -C )-alkyl, (C -C )-
1 6 1 6
4 12 13 2 11 12 13
alkyl-S(O) -, Phenyl C H -(O) -, Het -(O) -, -NR R , Het , R -O-, R -N(R )-C(O)-
m s 2s t t
O- and Het -C(O)-O- and NC-, wherein s is an integer chosen from the series
consisting of 0, 1, 2 and 3 and wherein t is an integer chosen from the series
consisting of 0 and 1;
R is hydrogen;
R is chosen from the series consisting hydrogen, halogen, (C -C )-alkyl, (C -C )-
1 6 1 6
12 13 2
-C )-alkyl-S(O) -, HO-, -NR R , Het , phenyl-C H -(O) -, wherein s is
alkyl-O-, (C
1 6 m s 2s t
an integer chosen from the series consisting of 0, 1, 2 and 3 and wherein t is an
integer chosen from the series consisting of 0 and 1;
A subject of the invention also is a compound of the formula I which is chosen from
any of the specific compounds of the formula I which are disclosed herein, or is any
one of the specific compounds of the formula I which are disclosed herein,
irrespective thereof whether they are disclosed as a free compound and/or as a
specific salt, or a physiologically acceptable salt thereof, or a physiologically
acceptable solvate of any of them, wherein the compound of the formula I is a
subject of the invention in any of its stereoisomeric forms or a mixture of
stereoisomeric forms in any ratio. For example, a subject of the invention is a
compound of the formula I which is chosen from
(S)[(5-Methoxyphenyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S)(2,4-Dichloro-phenyl)[(5-methoxyphenyl-pyridinecarbonyl)-amino]-
propionic acid
(S)[(6-Chloromethoxy-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S){[3-(4,6-Dimethoxy-pyrimidinyloxy)-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S)[(6-Bromomethoxy-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S){[4-(Pyrimidinylsulfanyl)-pyridinecarbonyl]-amino}o-tolyl-propionic
acid
(S)[(6-Phenyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S)[(5-Phenyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S){[5-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[5-(2,3-Dichloro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[5-(2,3-Dimethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S)o-Tolyl[(6-m-tolyl-pyridinecarbonyl)-amino]-propionic acid
(S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[6-(2-Fluoro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[6-(2,3-Difluoro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[6-(2,5-Difluoro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[6-(4-Fluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic
acid
(S){[6-(2,3-Dimethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[6-(5-Fluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic
acid
(S){[6-(2-Methoxytrifluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(4-Chloromethoxy-phenyl)-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2-Fluoromethoxy-phenyl)-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2-Fluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2-Fluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic
acid
(S)[(5-Methoxyphenyl-pyridinecarbonyl)-amino]p-tolyl-propionic acid
(S)[(5-Methoxyo-tolyl-pyridinecarbonyl)-amino]p-tolyl-propionic acid
(S){[5-Methoxy(2-trifluoromethyl-phenyl)-pyridinecarbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(3-Fluoro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl-
propionic acid
(S){[5-Methoxy(2-methoxy-phenyl)-pyridinecarbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(2-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(2-Fluoro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(2,4-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(2,3-Dichloro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(2-Chlorotrifluoromethyl-phenyl)methoxy-pyridinecarbonyl]-
amino}p-tolyl-propionic acid
(S){[6-(3-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
fluoro-phenyl)-propionic acid
(S){[6-(2-Chlorotrifluoromethyl-phenyl)methoxy-pyridinecarbonyl]-
amino}(2-fluoro-phenyl)-propionic acid
(S){[6-(2,3-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(2,5-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(2,5-Dichloro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(3,5-Dimethyl-isoxazolyl)methoxy-pyridinecarbonyl]-amino}p-
tolyl-propionic acid
(S){[6-(4-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}p-
tolyl-propionic acid
(S){[6-(2,3-Dimethyl-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl-
propionic acid
(S)[(3,2'-Dimethoxy-[2,3']bipyridinylcarbonyl)-amino]p-tolyl-propionic acid
(S){[6-(5-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}p-
tolyl-propionic acid
(S){[6-(4-Fluoromethoxy-phenyl)methoxy-pyridinecarbonyl]-amino}p-
tolyl-propionic acid
(S){[6-(5-Fluoromethoxy-phenyl)methoxy-pyridinecarbonyl]-amino}p-
tolyl-propionic acid
(S){[6-(2-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}p-
tolyl-propionic acid
(S){[6-(3-Chloromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}p-
tolyl-propionic acid
(S){[6-(3-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}p-
tolyl-propionic acid
(S){[6-(5-Chlorofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}p-
tolyl-propionic acid
(S)(2-Fluoro-phenyl)[(5-methoxyphenyl-pyridinecarbonyl)-amino]-
propionic acid
(S){[6-(2,4-Dichloro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)(2-Fluoro-phenyl)[(5-methoxyo-tolyl-pyridinecarbonyl)-amino]-
propionic acid
(S)(2-Fluoro-phenyl){[5-methoxy(2-trifluoromethyl-phenyl)-pyridine
carbonyl]-amino}-propionic acid
(S)(2-Fluoro-phenyl){[5-methoxy(2-methoxy-phenyl)-pyridinecarbonyl]-
amino}-propionic acid
(S){[6-(2-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)(2-Fluoro-phenyl){[6-(2-fluoro-phenyl)methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S){[6-(2,4-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(2,3-Dichloro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(2,3-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(2,5-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(4-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
fluoro-phenyl)-propionic acid
(S){[6-(3,5-Dimethyl-isoxazolyl)methoxy-pyridinecarbonyl]-amino}(2-
fluoro-phenyl)-propionic acid
(S){[6-(2,3-Dimethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)[(3,2'-Dimethoxy-[2,3']bipyridinylcarbonyl)-amino](2-fluoro-phenyl)-
propionic acid
(S){[6-(5-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
fluoro-phenyl)-propionic acid
(S){[6-(4-Fluoromethoxy-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
fluoro-phenyl)-propionic acid
(S){[6-(5-Fluoromethoxy-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
fluoro-phenyl)-propionic acid
(S){[6-(2-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
fluoro-phenyl)-propionic acid
(S){[6-(3-Chloromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
fluoro-phenyl)-propionic acid
(S){[6-(5-Chlorofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
fluoro-phenyl)-propionic acid
(S){[6-(3-Chlorofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
fluoro-phenyl)-propionic acid
(S)(2-Fluoro-phenyl){[5-methoxy(2-methyl-furanyl)-pyridinecarbonyl]-
amino}-propionic acid
(S){[6-(2-Chloromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
fluoro-phenyl)-propionic acid
(S)(2-Chloro-phenyl)[(5-methoxyphenyl-pyridinecarbonyl)-amino]-
propionic acid
(S)(2-Chloro-phenyl){[6-(2,4-dichloro-phenyl)methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(4-fluoro-phenyl)methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S){[5-Methoxy(3-trifluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2,4-Dichloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(4-Fluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(4-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S)[(5-Methoxyp-tolyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S){[6-(3-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[5-Methoxy(2-methoxy-phenyl)-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S)[(5-Methoxym-tolyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S){[6-(2-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(3,4-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2,5-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2,5-Dichloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(3,5-Dimethyl-isoxazolyl)methoxy-pyridinecarbonyl]-amino}o-
tolyl-propionic acid
(S){[6-(2,3-Dimethyl-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2,4-Dimethyl-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(4-Fluoromethoxy-phenyl)methoxy-pyridinecarbonyl]-amino}o-
tolyl-propionic acid
(S){[6-(2-Chloromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}o-
tolyl-propionic acid
(S)(2-Chloro-phenyl)[(6-methoxyo-tolyl-pyridinecarbonyl)-amino]-
propionic acid
(S)(2-Chloro-phenyl){[5-methoxy(2-methoxy-phenyl)-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl)[(5-methoxym-tolyl-pyridinecarbonyl)-amino]-
propionic acid
(S)(2-Chloro-phenyl){[6-(2-chloro-phenyl)methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2-fluoro-phenyl)methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2,4-difluoro-phenyl)methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2,3-dichloro-phenyl)methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2,3-difluoro-phenyl)methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2,5-difluoro-phenyl)methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(4-fluoromethyl-phenyl)methoxy-pyridine
carbonyl]-amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2,3-dimethyl-phenyl)methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl)[(3,2'-dimethoxy-[2,3']bipyridinylcarbonyl)-amino]-
propionic acid
(S)(2-Chloro-phenyl){[6-(5-fluoromethyl-phenyl)methoxy-pyridine
carbonyl]-amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(4-fluoromethoxy-phenyl)methoxy-pyridine
carbonyl]-amino}-propionic acid
(S){[6-(4-Chloromethoxy-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
chloro-phenyl)-propionic acid
(S)(2-Chloro-phenyl){[6-(5-fluoromethoxy-phenyl)methoxy-pyridine
carbonyl]-amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2-fluorotrifluoromethyl-phenyl)methoxy-
pyridinecarbonyl]-amino}-propionic acid
(S){[5-Methoxy(2-trifluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2,4-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(4-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}o-
tolyl-propionic acid
(S)[(3,2'-Dimethoxy-[2,3']bipyridinylcarbonyl)-amino]o-tolyl-propionic acid
(S)[(3'-Fluoromethoxy-[2,4']bipyridinylcarbonyl)-amino]o-tolyl-propionic
acid
(S){[5-Methoxy(2-methyl-furanyl)-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(4-Cyanofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-
tolyl-propionic acid
(S)(2-Chloro-phenyl){[6-(2-fluoromethoxy-phenyl)methoxy-pyridine
carbonyl]-amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2-fluoromethyl-phenyl)methoxy-pyridine
carbonyl]-amino}-propionic acid
(S){[6-(3-Chloromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
chloro-phenyl)-propionic acid
(S)(2-Chloro-phenyl){[6-(3-fluoromethyl-phenyl)methoxy-pyridine
carbonyl]-amino}-propionic acid
(S){[6-(5-Chlorofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
chloro-phenyl)-propionic acid
(S)(2-Chloro-phenyl)[(3'-fluoromethoxy-[2,4']bipyridinylcarbonyl)-amino]-
propionic acid
(S)(2-Chloro-phenyl)[(5-methoxypyrazinyl-pyridinecarbonyl)-amino]-
propionic acid
(S){[6-(3-Chlorofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
chloro-phenyl)-propionic acid
(S)(2-Chloro-phenyl){[5-methoxy(2-methyl-furanyl)-pyridinecarbonyl]-
amino}-propionic acid
(S){[6-(2-Chlorofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
chloro-phenyl)-propionic acid
(S){[6-(2-Chloromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2-
chloro-phenyl)-propionic acid
3-Biphenylyl[(6-chloro-pyridinecarbonyl)-amino]-propionic acid
(S)[(6-Chloro-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S)[(3,5-Diaminochloro-pyrazinecarbonyl)-amino]o-tolyl-propionic acid
3-Biphenylyl[(3,5-diaminochloro-pyrazinecarbonyl)-amino]-propionic
acid
(S){[6-(2-Fluoro-phenyl)-pyridinecarbonyl]-amino}phenyl-propionic acid
(S)(3-Fluoro-phenyl){[6-(2-fluoro-phenyl)-pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Fluoro-phenyl){[6-(2-fluoro-phenyl)-pyridinecarbonyl]-amino}-
propionic acid
(S)(4-Fluoro-phenyl){[6-(2-fluoro-phenyl)-pyridinecarbonyl]-amino}-
propionic acid
3-(2-Chloro-phenyl)[(6-methoxy-quinolinecarbonyl)-amino]-propionic acid
(S)[(6-Methoxy-biphenylcarbonyl)-amino]o-tolyl-propionic acid
(S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}m-tolyl-propionic acid
(S){[6-(2-Fluoro-phenyl)-pyridinecarbonyl]-amino}(4-methoxy-phenyl)-
propionic acid
(S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}(4-fluoro-phenyl)-
propionic acid
(S)(3-Chloro-phenyl){[6-(2-fluoro-phenyl)-pyridinecarbonyl]-amino}-
propionic acid
(S)(4-Chloro-phenyl){[6-(2-fluoro-phenyl)-pyridinecarbonyl]-amino}-
propionic acid
(S)(4-Chloro-phenyl){[6-(2-chloro-phenyl)-pyridinecarbonyl]-amino}-
propionic acid
(S)(3-Chloro-phenyl){[6-(2-chloro-phenyl)-pyridinecarbonyl]-amino}-
propionic acid
3-(2-Chloro-phenyl){[6-(2-chloro-phenyl)-pyridinecarbonyl]-amino}-propionic
acid
(S){[6-(2-Fluoro-phenyl)-pyridinecarbonyl]-amino}(3-trifluoromethyl-phenyl)-
propionic acid
(S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}(2,4-dichloro-phenyl)-
propionic acid
(S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}(4-trifluoromethyl-
phenyl)-propionic acid
(S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}(3-trifluoromethyl-
phenyl)-propionic acid
(S){[6-Bromo(3,3-dimethyloxo-butoxy)-pyridinecarbonyl]-amino}o-
tolyl-propionic acid.
For example, also a subject of the invention is a compound of the formula I which is
chosen from
(S)[(5-Methoxyphenyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S){[6-(2,3-Dimethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[6-(2-Fluoro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[6-(5-Fluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic
acid
(S)o-Tolyl[(6-m-tolyl-pyridinecarbonyl)-amino]-propionic acid
(S)({6-[3-(1-Hydroxymethyl-ethyl)-phenyl]-pyridinecarbonyl}-amino)o-
tolyl-propionic acid
(S)(2,4-Dichloro-phenyl)[(5-methoxyphenyl-pyridinecarbonyl)-amino]-
propionic acid
(S)[(2,6-Dimethoxy-pyrimidinecarbonyl)-amino]o-tolyl-propionic acid
(S)[(5-Phenyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S){[3-(4,6-Dimethoxy-pyrimidinyloxy)-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[4-(Pyrimidinylsulfanyl)-pyridinecarbonyl]-amino}o-tolyl-propionic
acid
(S){[5-(2,3-Dichloro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[5-(2,3-Dimethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[5-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[6-(2,3-Difluoro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid
(S){[6-(2-Fluoromethoxy-phenyl)-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2-Fluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic
acid
(S){[6-(2-Methoxytrifluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S)({5-Methoxy[3-(5-methyl-[1,3,4]oxadiazolyl)-phenyl]-pyridine
carbonyl}-amino)o-tolyl-propionic acid
(S)(2-Chloro-phenyl)[(5-methoxynaphthalenyl-pyridinecarbonyl)-
amino]-propionic acid
(S)(2-Chloro-phenyl)[(5-methoxypyrazinyl-pyridinecarbonyl)-amino]-
propionic acid
(S)(2-Chloro-phenyl)[(6-methoxynaphthalenyl-pyridinecarbonyl)-
amino]-propionic acid
(S)(2-Chloro-phenyl){[5-methoxy(2-methyl-furanyl)-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2,3-dimethyl-phenyl)methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2-chloro-phenyl)methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Fluoro-phenyl){[5-methoxy(1,3,5-trimethyl-1H-pyrazolyl)-pyridine-
2-carbonyl]-amino}-propionic acid
(S)(2-Fluoro-phenyl){[5-methoxy(1-methyl-1H-indolyl)-pyridine
carbonyl]-amino}-propionic acid
(S)[(5-Methoxym-tolyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S){[6-(2-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(3,5-Dimethyl-isoxazolyl)methoxy-pyridinecarbonyl]-amino}o-
tolyl-propionic acid
(S){[6-(4-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(4-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(5-Acetyl-thiophenyl)methoxy-pyridinecarbonyl]-amino}(2-
chloro-phenyl)-propionic acid
(S){[6-(2-Fluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl-
propionic acid
or which is any one of these compounds, or a physiologically acceptable salt
thereof, or a physiologically acceptable solvate of any of them, wherein the
compound of the formula I is a subject of the invention in any of its stereoisomeric
forms or a mixture of stereoisomeric forms in any ratio, unless a specific
stereoisomeric form is specified with respect to any carbon atoms in the respective
compound.
Another subject of the present invention are processes for the preparation of the
compounds of the formula I which are outlined below and by which the compounds
are obtainable. For example, the preparation of the compounds of the formula I can
be carried out by reacting a compound of the formula II with a compound of the
formula III with formation of an amide bond. Various synthetic methods for the
formation of the amide bond are described in C. A. G. N. Montalbetti et al.,
Tetrahedron 61 (2005), 10827-10852, for example.
In general the compounds described in this patent are synthesized according to the
general scheme:
R R10 R
O 40 R
L 40
2 60
J 50
D D R
The formation of the amide bond between the carboxylic acid and the ß-amino-acid
can be done by the use of coupling agents well known to a person skilled in the art
and described for example in Tetrahedron (2005), 61(46), 10827-10852. As
alternatives instead of a carboxylic acid a carboxylic acid chloride and instead of the
free ß-amino acid a ß-amino acid ester, especially methyl- or ethylester, may be
used.
The ß-amino-acids used within this work are either commercially available or
prepared by methods described for example in JACS 1935, 1279 or by Rhodionow
in Chem. Abstr. 1953, 1051. The Rhodionow scheme is depicted below:
O OH
NH3 in EtOH
HO O
Enantiopure ß-amino acids can either be obtained commercially or prepared from
the racemic material by procedures described in Bioscience, Biotechnology and
Biochemistry, 2006, 1941.
A general procedure for the coupling process using heterocyclic carboxylic acids is
described below. The used carboxylic acids are commercially available.
Procedure A
0.25 mmol of the carboxylic acid is weighed into a reaction vial, 1.25 mmol N-ethyl
morpholine in 1 ml DMF is added, followed by 0.245 mmol TOTU in 0.5 ml DMF.
The mixture is allowed to react for 30 min at RT. 0.275 mmol of the amino acid
suspended in 0.5 ml DMF is added, the vial is closed with a screw cap and shaken
over night at RT. 0.2 ml TFA is added, the solution is filtered through syringe filters
and directly submitted to prep HPLC.
Yield of the products: Between 5% and 80%
Another general procedure consists of the synthesis of amino acid derivatives with a
functional group suitable for a subsequent Suzuki reaction as shown below.
6 0 O
1) Amide coupling
O A R
k y O
L 6 0
procedure
R 3 0 R O H
R D A N R
D A O H 4 0
2) Hydrolysis H
[ l , r , I ]
C B 4 0
[ l , r , I ]
IIIa
S u z u k c o u p n g
i l i O
L 6 0
O ( ) R O H
6 0 A B O H P
L r 2 d - c a a y s 5 0
, t l t
D A N R
D A N R
H 4 0
C B R
[ , r , I ]
The synthetic steps are described below in more detail:
Step 1: Esterification of ß-amino acids
Synthesis of (S)Amino(2-fluoro-phenyl)-propionic acid ethyl ester
,0g (27,3mmol) (S)Amino(2-fluorophenyl)-propionic acid are suspended in
27ml Methyl-THF and 16ml ethanol and heated to 80°C
2,45ml (4,02; 33,8mml; 1,24 eq) SOCl2 are added and the resulting mixture is
stirred for 2,5h at 80°C. The mixture is allowed to reach RT and stirred overnight.
The solvent is evaporated in vacuo and 9,2g of crude material is obtained, which is
washed several times with diisopropylether to obtain 6,34g of pure material (Yield:
94%).
According to this procedure the following derivatives have been prepared:
(S)Amino(2-chloro-phenyl)-propionic acid ethyl ester
(S)Aminoo-tolyl-propionic acid ethyl ester
(S)Aminop-tolyl-propionic acid ethyl ester
Step 2: Coupling of products from 1 to heterocyclic carboxylic acids substituted with
chlorine or bromine atoms:
Synthesis of (S)[(6-Bromomethoxy-pyridinecarbonyl)-amino](2-chloro-
phenyl)-propionic acid ethyl ester
4,87g (21mmol) 6-Bromomethoxy-pyridinecarboxylic acid and 4,17g (25,2
mmol, 1,2eq) CDI are suspended in 54ml Me-THF and heated to 50°C. After stirring
for 3,5h at this temperature the mixture is cooled to 0°C in an ice bath and 3,39ml
(24,2, 1,15eq) triethyl-amine is added. After that 6,1g (23,1 mmol, 1,1eq)of (S)
Amino(2-chloro-phenyl)-propionic acid ethyl ester are added within 20 minutes
and the resulting mixture is allowed to reach RT and stirred overnight.
50 ml water is added, the phases are separated and the organic phase is washed
several times with 50ml of saturated NaHCO3 solution followed by 50ml of 1N HCl
solution. The organic phase is evaporated in vacuo and 8,43g of product are
obtained. Yield: 89%.
According to this procedure the following derivatives have been prepared:
(S)[(6-Bromomethoxy-pyridinecarbonyl)-amino]o-tolyl-propionic acid ethyl
ester
(S)[(6-Bromomethoxy-pyridinecarbonyl)-amino]p-tolyl-propionic acid ethyl
ester
(S)[(6-Bromomethoxy-pyridinecarbonyl)-amino](2-fluoro-phenyl)-
propionic acid ethyl ester
(S)[(5-Chloromethoxy-pyridinecarbonyl)-amino]o-tolyl-propionic acid ethyl
ester
(S)[(5-Chloromethoxy-pyridinecarbonyl)-amino](2-chloro-phenyl)-
propionic acid ethyl ester
(S)[(5-Bromo-pyridinecarbonyl)-amino]o-tolyl-propionic acid ethyl ester
(S)[(2-Chloromethoxy-pyridinecarbonyl)-amino]o-tolyl-propionic acid ethyl
ester
(S)[(2-Chloro-pyridinecarbonyl)-amino]o-tolyl-propionic acid ethyl ester
(S)[(6-Chloro-pyridinecarbonyl)-amino]o-tolyl-propionic acid ethyl ester
Step 3: Hydrolysis of products from step 2:
Synthesis of (S)[(5-Chloromethoxy-pyridinecarbonyl)-amino](2-chloro-
phenyl)-propionic acid
8,03g (20,21mmol) (S)[(5-Chloromethoxy-pyridinecarbonyl)-amino](2-
chloro-phenyl)-propionic acid ethyl ester are dissolved in 15,2 ml (30,32 mmol,
1,5eq) 2N NaOH solution and stirred at 50°C for 9hours. The resulting mixture is
stirred overnight at RT.
105ml water and 30ml isopropanol are added and the pH is adjusted to pH = 3,0
with 2N HCl. The precipitate is separated and dried in vacuo to deliver 3,74g of
product (Yield: 50%).
According to this procedure the following derivatives have been prepared:
(S)[(6-Bromomethoxy-pyridinecarbonyl)-amino](2-chloro-phenyl)-
propionic acid
(S)[(6-Bromomethoxy-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S)[(6-Bromomethoxy-pyridinecarbonyl)-amino]p-tolyl-propionic acid
(S)[(6-Bromomethoxy-pyridinecarbonyl)-amino](2-fluoro-phenyl)-
propionic acid
(S)[(5-Chloromethoxy-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S)[(5-Bromo-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S)[(2-Chloromethoxy-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S)[(2-Chloro-pyridinecarbonyl)-amino]o-tolyl-propionic acid
(S)[(6-Chloro-pyridinecarbonyl)-amino]o-tolyl-propionic acid
Procedures for Suzuki couplings:
General Procedure B
Synthesis of (S)(2-Fluoro-phenyl)[(5-methoxyphenyl-pyridinecarbonyl)-
amino]-propionic acid (Example 263)
50mg (0,12 mmol) of (S)[(6-Bromomethoxy-pyridinecarbonyl)-amino](2-
fluoro-phenyl)-propionic acid are dissolved in 3 ml of DMF, 120mg (0,16mmol,
1,35eq) phenylboronic acid,10mg of bis(triphenylphosphine)palladium(II)chloride as
catalyst and 1ml of 1N Na2CO3 solution are added and the resulting mixture is
heated to 100°C for 6 hours. The mixture is filtrated via a pad of celite and subjected
to preparative HPLC chromatography to yield 15mg (31%) of product.
General Procedure C
Synthesis of (S)(2-Chloro-phenyl)[(6-methoxyphenyl-pyridinecarbonyl)-
amino]-propionic acid (Example 353)
To a solution of 50mg (0,13mmol) of (S)[(5-Chloromethoxy-pyridine
carbonyl)-amino](2-chloro-phenyl)-propionic acid in 3 ml of DMF are added:
25mg (0,21mmol, 1,5eq) phenylboronic acid, 60mg Na2CO3 (0,56mmol, 4,2 eq)
and 10mg (0,13eq) DI-MICRO-CHLOROBIS[2-
[(DIMETHYLAMINO)METHYL]PHENYL-C,N]DIPAL as catalyst. After the addition of
1ml of water the resulting mixture is heated to 100°C for 6 hours, the reaction is
filtered via a pad of celite and the resulting solution subjected to preparative HPLC
chromatography yielding 16mg of product (Yield: 29%).
Synthesis of 6-Bromo(3,3-dimethyloxo-butoxy)-pyridinecarboxylic acid
methyl ester
3,85g (21.55mmol) of 1-bromopinacolone are added to 6-Bromohydroxy-pyridine-
2-carboxylic acid methyl ester (5,0g, 21.55mmol) and Cesium carbonate (21.06g,
64,65 mmol) in 100ml of acetone and the resulting mixture is stirred overnight at
room temperature. The mixture is filtrated, the solvent removed in vacuo and the
crude product obtained (6g, 84% yield) is used in the next step without further
purification
Synthesis of 6-Bromo(3,3-dimethyloxo-butoxy)-pyridinecarboxylic acid
6g (18,17mmol) of 6-Bromo(3,3-dimethyloxo-butoxy)-pyridinecarboxylic acid
methyl ester are dissolved in 80ml of MeOH and 36,34ml of 1N NaOH (2Eq) are
added and the resulting mixture is stirred overnight. The solvent is removed in
vacuo, the residue taken up in a mixture of 60ml CH2Cl2 and 40ml 1N HCl and the
organic phase is separated and dried over Na2SO4. The solvent is removed in
vacuo and the crude product is used in the next step without further purification
(5.0g, 73% yield)
Synthesis of 5-(3,3-Dimethyloxo-butoxy)phenyl-pyridinecarboxylic acid
3.4g (10.7mmol) of 6-Bromo(3,3-dimethyloxo-butoxy)-pyridinecarboxylic
acid and 1.5g (12.34 mmol) of phenylboronic acid are heated together with cesium
carbonate (5,22g, 16.02 mmol) and dichlorobis(triphenylphosphinepalladium(II)
chloride (750mg, 0.1mol%) in 180ml of DMF and 70ml of water at 100°C for 24
hours. The solvent is evaporated in vacuo and the residue subjected to HPLC
chromatography yielding 450mg of product (13%)
Synthesis of (S){[5-(3,3-Dimethyloxo-butoxy)phenyl-pyridinecarbonyl]-
amino}o-tolyl-propionic acid
-(3,3-Dimethyloxo-butoxy)phenyl-pyridinecarboxylic acid (300mg,
0,96mmol) are dissolved in 5 ml of DMF, triethylamine (194mg, 1.914mmol), TOTU
(345mg, 1,053mmol) and (S)amino(2-methyl-phenyl)-propionic acid are added
and the resulting mixture is stirred overnight at RT. The solvent is removed in vacuo
and the residue subjected to HPLC chromatography delivering 180mg (40%) of
product.
Synthesis of (S){[5-((R)Hydroxy-3,3-dimethyl-butoxy)phenyl-pyridine
carbonyl]-amino}o-tolyl-propionic acid and (R){[5-((R)Hydroxy-3,3-dimethyl-
butoxy)phenyl-pyridinecarbonyl]-amino}o-tolyl-propionic acid
HO N
O HO
(S){[5-(3,3-Dimethyloxo-butoxy)phenyl-pyridinecarbonyl]-amino}o-
tolyl-propionic acid (135mg, 0,284mmol) are dissolved in 5 ml of MeOH and 12.5mg
(0,330mmol) of NaBH4 are added at 0°C. The mixture is allowed to reach RT,
stirring continued for 4 hours and the reaction was quenched with water and 1N
HCl. (10ml each). After extraction with ethylacetat the solvent is removed in vacuo
and the residue subjected to HPLC chromatogrophy: Both diastereomers shown
above were isolated, the R configuration on the chiral alcohol carbon was arbitrarily
assigned to the diastereomer with the shorter retention time on the HPLC column.
30 40 50 60
The groups A, D, E, L, G, R , R , R , R and R in the compounds of the
formulae II and III are defined as in the compounds of the formula I and additionally
functional groups can be present in protected form or in the form of a precursor
group which is later converted into the final group. The group J in the compounds of
the formula II can be HO- (hydroxy), i.e. the compound of the formula II can thus be
a carboxylic acid, or another group which can be replaced by the group NH in the
compound of the formula III in a substitution reaction, for example an aryloxy group
such as optionally substituted phenoxy or an alkyloxy group such as a (C -C )-alkyl-
O- group, for example a (C -C )-alkyl-O- group like methoxy or ethoxy, or halogen,
for example chlorine or bromine, and the compound of the formula II can thus be a
reactive ester like an aryl ester or alkyl ester, for example a methyl ester or ethyl
ester, or an acid halide, for example an acid chloride or acid bromide, of the
respective carboxylic acid. The compounds of the formulae II and III can also be
employed, and the compounds of the formula I obtained, in the form of a salt, for
example an acid addition salt such as an hydrohalide, for example a hydrochloride,
of the compound of the formula III and/or an alkaline metal salt, for example a
sodium salt, of a compound of the formula II in which J is HO-. Likewise, in all other
reactions in the preparation of the compounds of the formula I, including the
preparation of starting compounds, compounds can also be employed and/or
products obtained in the form a salt.
In case a compound of the formula II is employed in which J is HO-, the carboxylic
acid group HO-C(O)- is generally activated in situ by means of a customary amide
coupling reagent or converted into a reactive carboxylic acid derivative which can be
prepared in situ or isolated. For example, the compound of the formula II in which J
is HO- can be converted into an acid halide, such as the compound of the formula II
in which J is chlorine or bromine, by treatment with thionyl chloride, phosphorus
pentachloride, phosphorus tribromide or oxalyl chloride, or treated with an alkyl
chloroformate like ethyl chloroformate or isobutyl chloroformate to give a mixed
anhydride. In a favorable method for the conversion into the acid chloride, the acid
is treated with oxalyl chloride in the presence of a catalytic amount of an amide such
as N,N-dimethylformamide in an inert solvent such as a hydrocarbon or chlorinated
hydrocarbon or an ether, at temperatures from about 0 °C to about 60 °C, for
example at room temperature. Customary amide coupling reagents which can be
employed, are propanephosphonic anhydride, N,N'-carbonyldiazoles like N,N'-
carbonyldiimidazole (CDI), carbodiimides like 1,3-diisopropylcarbodiimide (DIC),
1,3-dicyclohexylcarbodiimide (DCC) or 1-(3-dimethylaminopropyl)
ethylcarbodiimide hydrochloride (EDC), carbodiimides together with additives like 1-
hydroxy-benzotriazole (HOBT) or 1-hydroxyazabenzotriazole (HOAT), uronium-
based coupling reagents like O-(7-azabenzotriazolyl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate (HATU), O-(benzotriazolyl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate (HBTU) or O-
(cyano(ethoxycarbonyl)methyleneamino)-N,N,N',N'-tetramethyluronium
tetrafluoroborate (TOTU), and phosphonium-based coupling reagents like
(benzotriazolyloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP),
(benzotriazolyloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) or
bromotripyrrolidinophosphonium hexafluorophosphate (PyBroP).
The reaction conditions for the preparation of the compounds of the formula I from
compounds of the formulae II and III depend on the particulars of the specific case,
for example the meaning of the group J or the employed coupling reagent, and are
familiar to a skilled person in view of the general knowledge in the art. For example,
in case a compound of the formula II in which J is alkyl-O-, like methoxy or ethoxy,
is reacted with a compound of the formula III, generally the reaction is carried out in
an inert solvent, for example a hydrocarbon or chlorinated hydrocarbon like
benzene, toluene, xylene, chlorobenzene, dichloromethane, chloroform or
dichloroethane, an ether like tetrahydrofuran (THF), 2-methyltetrahydrofuran,
dioxane, dibutyl ether, diisopropyl ether or dimethoxyethane (DME), or a mixture of
solvents, at elevated temperatures, for example at temperatures from about 40 °C to
about 140 °C, in particular at temperatures from about 50 °C to about 120 °C, for
example at about the boiling temperature of the solvent. In case a compound of the
formula II in which J is halogen, like chlorine or bromine, is reacted with a compound
of the formula III, generally the reaction is likewise carried out in an inert solvent, for
example a hydrocarbon or chlorinated hydrocarbon or ether like the aforementioned
ones, an ester like ethyl acetate or butyl acetate, a nitrile like acetonitrile, or water,
or a mixture of solvents including a mixture of water and an organic solvent which is
miscible or immiscible with water, at temperatures from about -10 °C to about 100
°C, in particular at temperatures from about 0 °C to about 80 °C, for example at
about room temperature. Favorably, the reaction of a compound of the formula II in
which J is halogen with a compound of the formula III is carried out in the presence
of a base such as a tertiary amine, like triethylamine, N-ethyl-diisopropylamine
(EDIA), N-methylmorpholine, N-ethylmorpholine or pyridine, or an inorganic base
such as an alkaline metal hydroxide, carbonate or hydrogencarbonate, like sodium
hydroxide, potassium hydroxide, sodium carbonate or sodium hydrogencarbonate.
In case a compound of the formula II in which J is HO- is reacted with a compound
of the formula III and the carboxylic acid group is activated by means of an amide
coupling reagent such as, for example, a carbodiimide or TOTU, the reaction is
generally carried out under anhydrous conditions in an inert aprotic solvent, for
example an ether like THF, dioxane or DME, an amide like N,N-dimethylformamide
(DMF) or N-methylpyrrolidone (NMP), at temperatures from about -10 °C to about
40 °C, in particular at temperatures from about 0 °C to about 30 °C, for example at
room temperature, in the presence of a base such as a tertiary amine, like
triethylamine, EDIA, N-methylmorpholine or N-ethylmorpholine. In case the
compound of the formula III is employed in the form of an acid addition salt in the
reaction with the compound of the formula II, usually a sufficient amount of a base is
added in order to liberate the free compound of the formula III.
As indicated above, during the formation of the amide bond between the
compounds of the formulae II and III functional groups in the compounds of the
formulae II and III can be present in protected form or in the form of a precursor
group. Depending on the particulars of the specific case, it may be necessary or
advisable for avoiding an undesired course of the reaction or side reactions to
temporarily block any functional groups by protective groups and remove them later,
or to let functional groups be present in the form of a precursor group which is later
converted into the desired final group. This applies correspondingly to all reactions
in the course of the synthesis of the compounds of the formula I including the
synthesis of intermediates, starting compounds and building blocks. Respective
synthetic strategies are commonly used in the art. Details about protective groups
and their introduction and removal are described in P. G. M. Wuts and T. W.
Greene, Greene's Protective Groups in Organic Synthesis, 4. ed. (2007), John Wiley
& Sons, for example. Examples of protective groups which may be mentioned, are
benzyl protective groups which may occur in the form of benzyl ethers of hydroxy
groups and benzyl esters of carboxylic acid groups from which the benzyl group can
be removed by catalytic hydrogenation in the presence of a palladium catalyst, tert-
butyl protective groups which may occur in the form of tert-butyl esters of carboxylic
acid groups from which the tert-butyl group can be removed by treatment with
trifluoroacetic acid, acyl protective groups which may be used to protect hydroxy
groups and amino groups in the form of esters and amides and which can be
cleaved by acidic or basic hydrolysis, and alkyloxycarbonyl protective groups which
may occur in the form of tert-butoxycarbonyl derivatives of amino groups which can
be cleaved by treatment with trifluoroacetic acid. Undesired reactions of carboxylic
acid groups, for example the carboxylic acid group present in the compound of the
formula III in case G is a carboxylic acid group in the desired compound of the
formula I, can also be avoided by employing them in the reaction with the
compounds of the formula II in the form of other esters, for example in the form of
alkyl esters like the methyl or ethyl ester which can be cleaved by hydrolysis, for
example by means of an alkaline metal hydroxide like sodium hydroxide or lithium
hydroxide. As examples of a precursor group, the cyano group (NC-, N -) may be
mentioned which can be converted into a carboxylic acid group, a carboxylic acid
ester group and a carboxamide group under hydrolytic conditions or into a
aminomethyl group by reduction, and the nitro group which can be converted into an
amino group by reduction, for example by catalytic hydrogenation or by reduction
with sodium dithionite, for example. A further example of a precursor group is an
oxo group, which may initially be present in the course of the synthesis of
compounds of the formula I containing a hydroxy group, and which can be reduced,
for example with a complex hydride such as sodium borohydride, or reacted with an
organometallic compound, for example a Grignard compound. If any protective
groups or precursor groups are present in the compounds of the formulae II and III
and the direct product of the reaction is not yet the desired final compound, the
removal of the protective group or conversion into the desired compound can in
general also be carried out in situ.
The starting compounds for the synthesis of the compounds of the formula I can
generally be prepared according to procedures described in the literature or
analogously to such procedures, or are commercially available.
The -amino acids and derivatives of the formula III are commercially available or
can be synthesized by well-known standard methods, or analogously to such
methods, from readily available starting compounds. For example, for the
preparation of -amino acids and their alkyl esters of the formula III in which R and
60 30 40
R are hydrogen, can carbonyl compounds of the formula R -C(O)-R , in
particular aldehydes of the formula R -C(O)-H, be reacted with malonic acid mono-
ethyl ester and ammonia in the presence of a base such as an alkaline metal
hydroxide like potassium hydroxide in a solvent such as an alcohol like ethanol, as
described in V. M. Rodionov et al., Izv. Akad. Nauk SSSR, Ser. Khim. (1952), 696-
702 (Chem. Abstr. 47 (1953), abstr. no. 61888), or ammonia added to the double
bond in the condensation product of the carbonyl compound with malonic acid or
diethyl malonate and in the case of the condensation product with diethyl malonate
the reaction product treated with an acid such as hydrochloric acid, as described in
V. Scudi, J. Am. Chem. Soc. 57 (1935), 1279; or M. K. Tse et al., Chem. Eur. J. 12
(2006), 1855-1874, and in the obtained product an ester group hydrolyzed to the
carboxylic acid, or a carboxylic acid group esterified, respectively, as desired and
outlined above. Enantiomerically pure such compounds of the formula III, for
example, can be obtained from the racemic compounds by crystallization of a salt
with an optically active acid, such as tartaric acid, by stereoselective enzymatic or
microbial degradation, for example as described in the mentioned article by M. K.
Tse et al., or in J. Mano et al., Bioscience, Biotechnology and Biochemistry 70
(2006), 1941-1946. In another strategy for the synthesis of such compounds, in
40 50 60 30 32
particular compounds in which R , R and R are hydrogen and R is R , the
respective 3-substituted acrylic acid, which can be obtained from the corresponding
aldehyde, is converted into the acid chloride, for example with oxalyl chloride, and
the acid chloride converted with an alcohol into an ester, for example into the tert-
butyl ester using tert-butanol, and the amino group is then introduced by reaction
with the lithium salt of an optically active amine, for example the lithium salt of (R)-
(+)-N-benzyl-N-(1-phenylethyl)amine, and in the obtained 3-substituted tert-butyl 3-
(N-benzyl-N-(1-phenylethyl)amino)propionate the benzyl group and the phenylethyl
group is cleaved off by means of catalytic hydrogenation (cf. S. G. Davies et al.,
Tetrahedron: Asymmetry 2 (1991), 183-186); S. G. Davies et al., J. Chem. Soc.
Perkin Trans. 1 (1994), 1129-1139).
The introduction of the structural moieties of the compounds of the formula in the
course of the synthesis can also occur in another order than outlined above. For
example, in the case of compounds of the formula I in which R is another group
than hydroxy, instead of preparing a compound of the formula II which contains the
group R and reacting it with a compound of the formula III, also a compound of the
formula IIc, which specifically comprises a hydroxy group in place of the group R ,
can be reacted with a compound of the formula III, and the obtained compound of
the formula Ia then modified on the hydroxy group by reaction with a compound of
the formula VIII to give a compound of the formula I in which R is different from
hydroxy, i.e. a compound of the formula Ib. At the end, like in the compounds of the
formula I when prepared as outlined above, any protective groups in the compounds
of the formula Ib may still be deprotected and/or precursor group converted into the
final groups.
40
HO O
40
HO O
E 60
A 50
40
R a-O
10a R
R T L
E 60
VIII D
40 50 60
The groups A, D, E, L, G, R , R , R and R in the compounds of the formulae Ia,
Ib and IIc are defined as in the compounds of the formula I and additionally
functional groups can be present in protected form or in the form of a precursor
group which is later converted into the final group. The group J in the compounds of
the formula IIc is defined as in the compounds of the formula II. The group R in
the compounds of the formula Ib is defined as in the compounds of the formulae IIb
and VIII. The explanations given above on the reaction of the compounds of the
formulae II and III and the reaction of the compounds of the formulae IIa and VIII
apply correspondingly to the reaction of the compounds of the formulae IIc and III
and the reaction of the compounds Ia and VIII, respectively.
For obtaining further compounds of the formula I, various transformations of
functional groups can be carried out under standard conditions in compounds of the
formula I or intermediates or starting compounds of the synthesis of the compounds
of the formula I. For example, a hydroxy group, including a hydroxy group
representing R in a compound of the formula I, can be etherified, as outlined
above, for example by alkylation with a halogen compound, for example a bromide
or iodide, in the presence of a base such an alkali metal carbonate like potassium
carbonate or cesium carbonate in an inert solvent such as an amide like DMF or
NMP or a ketone like acetone or butanone, or with the respective alcohol under
the conditions of the Mitsunobu reaction referred to above. A hydroxy group can be
esterified to give a carboxylic acid ester or a sulfonic acid ester, or converted into a
halide by treatment with a halogenating agent. Halogen atoms can also be
introduced by means of suitable halogenating agents which replace a hydrogen
atom in the starting compound, for example by means of elemental bromine, sulfuryl
chloride or 1-chloromethylfluoro-1,4-diazoniabicyclo[2.2.2]octane
bis(tetrafluoroborate), which introduce a bromine, chlorine and fluorine substituent,
respectively, for example in the 4-position of a compound of the formula IIb. A
halogen atom can generally be replaced with a variety of groups in substitution
reactions which may also be transition-metal catalyzed reactions. A nitro group can
be reduced to an amino group, for example by catalytic hydrogenation. An amino
group can be modified under standard conditions for alkylation, for example by
reaction with a halogen compound or by reductive amination of a carbonyl
compound, or for acylation or sulfonylation, for example by reaction with an
activated carboxylic acid or a carboxylic acid derivate like an acid chloride or
anhydride or a sulfonic acid chloride. A carboxylic ester group can be hydrolyzed
under acidic or basic conditions to give a carboxylic acid. An acid group can be
activated or converted into a reactive derivative as outlined above and reacted with
an alcohol or an amine or ammonia to give an ester or amide. A primary amide can
be dehydrated to give a nitrile. A sulfur atom in an alkyl-S- group or in a heterocyclic
ring can be oxidized with a peroxide like hydrogen peroxide or a peracid to give a
sulfoxide moiety S(O) or a sulfone moiety S(O) . A carboxylic acid group, carboxylic
acid ester group and a ketone group can be reduced to an alcohol, for example with
a complex hydride such al lithium aluminium hydride, lithium borohydride or sodium
borohydride, or reacted with an organometallic compound or a Grignard compound
to give an alcohol. Primary and secondary hydroxy groups can also be oxidized to
the oxo groups. All reactions in the preparation of the compounds of the formula I
are known per se and can be carried out in a manner familiar to a person skilled in
the art according to, or analogously to, procedures which are described in the
standard literature, for example in Houben-Weyl, Methods of Organic Chemistry,
Thieme; or Organic Reactions, John Wiley & Sons; or R. C. Larock, Comprehensive
Organic Transformations: A Guide to Functional Group Preparations, 2. ed. (1999),
John Wiley & Sons, and the references quoted therein.
Another subject of the present invention are the novel starting compounds and
intermediates occurring in the synthesis of the compounds of the formula I, including
the compounds of the formulae Ia, Ib, Ic, II, IIc, III, IIIa, IV, V and VIII, wherein the
2 10 10a 30 40 50 60
groups A, D, E, L, G, J, T, R , R , R , R , R , R and R are defined as above,
in any of their stereoisomeric forms or a mixture of stereoisomeric forms in any ratio,
and their salts, and solvates of any of them, and their use as synthetic intermediates
or starting compounds. All general explanations, specifications of embodiments and
definitions of numbers and groups given above with respect to the compounds of
the formula I apply correspondingly to the said intermediates and starting
compounds. A subject of the invention are in particular the novel specific starting
compounds and intermediates described herein. Independently thereof whether they
are described as a free compound and/or as a specific salt, they are a subject of the
invention both in the form of the free compounds and in the form of their salts, and if
a specific salt is described, additionally in the form of this specific salt.
The compounds of the formula I inhibit the protease cathepsin A as can be
demonstrated in the pharmacological test described below and in other tests which
are known to a person skilled in the art. The compounds of the formula I and their
physiologically acceptable salts and solvates therefore are valuable pharmaceutical
active compounds. The compounds of the formula I and their physiologically
acceptable salts and solvates can be used for the treatment of cardiovascular
diseases such as heart failure including systolic heart failure, diastolic heart failure,
diabetic heart failure and heart failure with preserved ejection fraction,
cardiomyopathy, myocardial infarction, left ventricular dysfunction including left
ventricular dysfunction after myocardial infarction, cardiac hypertrophy, myocardial
remodeling including myocardial remodeling after infarction or after cardiac surgery,
valvular heart diseases, vascular hypertrophy, vascular remodeling including
vascular stiffness, hypertension including pulmonary hypertension, portal
hypertension and systolic hypertension, atherosclerosis, peripheral arterial occlusive
disease (PAOD), restenosis, thrombosis and vascular permeability disorders,
ischemia and/or reperfusion damage including ischemia and/or reperfusion damage
of the heart and ischemia and/or reperfusion damage of the retina, inflammation and
inflammatory diseases such as rheumatoid arthritis and osteoarthritis, renal
diseases such as renal papillary necrosis and renal failure including renal failure
after ischemia/reperfusion, pulmonary diseases such as cystic fibrosis, chronic
bronchitis, chronic obstructive pulmonary disease (COPD), asthma, acute
respiratory dystress syndrome (ARDS), respiratory tract infections and lung
carcinoma, immunological diseases, diabetic complications including diabetic
nephropathy and diabetic cardiomyopathy, fibrotic diseases such as pulmonary
fibrosis including idiopathic lung fibrosis, cardiac fibrosis, vascular fibrosis,
perivascular fibrosis, renal fibrosis including renal tubulointerstitial fibrosis, fibrosing
skin conditions including keloid formation, collagenosis and scleroderma, and liver
fibrosis, liver diseases such as liver cirrhosis, pain such as neuropathic pain,
diabetic pain and inflammatory pain, macular degeneration, neurodegenerative
diseases or psychiatric disorders, or for cardioprotection including cardioprotection
after myocardial infarction and after cardiac surgery, or for renoprotection, for
example. The treatment of diseases is to be understood as meaning both the
therapy of existing pathological changes or malfunctions of the organism or of
existing symptoms with the aim of relief, alleviation or cure, and the prophylaxis or
prevention of pathological changes or malfunctions of the organism or of symptoms
in humans or animals which are susceptible thereto and are in need of such a
prophylaxis or prevention, with the aim of a prevention or suppression of their
occurrence or of an attenuation in the case of their occurrence. For example, in
patients who on account of their disease history are susceptible to myocardial
infarction, by means of the prophylactic or preventive medicinal treatment the
occurrence or re-occurrence of a myocardial infarction can be prevented or its
extent and sequelae decreased, or in patients who are susceptible to attacks of
asthma, by means of the prophylactic or preventive medicinal treatment such
attacks can be prevented or their severity decreased. The treatment of diseases can
occur both in acute cases and in chronic cases. The efficacy of the compounds of
the formula I can be demonstrated in the pharmacological test described below and
in other tests which are known to a person skilled in the art. The compounds of the
72 73
formula I with G selected from R -N(R )-C(O)- and their physiologically acceptable
salts and solvates can also be used as prodrugs.
The compounds of the formula I and their physiologically acceptable salts and
solvates can therefore be used in animals, in particular in mammals and specifically
in humans, as a pharmaceutical or medicament on their own, in mixtures with one
another or in the form of pharmaceutical compositions. A subject of the present
invention also are the compounds of the formula I and their physiologically
acceptable salts and solvates for use as a pharmaceutical, as well as
pharmaceutical compositions and medicaments which comprise an efficacious dose
of at least one compound of the formula I and/or a physiologically acceptable salt
thereof and/or solvate thereof as an active ingredient and a pharmaceutically
acceptable carrier, i.e. one or more pharmaceutically innocuous, or nonhazardous,
vehicles and/or excipients, and optionally one or more other pharmaceutical active
compounds. A subject of the present invention furthermore are the compounds of
the formula I and their physiologically acceptable salts and solvates for use in the
treatment of the diseases mentioned above or below, including the treatment of any
one of the mentioned diseases, for example the treatment of heart failure,
myocardial infarction, cardiac hypertrophy, diabetic nephropathy, diabetic
cardiomyopathy, cardiac fibrosis, or ischemia and/or reperfusion damage, or for
cardioprotection, the use of the compounds of the formula I and their physiologically
acceptable salts and solvates for the manufacture of a medicament for the treatment
of the diseases mentioned above or below, including the treatment of any one of the
mentioned diseases, for example the treatment of heart failure, myocardial
infarction, cardiac hypertrophy, diabetic nephropathy, diabetic cardiomyopathy,
cardiac fibrosis, or ischemia and/or reperfusion damage, or for cardioprotection,
wherein the treatment of diseases comprises their therapy and prophylaxis as
mentioned above, as well as their use for the manufacture of a medicament for the
inhibition of cathepsin A. A subject of the invention also are methods for the
treatment of the diseases mentioned above or below, including the treatment of any
one of the mentioned diseases, for example the treatment of heart failure,
myocardial infarction, cardiac hypertrophy, diabetic nephropathy, diabetic
cardiomyopathy, cardiac fibrosis, or ischemia and/or reperfusion damage, or for
cardioprotection, which comprise administering an efficacious amount of at least
one compound of the formula I and/or a physiologically acceptable salt thereof
and/or solvate thereof to a human or an animal which is in need thereof. The
compounds of the formula I and pharmaceutical compositions and medicaments
comprising them can be administered enterally, for example by oral, sublingual or
rectal administration, parenterally, for example by intravenous, intramuscular,
subcutaneous or intraperitoneal injection or infusion, or by another type of
administration such as topical, percutaneous, transdermal, intra-articular or
intraocular administration.
The compounds of the formula I and their physiologically acceptable salts and
solvates can also be used in combination with other pharmaceutical active
compounds, wherein in such a combination use the compounds of the formula I
and/or their physiologically acceptable salts and/or solvates and one or more other
pharmaceutical active compounds can be present in one and the same
pharmaceutical composition or in two or more pharmaceutical compositions for
separate, simultaneous or sequential administration. Examples of such other
pharmaceutical active compounds are diuretics, aquaretics, angiotensin converting
enzyme (ACE) inhibitors, angiotensin receptor blockers, renin inhibitors, beta
blockers, digoxin, aldosterone antagonists, NO donors, nitrates, hydralazines,
ionotropes, vasopressin receptor antagonists, soluble guanylate cyclase activators,
a) activators,
statins, peroxisome proliferator-activated receptor-alpha (PPAR-
peroxisome proliferator-activated receptor-gamma (PPAR-g) activators,
rosiglitazone, pioglitazone, metformin, sulfonylureas, glucagon-like peptide 1 (GLP-
1) agonists, dipeptidyl peptidase IV (DPPIV) inhibitors, insulins, anti-arrhythmics,
endothelin receptor antagonists, calcium antagonists, phosphodiesterase inhibitors,
phosphodiesterase type 5 (PDE5) inhibitors, factor II/factor IIa inhibitors, factor
IX/factor IXa inhibitors, factor X/factor Xa inhibitors, factor XIII/factor XIIIa inhibitors,
heparins, glycoprotein IIb/IIIa antagonists, P2Y12 receptor antagonists, clopidogrel,
coumarins, cyclooxygenase inhibitors, acetylsalicylic acid, RAF kinase inhibitors and
p38 mitogen-activated protein kinase inhibitors. A subject of the present invention
also is the said combination use of any one or more of the compounds of the
formula I disclosed herein and their physiologically acceptable salts and solvates,
with any one or more, for example one or two, of the mentioned other
pharmaceutical active compounds.
The pharmaceutical compositions and medicaments according to the invention
normally contain from about 0.5 to about 90 percent by weight of compounds of the
formula I and/or physiologically acceptable salts and/or solvates thereof, and an
amount of active ingredient of the formula I and/or its physiologically acceptable salt
and/or solvate which in general is from about 0.2 mg to about 1.5 g, particularly from
about 0.2 mg to about 1 g, more particularly from about 0.5 mg to about 0.5 g, for
example from about 1 mg to about 0.3 g, per unit dose. Depending on the kind of
the pharmaceutical composition and other particulars of the specific case, the
amount may deviate from the indicated ones. The production of the pharmaceutical
compositions and medicaments can be carried out in a manner known per se. For
this, the compounds of the formula I and/or their physiologically acceptable salts
and/or solvates are mixed together with one or more solid or liquid vehicles and/or
excipients, if desired also in combination with one or more other pharmaceutical
active compounds such as those mentioned above, and brought into a suitable form
for dosage and administration, which can then be used in human medicine or
veterinary medicine.
As vehicles, which may also be looked upon as diluents or bulking agents, and
excipients suitable organic and inorganic substances can be used which do not
react in an undesired manner with the compounds of the formula I. As examples of
types of excipients, or additives, which can be contained in the pharmaceutical
compositions and medicaments, lubricants, preservatives, thickeners, stabilizers,
disintegrants, wetting agents, agents for achieving a depot effect, emulsifiers, salts,
for example for influencing the osmotic pressure, buffer substances, colorants,
flavorings and aromatic substances may be mentioned. Examples of vehicles and
excipients are water, vegetable oils, waxes, alcohols such as ethanol, isopropanol,
1,2-propanediol, benzyl alcohols, glycerol, polyols, polyethylene glycols or
polypropylene glycols, glycerol triacetate, polyvinylpyrrolidone, gelatin, cellulose,
carbohydrates such as lactose or starch like corn starch, sodium chloride, stearic
acid and its salts such as magnesium stearate, talc, lanolin, petroleum jelly, or
mixtures thereof, for example saline or mixtures of water with one or more organic
solvents such as mixtures of water with alcohols. For oral and rectal use,
pharmaceutical forms such as, for example, tablets, film-coated tablets, sugar-
coated tablets, granules, hard and soft gelatin capsules, suppositories, solutions,
including oily, alcoholic or aqueous solutions, syrups, juices or drops, furthermore
suspensions or emulsions, can be used. For parenteral use, for example by injection
or infusion, pharmaceutical forms such as solutions, for example aqueous solutions,
can be used. For topical use, pharmaceutical forms such as ointments, creams,
pastes, lotions, gels, sprays, foams, aerosols, solutions or powders can be used.
Further suitable pharmaceutical forms are, for example, implants and patches and
forms adapted to inhalation. The compounds of the formula I and their
physiologically acceptable salts can also be lyophilized and the obtained
lyophilizates used, for example, for the production of injectable compositions. In
particular for topical application, also liposomal compositions are suitable. The
pharmaceutical compositions and medicaments can also contain one or more other
active ingredients and/or, for example, one or more vitamins.
As usual, the dosage of the compounds of the formula I depends on the
circumstances of the specific case and is adjusted by the physician according to the
customary rules and procedures. It depends, for example, on the compound of the
formula I administered and its potency and duration of action, on the nature and
severity of the individual syndrome, on the sex, age, weight and the individual
responsiveness of the human or animal to be treated, on whether the treatment is
acute or chronic or prophylactic, or on whether further pharmaceutical active
compounds are administered in addition to a compound of the formula I. Normally,
in the case of administration to an adult weighing about 75 kg, a dose from about
0.1 mg to about 100 mg per kg per day, in particular from about 1 mg to about 20
mg per kg per day, for example from about 1 mg to about 10 mg per kg per day (in
each case in mg per kg of body weight), is administered. The daily dose can be
administered in the form of a single dose or divided into a number of individual
doses, for example two, three or four individual doses. The administration can also
be carried out continuously, for example by continuous injection or infusion.
Depending on the individual behavior in a specific case, it may be necessary to
deviate upward or downward from the indicated dosages.
Besides as a pharmaceutical active compound in human medicine and veterinary
medicine, the compounds of the formula I can also be employed as an aid in
biochemical investigations or as a scientific tool or for diagnostic purposes, for
example in in-vitro diagnoses of biological samples, if an inhibition of cathepsin A is
intended. The compounds of the formula I and their salts can also be used as
intermediates, for example for the preparation of further pharmaceutical active
substances.
The following examples illustrate the invention.
Abbreviations
ACN acetonitrile
DCM dichloromethane
DMF N,N-dimethylformamide
DMSO dimethyl sulfoxide
EA ethyl acetate
EDIA N-ethyl-diisopropylamine
FA formic acid
MOH methanol
NEM N-ethyl-morpholine
TFA trifluoroacetic acid
THF tetrahydrofuran
TOTU O-(cyano(ethoxycarbonyl)methyleneamino)-N,N,N',N'-
tetramethyluronium tetrafluoroborate
When example compounds containing a basic group were purified by preparative
high pressure liquid chromatography (HPLC) on reversed phase (RP) column
material and, as customary, the eluent was a gradient mixture of water and
acetonitrile containing trifluoroacetic acid, they were in part obtained in the form of
their acid addition salts with trifluoroacetic acid, depending on the details of the
work-up such as evaporation or lyophilization conditions. In the names of the
example compounds and the structural formulae such contained trifluoroacetic acid
is not specified. Likewise are other acid components of example compounds
obtained in the form of an acid addition salt in general not specified in the name and
the formula.
The prepared compounds were in general characterized by spectroscopic data and
chromatographic data, in particular mass spectra (MS) and HPLC retention times
(Rt; in min) which were obtained by combined analytical HPLC/MS characterization
(LC/MS), and/or nuclear magnetic resonance (NMR) spectra. Unless specified
otherwise, H-NMR spectra were recorded at 500 MHz in D -DMSO as solvent at
298 K. In the NMR characterization, the chemical shift d (in ppm), the number of
hydrogen atoms (H), and the multiplicity (s: singlet, d: doublet, dd: doublet of
doublets, t: triplet, q: quartet, m: multiplet) of the peaks as determined from the
graphically depicted spectra are given. In the MS characterization, in general the
mass number (m/z) of the peak of the molecular ion [M], for example [M ], or of a
related ion such as the ion [M+1], for example [(M+1) ], i.e. the protonated
molecular ion [(M+H) ], or the ion [M-1], for example [(M-1) ], i.e. the deprotonated
molecular ion [(M-H) ], which was formed depending on the ionization method used,
is given. Generally, the ionization method was electrospray ionization (ES).The
particulars of the LC/MS methods used are as follows.
Method LC1
Column: YMC-Pack Jsphere H80, 33 x 2.1 mm, 4 µm; flow: 1.3 ml/min; room
temperature; eluent A: water + 0.05 % TFA; eluent B: ACN + 0.05 % TFA; gradient:
from 95 % A + 5 % B to 5 % A +95 % B within 2.5 min; MS ionization method: ES
Method LC2
Column: Waters XBridge C18, 50 x 4.6 mm, 2.5 µm; flow: 1.3 ml/min; room
temperature; eluent A: water + 0.1 % FA; eluent B: ACN + 0.08 % FA; gradient: from
97 % A + 3 % B to 40 % A +60 % B within 3.5 min, then to 2 % A + 98 % B within
0.5 min, then 2 % A + 98 % B for 1.0 min, then to 97 % A + 3 % B within 0.2 min,
then 97 % A + 3 % B for 1.3 min; MS ionization method: ES
Method LC3
Column: YMC-Pack Jsphere H80, 33 x 2.1 mm, 4 µm; flow: 1.0 ml/min; room
temperature; eluent A: water + 0.05 % TFA; eluent B: ACN + 0.05 % TFA; gradient:
98 % A + 2 % B for 1.0 min, then to 5 % A +95 % B within 4.0 min, then 5 % A + 95
% B for 1.25 min; MS ionization method: ES
Method LC4
Column: Waters XBridge C18, 50 x 4.6 mm, 2.5 µm; flow: 1.3 ml/min; 40 °C; eluent
A: water + 0.1 % FA; eluent B: ACN + 0.1 % FA; gradient: from 97 % A + 3 % B to
40 % A + 60 % B within 3.5 min, then to 2 % A + 98 % B within 0.5 min, then 2 % A
+ 98 % B for 1.0 min, then to 97 % A + 3 % B within 0.2 min, then 97 % A + 3 % B
for 1.3 min; MS ionization method: ES
Method LC5
Column: Waters XBridge C18, 50 x 4.6 mm, 2.5 µm; flow: 1.7 ml/min; 40 °C; eluent
A: water + 0.05 % TFA; eluent B: ACN + 0.05 % TFA; gradient: from 95 % A + 5 %
B to 5 % A + 95 % B within 3.3 min, then 5 % A + 95 % B for 0.55 min, then to 95 %
A + 5 % B within 0.15 min; MS ionization method: ES
Method LC6
Column: Waters XBridge C18, 50 x 4.6 mm, 2.5 µm; flow: 1.7 ml/min; 50 °C; eluent
A: water + 0.05 % TFA; eluent B: ACN + 0.05 % TFA; gradient: 95 % A + 5 % B for
0.2 min, then to 5 % A +95 % B within 2.2 min, then 5 % A + 95 % B for 1.1 min,
then to 95 % A + 5 % B within 0.1 min, then 95 % A + 5 % B for 0.9 min; MS
ionization method: ES
Method LC7
Column: Waters XBridge C18, 50 x 4.6 mm, 2.5 µm; flow: 1.7 ml/min; 40 °C; eluent
A: water + 0.05 % TFA; eluent B: ACN + 0.05 % TFA; gradient: 95 % A + 5 % B for
0.2 min, then to 5 % A +95 % B within 2.2 min, then 5 % A + 95 % B for 0.8 min,
then to 95 % A + 5 % B within 0.1 min, then 95 % A + 5 % B for 0.7 min; MS
ionization method: ES
Method LC8
Column: Waters XBridge C18, 50 x 4.6 mm, 2.5 µm; flow: 1.7 ml/min; 40 °C; eluent
A: water + 0.05 % TFA; eluent B: ACN + 0.05 % TFA; gradient: 95 % A + 5 % B for
0.3 min, then to 5 % A +95 % B within 3.2 min, then 5 % A + 95 % B for 0.5 min; MS
ionization method: ES
Method LC9
Column: Merck Chromolith FastGrad RP-18e, 50 x 2 mm; flow: 2.0 ml/min; room
temperature; eluent A: water + 0.05 % TFA; eluent B: ACN + 0.05 % TFA; gradient:
98 % A + 2 % B for 0.2 min, then to 2 % A + 98 % B within 2.2 min, then 2 % A + 98
% B for 0.8 min, then to 98 % A + 2 % B within 0.1 min, then 98 % A + 2 % B for 0.7
min; MS ionization method: ES
Method LC10
Column: Waters XBridge C18, 50 x 4.6 mm, 2.5 µm; flow: 1.3 ml/min; 45 °C; eluent
A: water + 0.1 % FA; eluent B: ACN + 0.1 % FA; gradient: from 97 % A + 3 % B to
40 % A + 60 % B within 3.5 min, then to 2 % A + 98 % B within 0.5 min, then 2 % A
+ 98 % B for 1.0 min, then to 97 % A + 3 % B within 0.2 min, then 97 % A + 3 % B
for 1.3 min; MS ionization method: ES
Method LC11
Column: Waters UPLC BEH C18, 50 x 2.1 mm, 1.7 µm; flow: 0.9 ml/min; 55 °C;
eluent A: water + 0.1 % FA; eluent B: ACN + 0.08 % FA; gradient: from 95 % A + 5
% B to 5 % A + 95 % B within 1.1 min, then 5 % A + 95 % B for 0.6 min, then to 95
% A + 5 % B within 0.1 min, then 95 % A + 5 % B for 0.2 min; MS ionization method:
ES
Method LC11_2
Column: Waters UPLC BEH C18, 50 x 2.1 mm, 1.7 µm; flow: 0.9 ml/min; 55 °C;
eluent A: water + 0.05 % FA; eluent B: ACN + 0.035 % FA; gradient: from 95 % A +
5 % B to 5 % A + 95 % B within 1.1 min, then 5 % A + 95 % B for 0.6 min, then to 95
% A + 5 % B within 0.1 min, then 95 % A + 5 % B for 0.2 min; MS ionization method:
Method LC11_3
Column: Waters UPLC BEH C18, 50 x 2.1 mm, 1.7 µm; flow: 0.9 ml/min; 55 °C;
eluent A: water + 0.05 % FA; eluent B: ACN + 0.035 % FA; gradient: from 95 % A +
% B to 5 % A + 95 % B within 1.1 min, then 5 % A + 95 % B for 0.6 min, then to 95
% A + 5 % B within 0.2 min, then 95 % A + 5 % B for 0.1 min; MS ionization method:
Method LC11_X
Column: Waters UPLC BEH C18, 50 x 2.1 mm, 1.7 µm; flow: 0.9 ml/min; 55 °C;
eluent A: water + 0.05 % TFA; eluent B: ACN + 0.035 % TFA; gradient: from 98 % A
+ 2 % B to 5 % A + 95 % B within 2.0 min, then 5 % A + 95 % B for 0.6 min, then to
95 % A + 5 % B within 0.1 min, then 95 % A + 5 % B for 0.3 min; MS ionization
method: ES
Method LC_X
Column: Waters XBridge C18, 50 x 4.6 mm, 2.5 µm; flow: 1.7 ml/min; 40 °C; eluent
A: water + 0.05 % TFA; eluent B: ACN + 0.05 % TFA; gradient: from 95 % A + 5 %
B to 95 % A + 5 % B within 0.2 min, then to 5 % A + 95 % B within 2.2 min, then 5 %
A + 95 % B for 0.8 min, then to 95 % A + 5 % B within 0.1 min, then 95 % A + 5 % B
for 0.7 min; MS ionization method: ES
Method LC12
Column: YMC-Pack Jsphere H80, 33 x 2.1 mm, 4 µm; flow: 1.0 ml/min; room
temperature; eluent A: water + 0.05 % TFA; eluent B: MOH + 0.05 % TFA; gradient:
98 % A + 2 % B for 1.0 min, then to 5 % A +95 % B within 4.0 min, then 5 % A + 95
% B for 1.25 min; MS ionization method: ES
Method LC13.
Column: Waters XBridge C18, 50 x 4.6, 2.5 µm; flow: 1.3 ml/min; room temperature;
eluent A: water + 0.1 % FA; eluent B: ACN + 0.08 % FA; gradient: from 97 % A + 3
% B to 2 % A + 98 % B within 18.0 min, then 2 % A + 98 % B for 1.0 min, then to 97
% A + 3 % B within 0.5 min, then 97 % A + 3 % B for 0.5 min; MS ionization method:
ES
Method LC14
Column: Waters XBridge C18 4.6*50 mm; 2,5um, flow: 1.3 ml/min; eluent A
H O+0.1% FA; eluent B: ACN + 0.08% FA; gradient: from 97% A + 3% B to 2% A +
98% B within 18 min, then 2% A + 98% B for 1 min, then to 97% A + 3% B within
0.5 min then to 97:3 for 0.5 min.
Analogously as described in the synthesis examples, the example compounds of
the formula I listed in Table 1 were prepared.
Table 1. Example compounds of the formula I
Ex. Rt LC/MS Activity
Compound name m/z (1)
No. (min) Method (2) [µM]
(S)[(5-Methoxyphenyl-
1 pyridinecarbonyl)-amino]o- 391.19 1.27 LC11 0,1231
tolyl-propionic acid
(S)(2,4-Dichloro-phenyl)[(5-
2 methoxyphenyl-pyridine 445.1 1.33 LC11 0,547
carbonyl)-amino]-propionic acid
(S)[(6-Chloromethoxy-
3 pyridinecarbonyl)-amino]o- 349.09 1.06 LC11 0,274
tolyl-propionic acid
(S){[3-(4,6-Dimethoxy-
pyrimidinyloxy)-pyridine
4 439.17 1.19 LC11 0,353
carbonyl]-amino}o-tolyl-
propionic acid
(S)[(Pyridinecarbonyl)-
285.14 1.13 LC11 3,98
amino]o-tolyl-propionic acid
(S)[(Pyridinecarbonyl)-
6 285.16 0.97 LC11
amino]o-tolyl-propionic acid
(S)[(5-Bromo-pyridine
7 carbonyl)-amino]o-tolyl- 363.04 1.14 LC11 >10.0
propionic acid
(S)[(Pyridinecarbonyl)-
8 285.16 0.99 LC11 10,4
amino]o-tolyl-propionic acid
(S)[(3-Methoxy-pyridine
9 carbonyl)-amino]o-tolyl- 315.18 1.04 LC11 7,25
propionic acid
(S)[(6-Methyl-pyridine
carbonyl)-amino]o-tolyl- 299.17 1.18 LC11 1,24
propionic acid
(S)[(4,6-Dimethyl-pyridine
11 carbonyl)-amino]o-tolyl- 313.2 0.92 LC11 >10.0
propionic acid
(S)[(6-Methylamino-pyrazine
12 carbonyl)-amino]o-tolyl- 315.17 1.08 LC11 7,32
propionic acid
(S)[(2,6-Bis-dimethylamino-
13 pyrimidinecarbonyl)-amino] 372.24 3.25 LC2 10,1
o-tolyl-propionic acid
(S)[(4-Methyl-pyridine
14 carbonyl)-amino]o-tolyl- 299.17 1.18 LC11 4,35
propionic acid
(S)[(5-Phenyl-pyridine
carbonyl)-amino]o-tolyl- 361.32 3.85 LC2 2,16
propionic acid
(S)[(2,6-Dimethoxy-pyrimidine-
16 4-carbonyl)-amino]o-tolyl- 346.15 1.2 LC11 1,05
propionic acid
(S)[([1,6]Naphthyridine
17 carbonyl)-amino]o-tolyl- 336.16 1.09 LC11 3,09
propionic acid
(S)[(4-Ethyl-pyridine
18 carbonyl)-amino]o-tolyl- 313.2 1.22 LC11 3,06
propionic acid
(S)[(2-Acetylamino-pyridine
19 carbonyl)-amino]o-tolyl- 342.17 1.03 LC11 >10.0
propionic acid
(S)[(3,4,5,6-Tetrahydro-2H-
[1,2']bipyridinyl-4'-carbonyl)- 368.22 1.04 LC11
amino]o-tolyl-propionic acid
(S)[(2-Methoxy-pyridine
21 carbonyl)-amino]o-tolyl- 315.17 1.12 LC11
propionic acid
(S){[2-(2,2-Dimethyl-
propionylamino)-pyridine
22 384.2 1.17 LC11
carbonyl]-amino}o-tolyl-
propionic acid
(S)[(6-Bromomethoxy-
23 pyridinecarbonyl)-amino]o- 393.05 1.21 LC11 0,564
tolyl-propionic acid
(S)[(6-Methoxy-pyridine
24 carbonyl)-amino]o-tolyl- 315.17 1.11 LC11
propionic acid
(S)[(6-Morpholinyl-pyridine-
2-carbonyl)-amino]o-tolyl- 370.19 1.17 LC11
propionic acid
(S)[(2-Pyrrolidinyl-pyridine-
26 4-carbonyl)-amino]o-tolyl- 354.22 0.97 LC11
propionic acid
(S)[(1-Ethyl-3,6-dimethyl-1H-
pyrazolo[3,4-b]pyridine
27 381.23 1.15 LC11
carbonyl)-amino]o-tolyl-
propionic acid
(S)[(6-Cyclopropyl-1,3-
dimethyl-1H-pyrazolo[3,4-
28 393.21 1.2 LC11
b]pyridinecarbonyl)-amino]o-
tolyl-propionic acid
(S)[(2-Morpholinyl-pyridine-
29 4-carbonyl)-amino]o-tolyl- 370.21 1.03 LC11
propionic acid
(S)[(4,6-Dimethoxy-pyrimidine-
2-carbonyl)-amino]o-tolyl- 344.27 1.15 LC11 4,21
propionic acid
(S)[(6-Methoxy-pyridine
31 carbonyl)-amino]o-tolyl- 315.17 1.19 LC11 4,77
propionic acid
(S){[6-(Tetrahydro-pyran
32 yloxy)-pyridinecarbonyl]- 385.18 1.14 LC11
amino}o-tolyl-propionic acid
(S)[(3-Fluoro-pyridine
33 carbonyl)-amino]o-tolyl- 301.26 1.1 LC11 3,42
propionic acid
(S)[(3H-Imidazo[4,5-b]pyridine-
-carbonyl)-amino]o-tolyl-
34 325.16 1 LC11 5,07
propionic acid; compound with
trifluoro-acetic acid
(S){[4-(Pyrimidinylsulfanyl)-
pyridinecarbonyl]-amino}o- 395.13 1.19 LC11 0,844
tolyl-propionic acid
(S)[(2-Methyl-pyridine
36 carbonyl)-amino]o-tolyl- 299.18 0.94 LC11
propionic acid
(S)[(6-Phenyl-pyridine
37 carbonyl)-amino]o-tolyl- 361.2 1.14 LC11_2 0,1302
propionic acid
(S)[(3-Phenyl-pyridine
38 carbonyl)-amino]o-tolyl- 361.17 1.19 LC11
propionic acid
(S)[(4-Phenyl-pyridine
39 carbonyl)-amino]o-tolyl- 361.19 1.28 LC11 1,08
propionic acid
(S)[(5-Phenyl-pyridine
40 carbonyl)-amino]o-tolyl- 361.18 1.28 LC11 0,45
propionic acid
(S)[(5-Pyrrolidinyl-pyridine-
3-carbonyl)-amino]o-tolyl-
41 354.2 1.01 LC11
propionic acid; compound with
trifluoro-acetic acid
(S)[(5-Methyl-pyrazine
42 carbonyl)-amino]o-tolyl- 298.26 1.1 LC11
propionic acid
(S){[6-(3-Methoxy-phenyl)-
43 pyridinecarbonyl]-amino}o- 391.19 1.14 LC11_2 2,27
tolyl-propionic acid
(S){[6-(2-Methoxy-phenyl)-
44 pyridinecarbonyl]-amino}o- 391.23 1.14 LC11_2 1,192
tolyl-propionic acid
(S){[6-(4-Methoxy-phenyl)-
45 pyridinecarbonyl]-amino}o- 391.18 1.26 LC11 3,09
tolyl-propionic acid
(S)[(6-Phenoxy-pyridine
46 carbonyl)-amino]o-tolyl- 377.16 1.23 LC11 9,94
propionic acid
(S)[(4-Hydroxy-pyridine
47 carbonyl)-amino]o-tolyl- 301.14 0.97 LC11
propionic acid
(S)[(6-Fluoro-pyridine
48 carbonyl)-amino]o-tolyl- 301.28 1.15 LC11 1,67
propionic acid
(S)[(6-Pyrrolidinyl-pyridine-
49 3-carbonyl)-amino]o-tolyl- 354.21 0.95 LC11
propionic acid
(S)[(4-Morpholinyl-pyridine-
50 2-carbonyl)-amino]o-tolyl- 370.2 0.93 LC11 7,73
propionic acid
(S)[(4,6-Dimethyl-pyridine
51 carbonyl)-amino]o-tolyl- 313.19 1.2 LC11 1,81
propionic acid
(S)[(2-Aminoisobutyl-
pyrimidinecarbonyl)-amino]
52 357.03 1.18 LC11 3,68
o-tolyl-propionic acid; compound
with trifluoro-acetic acid
(S)[(3,6-Difluoro-pyridine
53 carbonyl)-amino]o-tolyl- 319.24 1.12 LC11 2,83
propionic acid
(S)[(3,4,5,6-Tetrahydro-2H-
54 [1,2']bipyridinyl-6'-carbonyl)- 368.22 1.3 LC11 8,93
amino]o-tolyl-propionic acid
(S)[(2,6-Dimethyl-pyrimidine
55 carbonyl)-amino]o-tolyl- 314.19 1.11 LC11 5,26
propionic acid
(S)[(6-Imidazolyl-pyridine
56 carbonyl)-amino]o-tolyl- 351.16 0.95 LC11 11,1
propionic acid
(S){[5-(4-Methoxy-phenyl)-
57 pyridinecarbonyl]-amino}o- 391.23 1.17 LC11 11,46
tolyl-propionic acid
(S)[(6-Methoxy-[2,4']bipyridinyl-
4-carbonyl)-amino]o-tolyl-
58 392.24 0.91 LC11_2 >30.0
propionic acid; compound with
trifluoro-acetic acid
(S)[(6-Methoxy-[2,3']bipyridinyl-
4-carbonyl)-amino]o-tolyl-
59 392.33 0.96 LC11_2 >30.0
propionic acid; compound with
trifluoro-acetic acid
(S)o-Tolyl{[5-(3-
60 trifluoromethyl-phenyl)-pyridine 429.41 4.36 LC2
carbonyl]-amino}-propionic acid
(S){[5-(2,4-Dichloro-phenyl)-
61 pyridinecarbonyl]-amino}o- 429.17 1.14 LC11_2 5,14
tolyl-propionic acid
(S){[5-(4-Fluoro-phenyl)-
62 pyridinecarbonyl]-amino}o- 377.23 1.06 LC11_2
tolyl-propionic acid
(S)o-Tolyl[(5-p-tolyl-pyridine-
63 375.39 4.09 LC2
3-carbonyl)-amino]-propionic acid
(S)o-Tolyl{[5-(4-
64 trifluoromethyl-phenyl)-pyridine 429.41 4.4 LC2
carbonyl]-amino}-propionic acid
(S){[5-(3-Methoxy-phenyl)-
65 pyridinecarbonyl]-amino}o- 391.41 3.91 LC2
tolyl-propionic acid
(S)o-Tolyl{[5-(2-
66 trifluoromethyl-phenyl)-pyridine 429.34 4.21 LC2 4,29
carbonyl]-amino}-propionic acid
(S){[5-(2-Methoxy-phenyl)-
67 pyridinecarbonyl]-amino}o- 391.41 3.83 LC2 4,97
tolyl-propionic acid
(S)o-Tolyl[(5-m-tolyl-
68 pyridinecarbonyl)-amino]- 375.39 4.1 LC2
propionic acid
(S){[5-(2-Fluoro-phenyl)-
69 pyridinecarbonyl]-amino}o- 379.38 3.92 LC2 1,4
tolyl-propionic acid
(S){[5-(3-Cyano-phenyl)-
70 pyridinecarbonyl]-amino}o- 386.38 3.78 LC2
tolyl-propionic acid
(S){[5-(4-Cyano-phenyl)-
71 pyridinecarbonyl]-amino}o- 386.26 1.03 LC11_2
tolyl-propionic acid
(S){[5-(3,4-Dimethoxy-phenyl)-
72 pyridinecarbonyl]-amino}o- 421.44 3.59 LC2
tolyl-propionic acid
(S){[5-(2,4-Difluoro-phenyl)-
73 pyridinecarbonyl]-amino}o- 395.21 1.07 LC11_2 3,25
tolyl-propionic acid
(S){[5-(3,4-Difluoro-phenyl)-
74 pyridinecarbonyl]-amino}o- 395.19 1.08 LC11_2
tolyl-propionic acid
(S){[5-(2,6-Difluoro-phenyl)-
75 pyridinecarbonyl]-amino}o- 395.17 1.07 LC11_2
tolyl-propionic acid
(S)[(5-Benzo[1,3]dioxolyl-
76 pyridinecarbonyl)-amino]o- 405.34 3.78 LC2 8,04
tolyl-propionic acid
(S){[5-(3,4-Dimethyl-phenyl)-
77 pyridinecarbonyl]-amino}o- 389.39 4.29 LC2
tolyl-propionic acid
(S)o-Tolyl{[5-(3,4,5-
78 trimethoxy-phenyl)-pyridine 451.31 1.03 LC11_2
carbonyl]-amino}-propionic acid
(S){[5-(2,3-Difluoro-phenyl)-
79 pyridinecarbonyl]-amino}o- 395.17 1.07 LC11_2 5,01
tolyl-propionic acid
(S){[5-(2-Cyano-phenyl)-
80 pyridinecarbonyl]-amino}o- 386.23 1.02 LC11_2
tolyl-propionic acid
(S){[5-(3,5-Dimethyl-isoxazol-
81 4-yl)-pyridinecarbonyl]-amino}- 380.26 0.98 LC11_2
3-o-tolyl-propionic acid
(S){[5-(4-Fluoromethyl-
82 phenyl)-pyridinecarbonyl]- 393.37 4.13 LC2 3,08
amino}o-tolyl-propionic acid
(S)[(5-Pyrimidinyl-pyridine-
3-carbonyl)-amino]o-tolyl-
83 363.22 0.88 LC11_2
propionic acid; compound with
trifluoro-acetic acid
(S){[5-(2-Dimethylcarbamoyl-
84 phenyl)-pyridinecarbonyl]- 432.42 3.34 LC2
amino}o-tolyl-propionic acid
(S){[5-(4-Fluoromethoxy-
85 phenyl)-pyridinecarbonyl]- 409.4 3.96 LC2 7,83
amino}o-tolyl-propionic acid
(S){[5-(2-Methoxy
trifluoromethyl-phenyl)-pyridine
86 459.37 4.42 LC2
carbonyl]-amino}o-tolyl-
propionic acid
(S){[5-(1-Benzyl-1H-pyrazol
87 yl)-pyridinecarbonyl]-amino} 441.45 3.78 LC2
o-tolyl-propionic acid
(S){[5-(2-Fluoromethoxy-
88 phenyl)-pyridinecarbonyl]- 407.26 1.07 LC11_2 8,51
amino}o-tolyl-propionic acid
(S){[5-(2-Dimethylamino-
pyrimidinyl)-pyridine
89 carbonyl]-amino}o-tolyl- 406.32 0.99 LC11_2
propionic acid; compound with
trifluoro-acetic acid
(S)[(2'-Morpholinyl-
90 [3,4']bipyridinylcarbonyl)- 447.34 0.88 LC11_2
amino]o-tolyl-propionic acid
(S)[(5'-Fluoro-[3,3']bipyridinyl-
91 5-carbonyl)-amino]o-tolyl- 380.22 0.97 LC11_2
propionic acid
(S){[2-(4-Methoxy-phenyl)-
92 pyridinecarbonyl]-amino}o- 391.2 1.16 LC11
tolyl-propionic acid
(S)o-Tolyl{[2-(4-
93 trifluoromethyl-phenyl)-pyridine 429.19 1.27 LC11
carbonyl]-amino}-propionic acid
(S){[2-(3-Methoxy-phenyl)-
94 pyridinecarbonyl]-amino}o- 391.23 1.18 LC11
tolyl-propionic acid
(S){[2-(2-Methoxy-phenyl)-
95 pyridinecarbonyl]-amino}o- 391.22 1.13 LC11
tolyl-propionic acid
(S)o-Tolyl[(2-m-tolyl-
96 pyridinecarbonyl)-amino]- 375.23 1.22 LC11
propionic acid
(S){[2-(2-Fluoro-phenyl)-
97 pyridinecarbonyl]-amino}o- 379.2 1.17 LC11 2,71
tolyl-propionic acid
(S){[2-(3,4-Dimethoxy-phenyl)-
98 pyridinecarbonyl]-amino}o- 421.23 1.13 LC11
tolyl-propionic acid
(S){[2-(3,5-Difluoro-phenyl)-
99 pyridinecarbonyl]-amino}o- 397.18 1.24 LC11
tolyl-propionic acid
(S){[2-(3,4-Difluoro-phenyl)-
100 pyridinecarbonyl]-amino}o- 397.2 1.23 LC11
tolyl-propionic acid
(S)[(2-Benzo[1,3]dioxolyl-
101 pyridinecarbonyl)-amino]o- 405.21 1.16 LC11
tolyl-propionic acid
(S)o-Tolyl{[2-(3,4,5-
102 trimethoxy-phenyl)-pyridine 451.26 1.16 LC11
carbonyl]-amino}-propionic acid
(S)[([2,3']Bipyridinyl
103 carbonyl)-amino]o-tolyl- 362.19 0.98 LC11
propionic acid
(S){[2-(2,5-Dichloro-phenyl)-
104 pyridinecarbonyl]-amino}o- 429.16 1.24 LC11
tolyl-propionic acid
(S){[2-(3,5-Dimethyl-isoxazol-
105 4-yl)-pyridinecarbonyl]-amino}- 380.2 1.11 LC11
3-o-tolyl-propionic acid
(S)[(2'-Methyl-[2,4']bipyridinyl-
106 4-carbonyl)-amino]o-tolyl- 376.21 0.94 LC11
propionic acid
(S){[2-(4-Fluoromethoxy-
107 phenyl)-pyridinecarbonyl]- 409.21 1.16 LC11
amino}o-tolyl-propionic acid
(S){[2-(1-Benzyl-1H-pyrazol
yl)-pyridinecarbonyl]-amino}
108 441.27 1.16 LC11
o-tolyl-propionic acid; compound
with trifluoro-acetic acid
(S){[2-(2-Fluoromethoxy-
109 phenyl)-pyridinecarbonyl]- 409.21 1.18 LC11
amino}o-tolyl-propionic acid
(S){[2-(3-Cyclopropylmethoxy-
110 phenyl)-pyridinecarbonyl]- 431.27 1.25 LC11
amino}o-tolyl-propionic acid
(S){[5-(3-Chlorofluoro-
111 phenyl)-pyridinecarbonyl]- 413.23 1.11 LC11_2
amino}o-tolyl-propionic acid
(S){[5-(2-Chloro-phenyl)-
112 pyridinecarbonyl]-amino}o- 395.33 4.09 LC2 0,826
tolyl-propionic acid
(S){[5-(4-tert-Butyl-phenyl)-
113 pyridinecarbonyl]-amino}o- 417.45 4.66 LC2
tolyl-propionic acid
(S){[5-(2,3-Dichloro-phenyl)-
114 pyridinecarbonyl]-amino}o- 429.21 1.13 LC11_2 0,95
tolyl-propionic acid
(S)[([3,4']Bipyridinyl
115 carbonyl)-amino]o-tolyl- 362.21 0.8 LC11_2
propionic acid
(S){[5-(2,3-Dimethyl-phenyl)-
116 pyridinecarbonyl]-amino}o- 389.39 4.24 LC2 1,01
tolyl-propionic acid
(S){[5-(2,4-Dimethyl-phenyl)-
117 pyridinecarbonyl]-amino}o- 389.39 4.29 LC2 5,27
tolyl-propionic acid
(S)[(2'-Methyl-[3,4']bipyridinyl-
118 5-carbonyl)-amino]o-tolyl- 376.26 0.79 LC11_2
propionic acid
(S){[5-(4-Chloromethoxy-
119 phenyl)-pyridinecarbonyl]- 425.24 1.11 LC11_2
amino}o-tolyl-propionic acid
(S)({5-[3-(5-Methyl-
[1,3,4]oxadiazolyl)-phenyl]-
120 443.3 1 LC11_2
pyridinecarbonyl}-amino)o-
tolyl-propionic acid
(S){[5-(3-Chloro
dimethylcarbamoyl-phenyl)-
121 466.27 0.99 LC11_2
pyridinecarbonyl]-amino}o-
tolyl-propionic acid
(S)[(2-Biphenylyl-pyridine
122 carbonyl)-amino]o-tolyl- 437.27 1.29 LC11
propionic acid
(S){[2-(2,3-Dichloro-phenyl)-
123 pyridinecarbonyl]-amino}o- 429.12 1.23 LC11 3,7
tolyl-propionic acid
(S){[2-(3,4-Dimethyl-phenyl)-
124 pyridinecarbonyl]-amino}o- 389.23 1.24 LC11
tolyl-propionic acid
(S){[2-(2,3-Difluoro-phenyl)-
125 pyridinecarbonyl]-amino}o- 397.18 1.19 LC11
tolyl-propionic acid
(S){[2-(2-Cyano-phenyl)-
126 pyridinecarbonyl]-amino}o- 386.18 1.14 LC11
tolyl-propionic acid
(S){[2-(4-Fluoromethyl-
127 phenyl)-pyridinecarbonyl]- 393.2 1.2 LC11
amino}o-tolyl-propionic acid
(S){[2-(2-Methoxy
trifluoromethyl-phenyl)-pyridine
128 459.22 1.25 LC11
carbonyl]-amino}o-tolyl-
propionic acid
(S){[2-(4-Chloromethoxy-
129 phenyl)-pyridinecarbonyl]- 425.17 1.21 LC11
amino}o-tolyl-propionic acid
(S)[(2'-Morpholinyl-
130 [2,4']bipyridinylcarbonyl)- 447.27 1 LC11
amino]o-tolyl-propionic acid
(S)[(5'-Fluoro-[2,3']bipyridinyl-
131 4-carbonyl)-amino]o-tolyl- 380.18 1.12 LC11
propionic acid
(S)({2-[3-(1-Hydroxymethyl-
ethyl)-phenyl]-pyridine
132 419.25 1.13 LC11
carbonyl}-amino)o-tolyl-
propionic acid
(S)o-Tolyl{[6-(3-
133 trifluoromethyl-phenyl)-pyridine 429.18 1.19 LC11_2 5,76
carbonyl]-amino}-propionic acid
(S){[6-(3-Chlorofluoro-
134 phenyl)-pyridinecarbonyl]- 413.14 1.19 LC11_2 3,62
amino}o-tolyl-propionic acid
(S){[6-(4-Fluoro-phenyl)-
135 pyridinecarbonyl]-amino}o- 379.17 1.15 LC11_2 1,18
tolyl-propionic acid
(S){[6-(4-Chloro-phenyl)-
136 pyridinecarbonyl]-amino}o- 395.13 1.19 LC11_2 4,85
tolyl-propionic acid
(S)o-Tolyl[(6-p-tolyl-pyridine-
137 375.21 1.18 LC11_2 1,24
2-carbonyl)-amino]-propionic acid
(S)o-Tolyl{[6-(4-
138 trifluoromethyl-phenyl)-pyridine 429.19 1.2 LC11_2 6,83
carbonyl]-amino}-propionic acid
(S)o-Tolyl{[6-(2-
139 trifluoromethyl-phenyl)-pyridine 429.19 1.16 LC11_2 1,09
carbonyl]-amino}-propionic acid
(S){[6-(3-Chloro-phenyl)-
140 pyridinecarbonyl]-amino}o- 395.18 1.18 LC11_2 1,57
tolyl-propionic acid
(S)o-Tolyl[(6-m-tolyl-
141 pyridinecarbonyl)-amino]- 375.21 1.18 LC11_2 0,1608
propionic acid
(S){[6-(2-Chloro-phenyl)-
142 pyridinecarbonyl]-amino}o- 395.14 1.16 LC11_2 0,05
tolyl-propionic acid
(S){[6-(2-Fluoro-phenyl)-
143 pyridinecarbonyl]-amino}o- 379.16 1.15 LC11_2 0,0733
tolyl-propionic acid
(S){[6-(4-tert-Butyl-phenyl)-
144 pyridinecarbonyl]-amino}o- 417.29 1.26 LC11_2
tolyl-propionic acid
(S){[6-(3-Cyano-phenyl)-
145 pyridinecarbonyl]-amino}o- 386.21 1.11 LC11_2 7,46
tolyl-propionic acid
(S){[6-(4-Cyano-phenyl)-
146 pyridinecarbonyl]-amino}o- 386.17 1.11 LC11_2 2,16
tolyl-propionic acid
(S)[(6-Biphenylyl-pyridine
147 carbonyl)-amino]o-tolyl- 437.26 1.24 LC11_2 3,16
propionic acid
(S){[6-(3,4-Dimethoxy-phenyl)-
148 pyridinecarbonyl]-amino}o- 421.22 1.1 LC11_2
tolyl-propionic acid
(S){[6-(2,4-Difluoro-phenyl)-
149 pyridinecarbonyl]-amino}o- 397.16 1.16 LC11_2 4,4
tolyl-propionic acid
(S){[6-(3,5-Difluoro-phenyl)-
150 pyridinecarbonyl]-amino}o- 397.15 1.16 LC11_2 1,02
tolyl-propionic acid
(S){[6-(3,4-Difluoro-phenyl)-
151 pyridinecarbonyl]-amino}o- 397.18 1.16 LC11_2 1,18
tolyl-propionic acid
(S)[(6-Benzo[1,3]dioxolyl-
152 pyridinecarbonyl)-amino]o- 405.19 1.12 LC11_2 1,55
tolyl-propionic acid
(S){[6-(3,4-Dimethyl-phenyl)-
153 pyridinecarbonyl]-amino}o- 389.23 1.21 LC11_2 1,19
tolyl-propionic acid
(S)o-Tolyl{[6-(3,4,5-
154 trimethoxy-phenyl)-pyridine 451.24 1.12 LC11_2
carbonyl]-amino}-propionic acid
(S)[([2,3']Bipyridinyl
155 carbonyl)-amino]o-tolyl- 362.17 0.93 LC11_2
propionic acid
(S){[6-(2,3-Difluoro-phenyl)-
156 pyridinecarbonyl]-amino}o- 397.18 1.16 LC11_2 0,272
tolyl-propionic acid
(S){[6-(2-Cyano-phenyl)-
157 pyridinecarbonyl]-amino}o- 386.14 1.1 LC11_2 2,46
tolyl-propionic acid
(S){[6-(2,5-Difluoro-phenyl)-
158 pyridinecarbonyl]-amino}o- 397.15 1.27 LC11 0,126
tolyl-propionic acid
(S){[6-(3,5-Dimethyl-isoxazol-
159 4-yl)-pyridinecarbonyl]-amino}- 380.15 1.18 LC11 14,4
3-o-tolyl-propionic acid
(S){[6-(4-Fluoromethyl-
160 phenyl)-pyridinecarbonyl]- 393.16 1.29 LC11 0,472
amino}o-tolyl-propionic acid
(S){[6-(2,3-Dimethyl-phenyl)-
161 pyridinecarbonyl]-amino}o- 389.19 1.31 LC11 0,0294
tolyl-propionic acid
(S){[6-(2,4-Dimethyl-phenyl)-
162 pyridinecarbonyl]-amino}o- 389.17 1.32 LC11 1,43
tolyl-propionic acid
(S)[(2'-Methyl-[2,4']bipyridinyl-
163 6-carbonyl)-amino]o-tolyl- 376.17 0.96 LC11
propionic acid
(S)[(6-Pyrimidinyl-pyridine-
2-carbonyl)-amino]o-tolyl-
164 363.15 1.09 LC11
propionic acid; compound with
trifluoro-acetic acid
(S){[6-(5-Fluoromethyl-
165 phenyl)-pyridinecarbonyl]- 393.16 1.29 LC11 0,0944
amino}o-tolyl-propionic acid
(S){[6-(4-Fluoromethoxy-
166 phenyl)-pyridinecarbonyl]- 409.16 1.27 LC11
amino}o-tolyl-propionic acid
(S){[6-(2-Methoxy
trifluoromethyl-phenyl)-pyridine
167 459.18 1.32 LC11 0,963
carbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(4-Chloromethoxy-
168 phenyl)-pyridinecarbonyl]- 425.13 1.31 LC11 0,425
amino}o-tolyl-propionic acid
(S){[6-(1-Benzyl-1H-pyrazol
yl)-pyridinecarbonyl]-amino}
169 441.19 1.23 LC11
o-tolyl-propionic acid; compound
with trifluoro-acetic acid
(S){[6-(2-Fluoromethoxy-
170 phenyl)-pyridinecarbonyl]- 409.16 1.28 LC11 0,815
amino}o-tolyl-propionic acid
(S){[6-(3-Cyclopropylmethoxy-
171 phenyl)-pyridinecarbonyl]- 431.22 1.33 LC11 6,98
amino}o-tolyl-propionic acid
(S){[6-(3-Fluoromethyl-
172 phenyl)-pyridinecarbonyl]- 393.17 1.29 LC11 3,21
amino}o-tolyl-propionic acid
(S){[6-(2-Dimethylamino-
pyrimidinyl)-pyridine
173 carbonyl]-amino}o-tolyl- 406.21 1.2 LC11
propionic acid; compound with
trifluoro-acetic acid
(S){[6-(3-Chloro
dimethylcarbamoyl-phenyl)-
174 464.31 1.18 LC11 1,59
pyridinecarbonyl]-amino}o-
tolyl-propionic acid
(S){[6-(5-Chlorofluoro
methyl-phenyl)-pyridine
175 427.13 1.34 LC11 2,36
carbonyl]-amino}o-tolyl-
propionic acid
(S)({6-[3-(1-Hydroxymethyl-
ethyl)-phenyl]-pyridine
176 419.2 1.2 LC11 3,32
carbonyl}-amino)o-tolyl-
propionic acid
(S){[2-(2-Dimethylamino-
pyrimidinyl)-pyridine
177 carbonyl]-amino}o-tolyl- 406.25 1.12 LC11
propionic acid; compound with
trifluoro-acetic acid
(S){[6-(2-Fluoro-phenyl)
178 methoxy-pyridinecarbonyl]- 409.1 1.12 LC11_2 0,0683
amino}o-tolyl-propionic acid
(S){[2-(3-Chloro-phenyl)-
179 pyridinecarbonyl]-amino}o- 395.23 4.51 LC2
tolyl-propionic acid
(S){[6-(2-Fluoromethyl-
180 phenyl)-pyridinecarbonyl]- 393.16 1.3 LC11 0,289
amino}o-tolyl-propionic acid
(S){[5-Methoxy(3-
trifluoromethyl-phenyl)-pyridine
181 459.28 1.19 LC11_2 5
carbonyl]-amino}p-tolyl-
propionic acid
(S)[(5-Methoxyphenyl-
182 pyridinecarbonyl)-amino]p- 389.28 1.14 LC11_2 0,232
tolyl-propionic acid
(S){[6-(2,4-Dichloro-phenyl)
183 methoxy-pyridinecarbonyl]- 459.21 1.2 LC11_2 1,009
amino}p-tolyl-propionic acid
(S){[6-(3-Chlorofluoro-
phenyl)methoxy-pyridine
184 443.23 1.19 LC11_2 >10.0
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(4-Fluoro-phenyl)
185 methoxy-pyridinecarbonyl]- 409.23 1.15 LC11_2 1,289
amino}p-tolyl-propionic acid
(S){[6-(4-Chloro-phenyl)
186 methoxy-pyridinecarbonyl]- 425.25 1.18 LC11_2 3,56
amino}p-tolyl-propionic acid
(S){[5-Methoxy(4-methoxy-
187 phenyl)-pyridinecarbonyl]- 419.32 1.13 LC11_2 4,85
amino}p-tolyl-propionic acid
(S)[(5-Methoxyp-tolyl-
188 pyridinecarbonyl)-amino]p- 403.31 1.17 LC11_2 4,45
tolyl-propionic acid
(S){[5-Methoxy(4-
trifluoromethyl-phenyl)-pyridine
189 457.35 1.2 LC11_2 >10.0
carbonyl]-amino}p-tolyl-
propionic acid
(S)[(5-Methoxyo-tolyl-
190 pyridinecarbonyl)-amino]p- 403.33 1.14 LC11_2 0,0813
tolyl-propionic acid
(S){[5-Methoxy(3-methoxy-
191 phenyl)-pyridinecarbonyl]- 419.34 1.14 LC11_2 4,57
amino}p-tolyl-propionic acid
(S){[5-Methoxy(2-
trifluoromethyl-phenyl)-pyridine
192 457.33 1.15 LC11_2 0,1457
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(3-Chloro-phenyl)
193 methoxy-pyridinecarbonyl]- 425.17 1.18 LC11_2 2,74
amino}p-tolyl-propionic acid
(S){[6-(3-Fluoro-phenyl)
194 methoxy-pyridinecarbonyl]- 407.29 1.15 LC11_2 0,725
amino}p-tolyl-propionic acid
(S)[(5-Methoxynaphthalen-
195 2-yl-pyridinecarbonyl)-amino]- 441 1.2 LC11_2 8,83
3-p-tolyl-propionic acid
(S){[5-Methoxy(2-methoxy-
196 phenyl)-pyridinecarbonyl]- 419.33 1.11 LC11_2 0,1191
amino}p-tolyl-propionic acid
(S)[(5-Methoxym-tolyl-
197 pyridinecarbonyl)-amino]p- 404.68 1.17 LC11_2 1,71
tolyl-propionic acid
(S){[6-(2-Chloro-phenyl)
198 methoxy-pyridinecarbonyl]- 423.24 1.14 LC11_2 0,159
amino}p-tolyl-propionic acid
(S){[6-(2-Fluoro-phenyl)
199 methoxy-pyridinecarbonyl]- 407.28 1.12 LC11_2 0,228
amino}p-tolyl-propionic acid
(S){[6-(4-tert-Butyl-phenyl)
200 methoxy-pyridinecarbonyl]- 445.39 1.25 LC11_2 >10.0
amino}p-tolyl-propionic acid
(S){[6-(3-Cyano-phenyl)
201 methoxy-pyridinecarbonyl]- 415.81 1.12 LC11_2 >10.0
amino}p-tolyl-propionic acid
(S){[6-(4-Cyano-phenyl)
202 methoxy-pyridinecarbonyl]- 416.24 1.11 LC11_2 >10.0
amino}p-tolyl-propionic acid
(S){[6-(3-Acetyl-phenyl)
203 methoxy-pyridinecarbonyl]- 433.31 1.1 LC11_2 8,35
amino}p-tolyl-propionic acid
(S)[(6-Biphenylyl
204 methoxy-pyridinecarbonyl)- 465.32 1.22 LC11_2 1,402
amino]p-tolyl-propionic acid
(S){[6-(4-Acetyl-phenyl)
205 methoxy-pyridinecarbonyl]- 431.43 1.1 LC11_2 >10.0
amino}p-tolyl-propionic acid
(S){[6-(2,4-Difluoro-phenyl)
206 methoxy-pyridinecarbonyl]- 425.26 1.14 LC11_2 0,1556
amino}p-tolyl-propionic acid
(S){[6-(3,5-Difluoro-phenyl)
207 methoxy-pyridinecarbonyl]- 425.28 1.16 LC11_2 2,65
amino}p-tolyl-propionic acid
(S){[6-(3,4-Difluoro-phenyl)
208 methoxy-pyridinecarbonyl]- 425.31 1.16 LC11_2 7,42
amino}p-tolyl-propionic acid
(S){[6-(2,3-Dichloro-phenyl)
209 methoxy-pyridinecarbonyl]- 457.27 1.18 LC11_2 0,0696
amino}p-tolyl-propionic acid
(S){[6-(5-Acetyl-thiophenyl)-
210 5-methoxy-pyridinecarbonyl]- 437.3 1.1 LC11_2 7,52
amino}p-tolyl-propionic acid
(S){[6-(2-Chloro
trifluoromethyl-phenyl)
211 493.24 1.19 LC11_2 0,421
methoxy-pyridinecarbonyl]-
amino}p-tolyl-propionic acid
(S){[6-(3-Fluoromethyl-
phenyl)methoxy-pyridine
212 427.27 1.13 LC11_2 0,1497
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(2-Chloro
trifluoromethyl-phenyl)
213 methoxy-pyridinecarbonyl]- 497.2 1.17 LC11_2 0,887
amino}(2-fluoro-phenyl)-
propionic acid
(S)(2-Chloro-phenyl){[6-(2-
fluorotrifluoromethyl-phenyl)
214 497.21 1.19 LC11_2 7,02
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)[(3-Methoxy-[2,4']bipyridinyl-
215 6-carbonyl)-amino]p-tolyl- 390.2 0.88 LC11_2 9,66
propionic acid
(S)[(3-Methoxy-[2,3']bipyridinyl-
216 6-carbonyl)-amino]p-tolyl- 390.25 0.93 LC11_2 >10.0
propionic acid
(S){[6-(2,3-Difluoro-phenyl)
217 methoxy-pyridinecarbonyl]- 425.32 1.13 LC11_2 0,0902
amino}p-tolyl-propionic acid
(S){[6-(2,5-Difluoro-phenyl)
218 methoxy-pyridinecarbonyl]- 425.31 1.13 LC11_2 0,0998
amino}p-tolyl-propionic acid
(S){[6-(2,5-Dichloro-phenyl)
219 methoxy-pyridinecarbonyl]- 457.25 1.18 LC11_2 0,91
amino}p-tolyl-propionic acid
(S){[6-(3,5-Dimethyl-isoxazol-
4-yl)methoxy-pyridine
220 408.28 1.07 LC11_2 0,143
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(4-Fluoromethyl-
phenyl)methoxy-pyridine
221 421.35 1.15 LC11_2 0,239
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(2,3-Dimethyl-phenyl)
222 methoxy-pyridinecarbonyl]- 417.34 1.17 LC11_2 0,037
amino}p-tolyl-propionic acid
(S){[6-(3-Fluoromethyl-
phenyl)methoxy-pyridine
223 423.27 1.18 LC11_2 1,294
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(2,4-Dimethyl-phenyl)
224 methoxy-pyridinecarbonyl]- 417.36 1.18 LC11_2 3,39
amino}p-tolyl-propionic acid
(S){[6-(4-Fluoromethyl-
phenyl)methoxy-pyridine
225 421.33 1.18 LC11_2 3,26
carbonyl]-amino}p-tolyl-
propionic acid
(S)[(5-Methoxypyrimidin
226 yl-pyridinecarbonyl)-amino] 391.29 1 LC11_2 >10.0
p-tolyl-propionic acid
(S)[(6'-Fluoromethoxy-
227 [2,3']bipyridinylcarbonyl)- 408.28 1.09 LC11_2 7,63
amino]p-tolyl-propionic acid
(S){[6-(2-Dimethylcarbamoyl-
phenyl)methoxy-pyridine
228 462.31 1.06 LC11_2 3,96
carbonyl]-amino}p-tolyl-
propionic acid
(S)[(3,2'-Dimethoxy-
229 [2,3']bipyridinylcarbonyl)- 422.29 1.07 LC11_2 0,609
amino]p-tolyl-propionic acid
(S){[6-(5-Fluoromethyl-
phenyl)methoxy-pyridine
230 423.27 1.15 LC11_2 0,1113
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(4-Fluoromethoxy-
phenyl)methoxy-pyridine
231 439.27 1.12 LC11_2 0,305
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(4-Chloromethoxy-
phenyl)methoxy-pyridine
232 455.26 1.16 LC11_2 2,33
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(5-Chloromethoxy-
phenyl)methoxy-pyridine
233 455.25 1.15 LC11_2 2,24
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(5-Fluoromethoxy-
phenyl)methoxy-pyridine
234 439.28 1.12 LC11_2 0,51
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(2,5-Dimethoxy-phenyl)-
235 5-methoxy-pyridinecarbonyl]- 451.3 1.1 LC11_2 >10.0
amino}p-tolyl-propionic acid
(S){[6-(2-Fluoro
trifluoromethyl-phenyl)
236 477.27 1.18 LC11_2 3,57
methoxy-pyridinecarbonyl]-
amino}p-tolyl-propionic acid
(S){[5-Methoxy(5-methyl-
237 furanyl)-pyridinecarbonyl]- 395.25 1.11 LC11_2 3,54
amino}p-tolyl-propionic acid
(S){[5-Methoxy(1-methyl-
1H-pyrazolyl)-pyridine
238 395.26 1.02 LC11_2 >10.0
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(2-Fluoromethoxy-
phenyl)methoxy-pyridine
239 439.28 1.12 LC11_2 1,16
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(5-tert-Butylmethoxy-
phenyl)methoxy-pyridine
240 477.37 1.22 LC11_2 >10.0
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(2-Fluoro
trifluoromethyl-phenyl)
241 477.27 1.19 LC11_2 >10.0
methoxy-pyridinecarbonyl]-
amino}p-tolyl-propionic acid
(S){[6-(2-Fluoromethyl-
phenyl)methoxy-pyridine
242 423.29 1.15 LC11_2 0,278
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(3-Chloromethyl-
phenyl)methoxy-pyridine
243 439.27 1.19 LC11_2 0,2027
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(3-Fluoromethyl-
phenyl)methoxy-pyridine
244 423.29 1.15 LC11_2 0,0901
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(5-Chlorofluoro-
phenyl)methoxy-pyridine
245 443.24 1.17 LC11_2 0,44
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(4-Chlorofluoro-
phenyl)methoxy-pyridine
246 443.22 1.2 LC11_2 4,48
carbonyl]-amino}p-tolyl-
propionic acid
(S)[(2'-Chloromethoxy-5'-
methyl-[2,3']bipyridinyl
247 440.27 1.09 LC11_2 8,43
carbonyl)-amino]p-tolyl-
propionic acid
(S){[6-(3-Chloromethyl-
phenyl)methoxy-pyridine
248 439.25 1.21 LC11_2 >10.0
carbonyl]-amino}p-tolyl-
propionic acid
(S)({5-Methoxy[3-(5-methyl-
[1,3,4]oxadiazolyl)-phenyl]-
249 473.29 1.08 LC11_2 8,71
pyridinecarbonyl}-amino)p-
tolyl-propionic acid
(S){[5-Methoxy(1,3,5-
trimethyl-1H-pyrazolyl)-
250 423.32 1.02 LC11_2 >10.0
pyridinecarbonyl]-amino}p-
tolyl-propionic acid
(S){[5-Methoxy(1-methyl-
1H-indolyl)-pyridine
251 444.31 1.16 LC11_2 8,94
carbonyl]-amino}p-tolyl-
propionic acid
(S){[6-(4-Chloromethoxy-
phenyl)methoxy-pyridine
252 455.26 1.18 LC11_2 >10.0
carbonyl]-amino}p-tolyl-
propionic acid
(S)(2-Fluoro-phenyl){[5-
methoxy(3-trifluoromethyl-
253 461.3 1.17 LC11_2 4,06
phenyl)-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Fluoro-phenyl)[(5-
254 methoxyphenyl-pyridine 395.25 1.11 LC11_2 0,1818
carbonyl)-amino]-propionic acid
(S){[6-(2,4-Dichloro-phenyl)
methoxy-pyridinecarbonyl]-
255 463.18 1.18 LC11_2 0,879
amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(3-Chlorofluoro-
phenyl)methoxy-pyridine
256 447.21 1.17 LC11_2 >10.0
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)(2-Fluoro-phenyl){[6-(4-
fluoro-phenyl)methoxy-
257 413.21 1.12 LC11_2 1,263
pyridinecarbonyl]-amino}-
propionic acid
(S){[6-(4-Chloro-phenyl)
methoxy-pyridinecarbonyl]-
258 429.24 1.17 LC11_2 5,27
amino}(2-fluoro-phenyl)-
propionic acid
(S)(2-Fluoro-phenyl){[5-
methoxy(4-methoxy-phenyl)-
259 425.27 1.11 LC11_2 5,01
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Fluoro-phenyl)[(5-
260 methoxyp-tolyl-pyridine 409.27 1.15 LC11_2 5,18
carbonyl)-amino]-propionic acid
(S)(2-Fluoro-phenyl){[5-
methoxy(4-trifluoromethyl-
261 463.27 1.18 LC11_2 >10.0
phenyl)-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Fluoro-phenyl)[(5-
262 methoxyo-tolyl-pyridine 407.26 1.12 LC11_2 0,0819
carbonyl)-amino]-propionic acid
(S)(2-Fluoro-phenyl){[5-
methoxy(3-methoxy-phenyl)-
263 425.27 1.11 LC11_2 5,06
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Fluoro-phenyl){[5-
methoxy(2-trifluoromethyl-
264 463.25 1.12 LC11_2 0,179
phenyl)-pyridinecarbonyl]-
amino}-propionic acid
(S){[6-(3-Chloro-phenyl)
methoxy-pyridinecarbonyl]-
265 429.23 1.16 LC11_2 1,719
amino}(2-fluoro-phenyl)-
propionic acid
(S)(2-Fluoro-phenyl){[6-(3-
fluoro-phenyl)methoxy-
266 413.23 1.13 LC11_2 1,26
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Fluoro-phenyl)[(5-
methoxynaphthalenyl-
267 445.3 1.18 LC11_2 >10.0
pyridinecarbonyl)-amino]-
propionic acid
(S)(2-Fluoro-phenyl){[5-
methoxy(2-methoxy-phenyl)-
268 425.25 1.08 LC11_2 0,102
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Fluoro-phenyl)[(5-
269 methoxym-tolyl-pyridine 409.26 1.15 LC11_2 1,015
carbonyl)-amino]-propionic acid
(S){[6-(2-Chloro-phenyl)
methoxy-pyridinecarbonyl]-
270 429.23 1.11 LC11_2 0,9178
amino}(2-fluoro-phenyl)-
propionic acid
(S)(2-Fluoro-phenyl){[6-(2-
fluoro-phenyl)methoxy-
271 413.23 1.1 LC11_2 0,0418
pyridinecarbonyl]-amino}-
propionic acid
(S){[6-(4-tert-Butyl-phenyl)
methoxy-pyridinecarbonyl]-
272 451.34 1.23 LC11_2 >10.0
amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(3-Cyano-phenyl)
methoxy-pyridinecarbonyl]-
273 420.25 1.09 LC11_2 9,57
amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(4-Cyano-phenyl)
methoxy-pyridinecarbonyl]-
274 420.23 1.09 LC11_2 >10.0
amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(3-Acetyl-phenyl)
methoxy-pyridinecarbonyl]-
275 437.25 1.08 LC11_2 8,54
amino}(2-fluoro-phenyl)-
propionic acid
(S)[(6-Biphenylyl
methoxy-pyridinecarbonyl)-
276 471.33 1.21 LC11_2 2,16
amino](2-fluoro-phenyl)-
propionic acid
(S){[6-(4-Acetyl-phenyl)
methoxy-pyridinecarbonyl]-
277 437.27 1.07 LC11_2 >10.0
amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(2,4-Difluoro-phenyl)
methoxy-pyridinecarbonyl]-
278 431.24 1.12 LC11_2 0,1201
amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(3,5-Difluoro-phenyl)
methoxy-pyridinecarbonyl]-
279 431.21 1.15 LC11_2 3,85
amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(3,4-Difluoro-phenyl)
methoxy-pyridinecarbonyl]-
280 431.23 1.14 LC11_2 3,12
amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(2,3-Dichloro-phenyl)
methoxy-pyridinecarbonyl]-
281 463.16 1.15 LC11_2 0,114
amino}(2-fluoro-phenyl)-
propionic acid
(S)(2-Fluoro-phenyl)[(3-
282 methoxy-[2,4']bipyridinyl 396.21 0.84 LC11_2 >10.0
carbonyl)-amino]-propionic acid
(S){[6-(5-Cyano-thiophenyl)-
-methoxy-pyridinecarbonyl]-
283 426.15 1.1 LC11_2 5,4
amino}(2-fluoro-phenyl)-
propionic acid
(S)(2-Fluoro-phenyl)[(3-
284 methoxy-[2,3']bipyridinyl 396.22 0.88 LC11_2 >10.0
carbonyl)-amino]-propionic acid
(S){[6-(2,3-Difluoro-phenyl)
methoxy-pyridinecarbonyl]-
285 431.25 1.11 LC11_2 0,234
amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(2,5-Difluoro-phenyl)
methoxy-pyridinecarbonyl]-
286 431.23 1.11 LC11_2 0,171
amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(3,5-Dimethyl-isoxazol-
4-yl)methoxy-pyridine
287 414.25 1.04 LC11_2 0,645
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(4-Fluoromethyl-
phenyl)methoxy-pyridine
288 427.27 1.13 LC11_2 0,394
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(2,3-Dimethyl-phenyl)
methoxy-pyridinecarbonyl]-
289 423.29 1.14 LC11_2 0,0528
amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(3-Fluoromethyl-
phenyl)methoxy-pyridine
290 427.26 1.16 LC11_2 3,81
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(2,4-Dimethyl-phenyl)
methoxy-pyridinecarbonyl]-
291 423.29 1.15 LC11_2 4,02
amino}(2-fluoro-phenyl)-
propionic acid
(S){[6-(4-Fluoromethyl-
phenyl)methoxy-pyridine
292 427.25 1.16 LC11_2 4,13
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)(2-Fluoro-phenyl)[(5-
293 methoxypyrimidinyl-pyridine- 397.2 0.96 LC11_2 >10.0
2-carbonyl)-amino]-propionic acid
(S)[(6'-Fluoromethoxy-
[2,3']bipyridinylcarbonyl)-
294 414.22 1.06 LC11_2 >10.0
amino](2-fluoro-phenyl)-
propionic acid
(S){[6-(2-Dimethylcarbamoyl-
phenyl)methoxy-pyridine
295 464.38 1.02 LC11_2 4,51
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)[(3,2'-Dimethoxy-
[2,3']bipyridinylcarbonyl)-
296 426.26 1.04 LC11_2 0,756
amino](2-fluoro-phenyl)-
propionic acid
(S){[6-(5-Fluoromethyl-
phenyl)methoxy-pyridine
297 427.25 1.13 LC11_2 0,475
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(4-Fluoromethoxy-
phenyl)methoxy-pyridine
298 443.26 1.1 LC11_2 0,389
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(4-Chloromethoxy-
phenyl)methoxy-pyridine
299 459.24 1.14 LC11_2 1,83
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(5-Chloromethoxy-
phenyl)methoxy-pyridine
300 459.25 1.13 LC11_2 4,11
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(5-Fluoromethoxy-
phenyl)methoxy-pyridine
301 443.26 1.1 LC11_2 0,0737
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)(2-Fluoro-phenyl){[5-
methoxy(1-methyl-1H-indol
302 448.3 1.12 LC11_2 >10.0
yl)-pyridinecarbonyl]-amino}-
propionic acid
(S){[6-(2,5-Dimethoxy-phenyl)-
-methoxy-pyridinecarbonyl]-
303 455.29 1.08 LC11_2 >10.0
amino}(2-fluoro-phenyl)-
propionic acid
(S)(2-Fluoro-phenyl){[6-(2-
fluorotrifluoromethyl-phenyl)
304 481.23 1.16 LC11_2 3,99
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Fluoro-phenyl){[5-
methoxy(5-methyl-furanyl)-
305 399.23 1.09 LC11_2 >10.0
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Fluoro-phenyl){[5-
306 methoxy(1-methyl-1H-pyrazol- 399.22 0.99 LC11_2 >10.0
4-yl)-pyridinecarbonyl]-amino}-
propionic acid
(S){[6-(2-Fluoromethoxy-
phenyl)methoxy-pyridine
307 443.26 1.1 LC11_2 2,92
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(5-tert-Butylmethoxy-
phenyl)methoxy-pyridine
308 481.44 1.2 LC11_2 >10.0
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)(2-Fluoro-phenyl){[6-(2-
fluorotrifluoromethyl-phenyl)
309 481.25 1.17 LC11_2 >10.0
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S){[6-(2-Fluoromethyl-
phenyl)methoxy-pyridine
310 427.26 1.13 LC11_2 0,262
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(3-Chloromethyl-
phenyl)methoxy-pyridine
311 443.25 1.16 LC11_2 0,2019
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(5-Chlorofluoro-
phenyl)methoxy-pyridine
312 447.19 1.14 LC11_2 0,481
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(4-Chlorofluoro-
phenyl)methoxy-pyridine
313 447.21 1.18 LC11_2 3,55
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)[(2'-Chloromethoxy-5'-
methyl-[2,3']bipyridinyl
314 444.23 1.06 LC11_2 >10.0
carbonyl)-amino](2-fluoro-
phenyl)-propionic acid
(S){[6-(3-Chloromethyl-
phenyl)methoxy-pyridine
315 443.25 1.19 LC11_2 >10.0
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)(2-Fluoro-phenyl)({5-
methoxy[3-(5-methyl-
316 [1,3,4]oxadiazolyl)-phenyl]- 477.31 1.06 LC11_2 >10.0
pyridinecarbonyl}-amino)-
propionic acid
(S)(2-Fluoro-phenyl){[5-
317 methoxy(1,3,5-trimethyl-1H- 427.27 0.99 LC11_2 >10.0
pyrazolyl)-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Fluoro-phenyl){[5-
methoxy(1-methyl-1H-indol
318 448.3 1.13 LC11_2 >10.0
yl)-pyridinecarbonyl]-amino}-
propionic acid
(S){[6-(4-Chloromethoxy-
phenyl)methoxy-pyridine
319 459.22 1.16 LC11_2 >10.0
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(3-Chlorofluoro-
phenyl)methoxy-pyridine
320 447.22 1.14 LC11_2 0,0484
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)(2-Fluoro-phenyl)[(3-
methoxy-2'-morpholinyl-
321 481.33 0.91 LC11_2 >10.0
[2,4']bipyridinylcarbonyl)-
amino]-propionic acid
(S)(2-Fluoro-phenyl){[5-
methoxy(2-methyl-furanyl)-
322 399.21 1.11 LC11_2 0,0813
pyridinecarbonyl]-amino}-
propionic acid
(S){[6-(2-Chloromethyl-
phenyl)methoxy-pyridine
323 443.18 1.14 LC11_2 2,31
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(2-Chlorofluoro-
phenyl)methoxy-pyridine
324 447.2 1.12 LC11_2 1,266
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S){[6-(4-Cyanofluoro-
phenyl)methoxy-pyridine
325 438.23 1.08 LC11_2 3,58
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)(2-Fluoro-phenyl)({6-[3-
(3-hydroxy-oxetanyl)-phenyl]
326 467.29 1 LC11_2 8,46
methoxy-pyridinecarbonyl}-
amino)-propionic acid
(S)(2-Fluoro-phenyl)({6-[3-
(1-hydroxymethyl-ethyl)-
327 453.32 1.07 LC11_2 7,32
phenyl]methoxy-pyridine
carbonyl}-amino)-propionic acid
(S){[6-(2-Chloromethyl-
phenyl)methoxy-pyridine
328 443.24 1.14 LC11_2 0,1192
carbonyl]-amino}(2-fluoro-
phenyl)-propionic acid
(S)(2-Chloro-phenyl){[5-
methoxy(3-trifluoromethyl-
329 479.11 1.21 LC11_3 3,74
phenyl)-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl)[(5-
330 methoxyphenyl-pyridine 411.12 1.14 LC11_3 0,0751
carbonyl)-amino]-propionic acid
(S)(2-Chloro-phenyl){[6-(2,4-
dichloro-phenyl)methoxy-
331 479.05 1.21 LC11_3 0,589
pyridinecarbonyl]-amino}-
propionic acid
(S){[6-(3-Chlorofluoro-
phenyl)methoxy-pyridine
332 463.07 1.2 LC11_3 5,24
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S)(2-Chloro-phenyl){[6-(4-
fluoro-phenyl)methoxy-
333 429.12 1.16 LC11_3 0,909
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-(4-
chloro-phenyl)methoxy-
334 445.09 1.2 LC11_3 1,81
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[5-
methoxy(4-methoxy-phenyl)-
335 441.13 1.14 LC11_3 2,25
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl)[(5-
336 methoxyp-tolyl-pyridine 425.14 1.18 LC11_3 3,13
carbonyl)-amino]-propionic acid
(S)(2-Chloro-phenyl){[5-
methoxy(4-trifluoromethyl-
337 479.11 1.21 LC11_3 9,5
phenyl)-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl)[(5-
338 methoxyo-tolyl-pyridine 425.14 1.15 LC11_3 >10.0
carbonyl)-amino]-propionic acid
(S)(2-Chloro-phenyl){[5-
methoxy(3-methoxy-phenyl)-
339 441.13 1.14 LC11_3 2,78
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-(3-
chloro-phenyl)methoxy-
340 445.09 1.19 LC11_3 1,51
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[5-(3-
fluoro-phenyl)methoxy-
341 429.22 1.13 LC11_2 9,86
pyridinecarbonyl]-amino}-
propionic acid
(S){[6-Methoxy(4-
trifluoromethyl-phenyl)-pyridine
342 459.27 1.18 LC11_2 >10.0
carbonyl]-amino}o-tolyl-
propionic acid
(S)(2-Chloro-phenyl){[6-
methoxy(3-trifluoromethyl-
343 479.22 1.18 LC11_2 >10.0
phenyl)-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl)[(6-
344 methoxyphenyl-pyridine 411.23 1.12 LC11_2 3,49
carbonyl)-amino]-propionic acid
(S){[5-(3-Chlorofluoro-
phenyl)methoxy-pyridine
345 463.16 1.17 LC11_2 >10.0
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S)(2-Chloro-phenyl){[5-(4-
fluoro-phenyl)methoxy-
346 429.2 1.13 LC11_2 8,26
pyridinecarbonyl]-amino}-
propionic acid
(S){[5-Methoxy(3-
trifluoromethyl-phenyl)-pyridine
347 459.08 1.19 LC11_2 0,981
carbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2,4-Dichloro-phenyl)
348 methoxy-pyridinecarbonyl]- 459.01 1.19 LC11_2 0,161
amino}o-tolyl-propionic acid
(S){[6-(3-Chlorofluoro-
phenyl)methoxy-pyridine
349 443.03 1.19 LC11_2 1,458
carbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(4-Fluoro-phenyl)
350 methoxy-pyridinecarbonyl]- 409.08 1.14 LC11_2 0,267
amino}o-tolyl-propionic acid
(S){[6-(4-Chloro-phenyl)
351 methoxy-pyridinecarbonyl]- 425.04 1.18 LC11_2 0,501
amino}o-tolyl-propionic acid
(S)[(5-Methoxyp-tolyl-
352 pyridinecarbonyl)-amino]o- 405.12 1.17 LC11_2 0,586
tolyl-propionic acid
(S){[5-Methoxy(4-
353 trifluoromethyl-phenyl)-pyridine 459.08 1.19 LC11_2 >10.0
carbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(3-Chloro-phenyl)
354 methoxy-pyridinecarbonyl]- 425.05 1.18 LC11_2 0,53
amino}o-tolyl-propionic acid
(S){[5-Methoxy(2-methoxy-
355 phenyl)-pyridinecarbonyl]- 421.13 1.1 LC11_2 0,0833
amino}o-tolyl-propionic acid
(S)[(5-Methoxym-tolyl-
356 pyridinecarbonyl)-amino]o- 405.09 1.16 LC11_2 0,152
tolyl-propionic acid
(S){[6-(2-Chloro-phenyl)
357 methoxy-pyridinecarbonyl]- 425.06 1.13 LC11_2 0,223
amino}o-tolyl-propionic acid
(S){[6-(4-tert-Butyl-phenyl)
358 methoxy-pyridinecarbonyl]- 447.19 1.25 LC11_2 >10.0
amino}o-tolyl-propionic acid
(S){[6-(3-Cyano-phenyl)
359 methoxy-pyridinecarbonyl]- 416.1 1.11 LC11_2 4,49
amino}o-tolyl-propionic acid
(S){[6-(3-Acetyl-phenyl)
360 methoxy-pyridinecarbonyl]- 433.13 1.1 LC11_2 2,42
amino}o-tolyl-propionic acid
(S){[6-(4-Acetyl-phenyl)
361 methoxy-pyridinecarbonyl]- 433.12 1.09 LC11_2 9,24
amino}o-tolyl-propionic acid
(S){[6-(3,5-Difluoro-phenyl)
362 methoxy-pyridinecarbonyl]- 427.08 1.16 LC11_2 1,43
amino}o-tolyl-propionic acid
(S){[6-(3,4-Difluoro-phenyl)
363 methoxy-pyridinecarbonyl]- 427.11 1.16 LC11_2 0,258
amino}o-tolyl-propionic acid
(S){[6-(5-Acetyl-thiophenyl)-
364 5-methoxy-pyridinecarbonyl]- 439.09 1.1 LC11_2 9,25
amino}o-tolyl-propionic acid
(S)[(3-Methoxy-[2,4']bipyridinyl-
365 6-carbonyl)-amino]o-tolyl- 392.13 0.87 LC11_2 5,45
propionic acid
(S){[6-(2,5-Difluoro-phenyl)
366 methoxy-pyridinecarbonyl]- 427.09 1.13 LC11_2 0,121
amino}o-tolyl-propionic acid
(S){[6-(2,5-Dichloro-phenyl)
367 methoxy-pyridinecarbonyl]- 459.01 1.18 LC11_2 0,385
amino}o-tolyl-propionic acid
(S){[6-(3,5-Dimethyl-isoxazol-
4-yl)methoxy-pyridine
368 410.24 4 LC2 0,1873
carbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2,3-Dimethyl-phenyl)
369 methoxy-pyridinecarbonyl]- 419.14 1.16 LC11_2 0,1318
amino}o-tolyl-propionic acid
(S){[6-(3-Fluoromethyl-
phenyl)methoxy-pyridine
370 423.11 1.18 LC11_2 1,585
carbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2,4-Dimethyl-phenyl)
371 methoxy-pyridinecarbonyl]- 419.16 1.17 LC11_2 0,457
amino}o-tolyl-propionic acid
(S)[(5-Methoxypyrimidin
372 yl-pyridinecarbonyl)-amino] 393.11 0.98 LC11_2 8,88
o-tolyl-propionic acid
(S)[(6'-Fluoromethoxy-
373 [2,3']bipyridinylcarbonyl)- 410.1 1.08 LC11_2 1,6
amino]o-tolyl-propionic acid
(S){[6-(2-Dimethylcarbamoyl-
phenyl)methoxy-pyridine
374 460.12 1.04 LC11_2 2,48
carbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(4-Fluoromethoxy-
phenyl)methoxy-pyridine
375 439.13 1.12 LC11_2 0,216
carbonyl]-amino}o-tolyl-
propionic acid
(S){[5-Methoxy(5-methyl-
376 furanyl)-pyridinecarbonyl]- 395.11 1.11 LC11_2 6,1
amino}o-tolyl-propionic acid
(S){[5-Methoxy(1-methyl-
1H-pyrazolyl)-pyridine
377 395.13 1.01 LC11_2 >10.0
carbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(3-Chloromethyl-
phenyl)methoxy-pyridine
378 439.1 1.21 LC11_2 7,49
carbonyl]-amino}o-tolyl-
propionic acid
(S){[5-Methoxy(1,3,5-
trimethyl-1H-pyrazolyl)-
379 421.13 1 LC11_2 >10.0
pyridinecarbonyl]-amino}o-
tolyl-propionic acid
(S){[5-Methoxy(1-methyl-
380 1H-indolyl)-pyridine 444.15 1.15 LC11_2 5,33
carbonyl]-amino}o-tolyl-
propionic acid
(S)[(3-Methoxy-2'-morpholin
381 yl-[2,4']bipyridinylcarbonyl)- 477.16 0.93 LC11_2 >10.0
amino]o-tolyl-propionic acid
(S){[6-(2-Chloromethyl-
phenyl)methoxy-pyridine
382 439.13 1.16 LC11_2 0,497
carbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(2-Chlorofluoro-
phenyl)methoxy-pyridine
383 443.06 1.14 LC11_2 1,635
carbonyl]-amino}o-tolyl-
propionic acid
(S)({6-[3-(3-Hydroxy-oxetan
yl)-phenyl]methoxy-pyridine
384 463.15 1.02 LC11_2 2,39
carbonyl}-amino)o-tolyl-
propionic acid
(S)({6-[3-(1-Hydroxymethyl-
ethyl)-phenyl]methoxy-
385 449.17 1.08 LC11_2 1,15
pyridinecarbonyl}-amino)o-
tolyl-propionic acid
(S)(2-Chloro-phenyl){[5-(4-
chloro-phenyl)methoxy-
386 445.17 1.17 LC11_2 10,4
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-
methoxy(4-methoxy-phenyl)-
387 441.24 1.11 LC11_2 9,43
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl)[(6-
388 methoxyp-tolyl-pyridine 425.24 1.15 LC11_2 7,12
carbonyl)-amino]-propionic acid
(S)(2-Chloro-phenyl){[6-
methoxy(4-trifluoromethyl-
389 479.21 1.18 LC11_2 >10.0
phenyl)-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl)[(6-
390 methoxyo-tolyl-pyridine 425.25 1.13 LC11_2 0,702
carbonyl)-amino]-propionic acid
(S)(2-Chloro-phenyl){[6-
methoxy(3-methoxy-phenyl)-
391 441.24 1.12 LC11_2 10,6
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[5-(3-
chloro-phenyl)methoxy-
392 445.2 1.16 LC11_2 10,3
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl)[(6-
methoxynaphthalenyl-
393 461.25 1.18 LC11_2 >10.0
pyridinecarbonyl)-amino]-
propionic acid
(S)(2-Chloro-phenyl){[6-
methoxy(2-methoxy-phenyl)-
394 441.25 1.1 LC11_2 3,76
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl)[(6-
395 methoxym-tolyl-pyridine 425.24 1.15 LC11_2 6,57
carbonyl)-amino]-propionic acid
(S){[5-(4-tert-Butyl-phenyl)
methoxy-pyridinecarbonyl]-
396 467.31 1.24 LC11_2 >10.0
amino}(2-chloro-phenyl)-
propionic acid
(S)(2-Chloro-phenyl){[5-(3-
cyano-phenyl)methoxy-
397 436.23 1.09 LC11_2 >10.0
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[5-(4-
cyano-phenyl)methoxy-
398 436.23 1.09 LC11_2 >10.0
pyridinecarbonyl]-amino}-
propionic acid
(S){[5-(3-Acetyl-phenyl)
methoxy-pyridinecarbonyl]-
399 453.25 1.08 LC11_2 >10.0
amino}(2-chloro-phenyl)-
propionic acid
(S)[(5-Biphenylyl
methoxy-pyridinecarbonyl)-
400 487.27 1.21 LC11_2 >10.0
amino](2-chloro-phenyl)-
propionic acid
(S){[5-(4-Acetyl-phenyl)
methoxy-pyridinecarbonyl]-
401 453.25 1.08 LC11_2 >10.0
amino}(2-chloro-phenyl)-
propionic acid
(S)(2-Chloro-phenyl){[5-(3,5-
difluoro-phenyl)methoxy-
402 447.2 1.15 LC11_2 >10.0
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[5-(3,4-
difluoro-phenyl)methoxy-
403 447.2 1.14 LC11_2 >10.0
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[5-(4-
fluoromethyl-phenyl)
404 443.26 1.14 LC11_2 7,14
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)[(6-Methoxyphenyl-
405 pyridinecarbonyl)-amino]o- 391.28 1.12 LC11_2 3,9
tolyl-propionic acid
(S){[5-(3-Chlorofluoro-
phenyl)methoxy-pyridine
406 443.22 1.17 LC11_2 10
carbonyl]-amino}o-tolyl-
propionic acid
(S){[5-(4-Fluoro-phenyl)
407 methoxy-pyridinecarbonyl]- 409.24 1.13 LC11_2 4,39
amino}o-tolyl-propionic acid
(S){[5-(4-Chloro-phenyl)
408 methoxy-pyridinecarbonyl]- 425.22 1.17 LC11_2 5,73
amino}o-tolyl-propionic acid
(S){[6-Methoxy(4-methoxy-
409 phenyl)-pyridinecarbonyl]- 421.3 1.11 LC11_2 9,04
amino}o-tolyl-propionic acid
(S)[(6-Methoxyp-tolyl-
410 pyridinecarbonyl)-amino]o- 405.26 1.15 LC11_2 5,38
tolyl-propionic acid
(S)[(6-Methoxyo-tolyl-
411 pyridinecarbonyl)-amino]o- 405.27 1.13 LC11_2 1,186
tolyl-propionic acid
(S){[6-Methoxy(3-methoxy-
412 phenyl)-pyridinecarbonyl]- 421.27 1.12 LC11_2 8,36
amino}o-tolyl-propionic acid
(S){[5-(3-Chloro-phenyl)
413 methoxy-pyridinecarbonyl]- 425.21 1.16 LC11_2 6,24
amino}o-tolyl-propionic acid
(S){[5-(3-Fluoro-phenyl)
414 methoxy-pyridinecarbonyl]- 409.22 1.13 LC11_2 8,07
amino}o-tolyl-propionic acid
(S)[(6-Methoxynaphthalen-
415 2-yl-pyridinecarbonyl)-amino]- 441.33 1.18 LC11_2 >10.0
3-o-tolyl-propionic acid
(S){[6-Methoxy(2-methoxy-
416 phenyl)-pyridinecarbonyl]- 421.31 1.1 LC11_2 3,42
amino}o-tolyl-propionic acid
(S)[(6-Methoxym-tolyl-
417 pyridinecarbonyl)-amino]o- 405.28 1.15 LC11_2 4,86
tolyl-propionic acid
(S){[5-(2-Fluoro-phenyl)
418 methoxy-pyridinecarbonyl]- 409.23 1.11 LC11_2 1,083
amino}o-tolyl-propionic acid
(S){[5-(4-tert-Butyl-phenyl)
419 methoxy-pyridinecarbonyl]- 447.38 1.24 LC11_2 >10.0
amino}o-tolyl-propionic acid
(S){[5-(3-Cyano-phenyl)
420 methoxy-pyridinecarbonyl]- 416.25 1.09 LC11_2 >10.0
amino}o-tolyl-propionic acid
(S){[5-(4-Cyano-phenyl)
421 methoxy-pyridinecarbonyl]- 416.29 1.09 LC11_2 10,4
amino}o-tolyl-propionic acid
(S){[5-(3-Acetyl-phenyl)
422 methoxy-pyridinecarbonyl]- 433.28 1.08 LC11_2 >10.0
amino}o-tolyl-propionic acid
(S)[(5-Biphenylyl
423 methoxy-pyridinecarbonyl)- 467.34 1.21 LC11_2 >10.0
amino]o-tolyl-propionic acid
(S){[5-(4-Acetyl-phenyl)
424 methoxy-pyridinecarbonyl]- 433.28 1.08 LC11_2 >10.0
amino}o-tolyl-propionic acid
(S){[5-(3,4-Difluoro-phenyl)
425 methoxy-pyridinecarbonyl]- 427.25 1.15 LC11_2 8,84
amino}o-tolyl-propionic acid
(S)(2-Chloro-phenyl){[6-(3-
fluoro-phenyl)methoxy-
426 429.12 1.16 LC11_3 1,54
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl)[(5-
methoxynaphthalenyl-
427 461.14 1.21 LC11_3 7,11
pyridinecarbonyl)-amino]-
propionic acid
(S)(2-Chloro-phenyl){[5-
methoxy(2-methoxy-phenyl)-
428 441.14 1.11 LC11_3 0,1161
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl)[(5-
429 methoxym-tolyl-pyridine 425.14 1.18 LC11_3 0,335
carbonyl)-amino]-propionic acid
(S)(2-Chloro-phenyl){[6-(2-
chloro-phenyl)methoxy-
430 445.09 1.14 LC11_3 0,147
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-(2-
431 fluoro-phenyl)methoxy- 429.11 1.13 LC11_3 0,132
pyridinecarbonyl]-amino}-
propionic acid
(S){[6-(4-tert-Butyl-phenyl)
methoxy-pyridinecarbonyl]-
432 467.18 1.26 LC11_3 >10.0
amino}(2-chloro-phenyl)-
propionic acid
(S)(2-Chloro-phenyl){[6-(3-
cyano-phenyl)methoxy-
433 436.12 1.12 LC11_3 8,26
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-(4-
cyano-phenyl)methoxy-
434 436.12 1.12 LC11_3 >10.0
pyridinecarbonyl]-amino}-
propionic acid
(S){[6-(3-Acetyl-phenyl)
methoxy-pyridinecarbonyl]-
435 453.13 1.11 LC11_3 4,2
amino}(2-chloro-phenyl)-
propionic acid
(S)[(6-Biphenylyl
methoxy-pyridinecarbonyl)-
436 487.16 1.24 LC11_3 2,97
amino](2-chloro-phenyl)-
propionic acid
(S){[6-(4-Acetyl-phenyl)
methoxy-pyridinecarbonyl]-
437 453.13 1.1 LC11_3 >10.0
amino}(2-chloro-phenyl)-
propionic acid
(S)(2-Chloro-phenyl){[6-(2,4-
difluoro-phenyl)methoxy-
438 447.19 1.13 LC11_2 0,0491
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-(3,5-
difluoro-phenyl)methoxy-
439 447.11 1.18 LC11_3 2,39
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-(3,4-
difluoro-phenyl)methoxy-
440 447.11 1.17 LC11_3 1,96
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-(2,3-
dichloro-phenyl)methoxy-
441 479.05 1.18 LC11_3 0,2352
pyridinecarbonyl]-amino}-
propionic acid
(S){[6-(5-Acetyl-thiophenyl)-
-methoxy-pyridinecarbonyl]-
442 459.09 1.11 LC11_3 >10.0
amino}(2-chloro-phenyl)-
propionic acid
(S)(2-Chloro-phenyl)[(3-
443 methoxy-[2,4']bipyridinyl 412.12 0.86 LC11_3 8,04
carbonyl)-amino]-propionic acid
(S)(2-Chloro-phenyl)[(3-
444 methoxy-[2,3']bipyridinyl 412.12 0.91 LC11_3 10,1
carbonyl)-amino]-propionic acid
(S)(2-Chloro-phenyl){[6-(2,3-
difluoro-phenyl)methoxy-
445 447.11 1.14 LC11_3 0,1505
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-(2,5-
difluoro-phenyl)methoxy-
446 447.1 1.14 LC11_3 0,0571
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-(4-
fluoromethyl-phenyl)
447 443.13 1.16 LC11_3 0,1106
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2,3-
dimethyl-phenyl)methoxy-
448 439.15 1.17 LC11_3 0,1393
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-(3-
fluoromethyl-phenyl)
449 443.13 1.2 LC11_3 2,016
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2,4-
dimethyl-phenyl)methoxy-
450 439.15 1.18 LC11_3 1,6
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-(4-
fluoromethyl-phenyl)
451 443.13 1.19 LC11_3 3,79
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl)[(5-
452 methoxypyrimidinyl-pyridine- 413.11 0.99 LC11_3 >10.0
2-carbonyl)-amino]-propionic acid
(S)(2-Chloro-phenyl)[(6'-
453 fluoromethoxy-[2,3']bipyridinyl- 430.11 1.09 LC11_3 6,49
6-carbonyl)-amino]-propionic acid
(S)(2-Chloro-phenyl){[6-(2-
dimethylcarbamoyl-phenyl)
454 482.3 1.04 LC11_2 2,5
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl)[(3,2'-
455 dimethoxy-[2,3']bipyridinyl 442.13 1.07 LC11_3 0,185
carbonyl)-amino]-propionic acid
(S)(2-Chloro-phenyl){[6-(5-
fluoromethyl-phenyl)
456 443.13 1.16 LC11_3 0,1193
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(4-
fluoromethoxy-phenyl)
457 459.13 1.13 LC11_3 0,1072
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S){[6-(4-Chloromethoxy-
phenyl)methoxy-pyridine
458 475.1 1.17 LC11_3 0,415
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S){[6-(5-Chloromethoxy-
phenyl)methoxy-pyridine
459 475.1 1.16 LC11_3 1,147
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S)(2-Chloro-phenyl){[6-(5-
fluoromethoxy-phenyl)
460 459.12 1.12 LC11_3 0,1073
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[6-(2,5-
dimethoxy-phenyl)methoxy-
461 471.14 1.11 LC11_3 8,31
pyridinecarbonyl]-amino}-
propionic acid
(S)(2-Chloro-phenyl){[6-(2-
fluorotrifluoromethyl-phenyl)
462 497.2 1.18 LC11_2 0,597
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[5-
methoxy(5-methyl-furanyl)-
463 415.15 1.11 LC11_2 >10.0
pyridinecarbonyl]-amino}-
propionic acid
(S){[5-Methoxy(2-
trifluoromethyl-phenyl)-pyridine
464 459.1 1.14 LC11_2 0,0993
carbonyl]-amino}o-tolyl-
propionic acid
(S){[6-(4-Cyano-phenyl)
465 methoxy-pyridinecarbonyl]- 416.1 1.1 LC11_2 6,8
amino}o-tolyl-propionic acid
(S){[6-(2,4-Difluoro-phenyl)
466 methoxy-pyridinecarbonyl]- 427.09 1.13 LC11_2 0,0463
amino}o-tolyl-propionic acid
(S){[6-(4-Fluoromethyl-
phenyl)methoxy-pyridine
467 423.09 1.14 LC11_2 0,1768
carbonyl]-amino}o-tolyl-
propionic acid
(S)[(3,2'-Dimethoxy-
468 [2,3']bipyridinylcarbonyl)- 422.12 1.06 LC11_2 0,347
amino]o-tolyl-propionic acid
(S)[(2'-Chloromethoxy-5'-
methyl-[2,3']bipyridinyl
469 440.1 1.08 LC11_2 5,63
carbonyl)-amino]o-tolyl-
propionic acid
(S)[(3'-Fluoromethoxy-
470 [2,4']bipyridinylcarbonyl)- 410.06 1.06 LC11_2 0,1182
amino]o-tolyl-propionic acid
(S)({5-Methoxy[3-(5-methyl-
[1,3,4]oxadiazolyl)-phenyl]-
471 473.13 1.07 LC11_2 4,23
pyridinecarbonyl}-amino)o-
tolyl-propionic acid
(S){[5-Methoxy(2-methyl-
472 furanyl)-pyridinecarbonyl]- 395.04 1.13 LC11_2 0,096
amino}o-tolyl-propionic acid
(S){[6-(4-Cyanofluoro-
phenyl)methoxy-pyridine
473 434.13 1.1 LC11_2 0,288
carbonyl]-amino}o-tolyl-
propionic acid
(S)(2-Chloro-phenyl){[6-(2-
fluoromethoxy-phenyl)
474 459.12 1.13 LC11_3 0,58
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S){[6-(5-tert-Butylmethoxy-
phenyl)methoxy-pyridine
475 497.2 1.23 LC11_3 >10.0
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S)(2-Chloro-phenyl){[6-(2-
fluoromethyl-phenyl)
476 443.13 1.16 LC11_3 0,3695
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S){[6-(3-Chloromethyl-
phenyl)methoxy-pyridine
477 459.1 1.19 LC11_3 0,11
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S)(2-Chloro-phenyl){[6-(3-
fluoromethyl-phenyl)
478 443.13 1.16 LC11_3 0,192
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S){[6-(5-Chlorofluoro-
phenyl)methoxy-pyridine
479 463.08 1.17 LC11_3 0,262
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S){[6-(4-Chlorofluoro-
phenyl)methoxy-pyridine
480 463.07 1.21 LC11_3 4,37
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S)[(2'-Chloromethoxy-5'-
methyl-[2,3']bipyridinyl
481 460.1 1.09 LC11_3 8,77
carbonyl)-amino](2-chloro-
phenyl)-propionic acid
(S)(2-Chloro-phenyl)[(3'-
482 fluoromethoxy-[2,4']bipyridinyl- 430.2 1.03 LC11_2 0,1153
6-carbonyl)-amino]-propionic acid
(S){[6-(3-Chloromethyl-
phenyl)methoxy-pyridine
483 459.1 1.22 LC11_3 9,49
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S)(2-Chloro-phenyl)({5-
methoxy[3-(5-methyl-
484 [1,3,4]oxadiazolyl)-phenyl]- 493.14 1.09 LC11_3 6,69
pyridinecarbonyl}-amino)-
propionic acid
(S)(2-Chloro-phenyl)[(5-
485 methoxypyrazinyl-pyridine- 413 1.07 LC11_3 0,1588
2-carbonyl)-amino]-propionic acid
(S)(2-Chloro-phenyl){[5-
methoxy(1,3,5-trimethyl-1H-
486 443.16 1.02 LC11_3 4,95
pyrazolyl)-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl){[5-
methoxy(1-methyl-1H-indol
487 464.15 1.17 LC11_3 >10.0
yl)-pyridinecarbonyl]-amino}-
propionic acid
(S){[6-(4-Chloromethoxy-
phenyl)methoxy-pyridine
488 475.09 1.19 LC11_3 >10.0
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S){[6-(3-Chlorofluoro-
phenyl)methoxy-pyridine
489 463.08 1.17 LC11_3 0,1314
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S)(2-Chloro-phenyl)[(3-
methoxy-2'-morpholinyl-
490 497.17 0.92 LC11_3 9,08
[2,4']bipyridinylcarbonyl)-
amino]-propionic acid
(S)(2-Chloro-phenyl){[5-
methoxy(2-methyl-furanyl)-
491 415.12 1.14 LC11_3 0,199
pyridinecarbonyl]-amino}-
propionic acid
(S){[6-(2-Chloromethyl-
phenyl)methoxy-pyridine
492 459.1 1.17 LC11_3 1,053
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S){[6-(2-Chlorofluoro-
phenyl)methoxy-pyridine
493 463.07 1.15 LC11_3 0,05065
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
(S)(2-Chloro-phenyl){[6-(4-
cyanofluoro-phenyl)
494 454.11 1.11 LC11_3 11,4
methoxy-pyridinecarbonyl]-
amino}-propionic acid
(S)(2-Chloro-phenyl)({6-[3-
(3-hydroxy-oxetanyl)-phenyl]
495 483.14 1.04 LC11_3 3,89
methoxy-pyridinecarbonyl}-
amino)-propionic acid
(S)(2-Chloro-phenyl)({6-[3-
(1-hydroxymethyl-ethyl)-
496 469.16 1.1 LC11_3 2,86
phenyl]methoxy-pyridine
carbonyl}-amino)-propionic acid
(S){[6-(2-Chloromethyl-
phenyl)methoxy-pyridine
497 459.1 1.17 LC11_3 0,0678
carbonyl]-amino}(2-chloro-
phenyl)-propionic acid
3-Biphenylyl[(3,6-dichloro-
498 pyridinecarbonyl)-amino]- 413.24 1.13 LC11_2 8,55
propionic acid
3-Biphenylyl[(4-chloro
499 methoxy-pyridinecarbonyl)- 409.23 1.11 LC11_2 >10.0
amino]-propionic acid
3-Biphenylyl[(2-chloro
500 methyl-pyridinecarbonyl)- 395.22 1.12 LC11_2 >10.0
amino]-propionic acid
3-Biphenylyl[(6-chloro-
501 pyridinecarbonyl)-amino]- 381.18 1.13 LC11_2 0,463
propionic acid
3-Biphenylyl[(5-chloro
502 hydroxy-pyridinecarbonyl)- 397.18 1.01 LC11_2 >10.0
amino]-propionic acid
3-Biphenylyl[(2-chloro-
503 pyridinecarbonyl)-amino]- 381.18 1.09 LC11_2 >10.0
propionic acid
3-Biphenylyl[(5-chloro-
504 pyridinecarbonyl)-amino]- 381.45 1.09 LC11_2 >10.0
propionic acid
3-Biphenylyl[(5-chloro
505 methoxy-pyridinecarbonyl)- 411.2 1.14 LC11_2 >10.0
amino]-propionic acid
(S)[(3,6-Dichloro-pyridine
506 carbonyl)-amino]o-tolyl- 353.11 1.03 LC11_2 8,48
propionic acid
(S)[(2-Chloromethyl-
507 pyridinecarbonyl)-amino]o- 331.17 1.02 LC11_2 >10.0
tolyl-propionic acid
(S)[(2-Chloromethoxy-
508 pyridinecarbonyl)-amino]o- 349.18 1.07 LC11_2 >10.0
tolyl-propionic acid
(S)[(2,6-Dichloro-pyridine
509 carbonyl)-amino]o-tolyl- 353.12 1.08 LC11_2 >10.0
propionic acid
(S)[(6-Chloro-pyridine
510 carbonyl)-amino]o-tolyl- 319.16 1.05 LC11_2 0,2049
propionic acid
(S)[(5-Chlorohydroxy-
511 pyridinecarbonyl)-amino]o- 333.14 0.88 LC11_2 >10.0
tolyl-propionic acid
(S)[(2-Chloro-pyridine
512 carbonyl)-amino]o-tolyl- 317.16 0.99 LC11_2 >10.0
propionic acid
(S)[(5-Chloro-pyridine
513 carbonyl)-amino]o-tolyl- 319.17 0.98 LC11_2 >10.0
propionic acid
(S)[(6-Chloro-pyrazine
514 carbonyl)-amino]o-tolyl- 320.03 3.67 LC2 1,21
propionic acid
(S)[(3,5-Diaminochloro-
515 pyrazinecarbonyl)-amino]o- 350.16 0.97 LC11_2 0,0871
tolyl-propionic acid
3-Biphenylyl{[5-chloro(2-
516 hydroxy-ethylamino)-pyridine 438.29 1.04 LC11_2 >10.0
carbonyl]-amino}-propionic acid
(S)[(5-Chloromethoxy-
517 pyridinecarbonyl)-amino]o- 347.15 1.05 LC11_2 >10.0
tolyl-propionic acid
(S)[(2,5-Dichloro-pyridine
518 carbonyl)-amino]o-tolyl- 351.11 1.01 LC11_2 >10.0
propionic acid
3-Biphenylyl[(3,5-diamino
519 chloro-pyrazinecarbonyl)- 412.19 1.07 LC11_2 0,563
amino]-propionic acid
(S)[(4-Chloromethoxy-
520 pyridinecarbonyl)-amino]o- 347.16 1.01 LC11_2 >10.0
tolyl-propionic acid
3-(2-Chloro-phenyl)[(pyrazine-
521 304.19 1.05 LC11_2 12,8
2-carbonyl)-amino]-propionic acid
3-(2-Chloro-phenyl)[(pyridine-
522 305.07 0.98 LC11_2
3-carbonyl)-amino]-propionic acid
3-(2-Chloro-phenyl)[(pyridine-
523 305.08 1.12 LC11_2
2-carbonyl)-amino]-propionic acid
3-(2-Chloro-phenyl)[(pyridine-
524 305.08 0.97 LC11_2 10,2
4-carbonyl)-amino]-propionic acid
3-(2-Chloro-phenyl)[(5-methyl-
525 pyrazinecarbonyl)-amino]- 318.17 1.09 LC11_2
propionic acid
3-(2-Chloro-phenyl)[(2-methyl-
526 pyridinecarbonyl)-amino]- 319.09 0.94 LC11_2
propionic acid
3-(2-Chloro-phenyl)[(6-methyl-
527 pyridinecarbonyl)-amino]- 319.1 1.16 LC11_2 4,96
propionic acid
3-(2-Chloro-phenyl)[(4-methyl-
528 pyridinecarbonyl)-amino]- 319.1 1.16 LC11_2 5,81
propionic acid
3-(2-Chloro-phenyl)[(4-
529 hydroxy-pyridinecarbonyl)- 321.06 0.97 LC11_2 5,12
amino]-propionic acid
3-(2-Chloro-phenyl)[(3-fluoro-
530 pyridinecarbonyl)-amino]- 321.14 1.09 LC11_2 5,27
propionic acid
3-(2-Chloro-phenyl)[(6-fluoro-
531 pyridinecarbonyl)-amino]- 323.06 1.15 LC11_2 7,65
propionic acid
3-(2-Chloro-phenyl)[(4-ethyl-
532 pyridinecarbonyl)-amino]- 331.22 1.21 LC11_2 10,2
propionic acid
3-(2-Chloro-phenyl)[(4,6-
533 dimethyl-pyridinecarbonyl)- 331.22 1.2 LC11_2 6,29
amino]-propionic acid
3-(2-Chloro-phenyl)[(4,6-
534 dimethyl-pyridinecarbonyl)- 333.11 0.92 LC11_2
amino]-propionic acid
3-(2-Chloro-phenyl)[(6-
535 methylamino-pyrazine 335.08 1.07 LC11_2
carbonyl)-amino]-propionic acid
3-(2-Chloro-phenyl)[(2-
536 methoxy-pyridinecarbonyl)- 335.08 1.11 LC11_2 5,08
amino]-propionic acid
3-(2-Chloro-phenyl)[(6-
537 methoxy-pyridinecarbonyl)- 335.08 1.1 LC11_2
amino]-propionic acid
3-(2-Chloro-phenyl)[(6-
538 methoxy-pyridinecarbonyl)- 335.08 1.18 LC11_2
amino]-propionic acid
3-(2-Chloro-phenyl)[(3-
539 methoxy-pyridinecarbonyl)- 335.09 1.03 LC11_2 >10.0
amino]-propionic acid
3-(2-Chloro-phenyl)[(6-chloro-
540 pyridinecarbonyl)-amino]- 339.02 1.18 LC11_2 1,6
propionic acid
3-(2-Chloro-phenyl)[(3,6-
541 difluoro-pyridinecarbonyl)- 339.14 1.12 LC11_2
amino]-propionic acid
3-(2-Chloro-phenyl)[(3H-
imidazo[4,5-b]pyridine
542 carbonyl)-amino]-propionic acid; 345.06 1.0 LC11_2 10,8
compound with trifluoro-acetic
acid
3-(2-Chloro-phenyl)
543 [([1,8]naphthyridinecarbonyl)- 356.07 1.09 LC11_2
amino]-propionic acid
3-(2-Chloro-phenyl)
544 [([1,6]naphthyridinecarbonyl)- 356.07 1.08 LC11_2 11,1
amino]-propionic acid
3-[(2-Acetylamino-pyridine
545 carbonyl)-amino](2-chloro- 362.08 1.02 LC11_2
phenyl)-propionic acid
3-[(2-Aminoisopropyl-
pyrimidinecarbonyl)-amino]
546 (2-chloro-phenyl)-propionic acid; 363.12 1.15 LC11_2
compound with trifluoro-acetic
acid
(S){[6-(2-Fluoro-phenyl)-
547 pyridinecarbonyl]-amino} 365.29 1.75 LC X 0,345
phenyl-propionic acid
3-(2-Chloro-phenyl)[(4,6-
548 dimethoxy-pyrimidinecarbonyl)- 366.07 1.24 LC X
amino]-propionic acid
3-(2-Chloro-phenyl)[(2,6-
549 dimethoxy-pyrimidinecarbonyl)- 366.08 1.19 LC X
amino]-propionic acid
3-[(6-Chloromethoxy-pyridine-
550 2-carbonyl)-amino](2-chloro- 369.03 1.19 LC X 1,08
phenyl)-propionic acid
3-(2-Chloro-phenyl)[(6-
551 imidazolyl-pyridinecarbonyl)- 371.08 0.96 LC X
amino]-propionic acid
3-(2-Chloro-phenyl)[(3,6-
552 dichloro-pyridinecarbonyl)- 371.1 1.18 LC X
amino]-propionic acid
3-(2-Chloro-phenyl)[(2-
pyrrolidinyl-pyridine
553 carbonyl)-amino]-propionic acid; 374.11 0.96 LC X 11,1
compound with trifluoro-acetic
acid
3-(2-Chloro-phenyl)[(6-
pyrrolidinyl-pyridine
554 carbonyl)-amino]-propionic acid; 374.11 0.95 LC X
compound with trifluoro-acetic
acid
3-(2-Chloro-phenyl)[(5-
pyrrolidinyl-pyridine
555 carbonyl)-amino]-propionic acid; 374.13 1.01 LC11_2 >10.0
compound with trifluoro-acetic
acid
(S){[5-Chloro(2-hydroxy-
556 ethylamino)-pyridinecarbonyl]- 376.22 0.92 LC11_2 >10.0
amino}o-tolyl-propionic acid
3-[(2-Aminoisobutyl-pyrimidine-
557 4-carbonyl)-amino](2-chloro- 377.12 1.19 LC11_2 14
phenyl)-propionic acid
(S){[6-(2-Fluoro-phenyl)-
558 pyridinecarbonyl]-amino} 379.33 1.8 LC X
phenyl-butyric acid
(S){[6-(2-Fluoro-phenyl)-
559 pyridinecarbonyl]-amino}p- 379.33 1.81 LC X 4,38
tolyl-propionic acid
(S){[6-(2-Fluoro-phenyl)-
560 pyridinecarbonyl]-amino}m- 379.33 1.81 LC X 12,9
tolyl-propionic acid
(R){[6-(2-Fluoro-phenyl)-
561 pyridinecarbonyl]-amino} 379.34 1.79 LC X 5,33
phenyl-butyric acid
3-[(6-Bromo-pyridinecarbonyl)-
562 amino](2-chloro-phenyl)- 381.04 1.2 LC11_2 2,1
propionic acid
3-(2-Chloro-phenyl)[(6-phenyl-
563 pyridinecarbonyl)-amino]- 381.1 1.27 LC11_2 3,09
propionic acid
3-(2-Chloro-phenyl)[(3-phenyl-
564 pyridinecarbonyl)-amino]- 381.1 1.18 LC11_2
propionic acid
3-(2-Chloro-phenyl)[(4-phenyl-
565 pyridinecarbonyl)-amino]- 381.1 1.27 LC11_2 4,07
propionic acid
3-(2-Chloro-phenyl)[(5-phenyl-
566 pyridinecarbonyl)-amino]- 381.11 1.18 LC11_2 11,7
propionic acid
(S){[6-(2-Chloro-phenyl)-
567 pyridinecarbonyl]-amino} 381.27 1.77 LC X 2,18
phenyl-propionic acid
3-[(5-Bromo-pyridinecarbonyl)-
568 amino](2-chloro-phenyl)- 382.97 1.13 LC11_2
propionic acid
(S)(3-Fluoro-phenyl){[6-(2-
569 fluoro-phenyl)-pyridine 383.29 1.77 LC11_X 0,429
carbonyl]-amino}-propionic acid
(S)(2-Fluoro-phenyl){[6-(2-
570 fluoro-phenyl)-pyridine 383.3 1.76 LC11_X 0,195
carbonyl]-amino}-propionic acid
(S)(4-Fluoro-phenyl){[6-(2-
571 fluoro-phenyl)-pyridine 383.3 1.77 LC11_X 0,514
carbonyl]-amino}-propionic acid
3-(2-Chloro-phenyl)[(3,4,5,6-
tetrahydro-2H-[1,2']bipyridinyl-4'-
572 carbonyl)-amino]-propionic acid; 388.15 1.03 LC11_2 >10.0
compound with trifluoro-acetic
acid
3-(2-Chloro-phenyl)[(3,4,5,6-
tetrahydro-2H-[1,2']bipyridinyl-6'-
573 carbonyl)-amino]-propionic acid; 388.16 1.29 LC11_2
compound with trifluoro-acetic
acid
3-(2-Chloro-phenyl)[(6-
morpholinyl-pyridine
574 carbonyl)-amino]-propionic acid; 390.12 1.16 LC11_2
compound with trifluoro-acetic
acid
3-(2-Chloro-phenyl)[(4-
morpholinyl-pyridine
575 carbonyl)-amino]-propionic acid; 390.12 0.93 LC11_2
compound with trifluoro-acetic
acid
3-(2-Chloro-phenyl)[(2-
morpholinyl-pyridine
576 carbonyl)-amino]-propionic acid; 390.13 1.03 LC11_2
compound with trifluoro-acetic
acid
(S)[(6-Methoxy-biphenyl
577 carbonyl)-amino]o-tolyl- 390.2 1.26 LC11_ 0,414
propionic acid
(S)[(3-Methoxy-[2,3']bipyridinyl-
578 6-carbonyl)-amino]o-tolyl- 392.08 0.91 LC11_ 7,54
propionic acid
3-[(2,6-Bis-dimethylamino-
pyrimidinecarbonyl)-amino]
579 (2-chloro-phenyl)-propionic acid; 392.14 1.01 LC11_2
compound with trifluoro-acetic
acid
(S){[6-(2-Chloro-phenyl)-
580 pyridinecarbonyl]-amino}p- 393.19 1.95 LC 11_X 15,6
tolyl-propionic acid
(S){[6-(2-Chloro-phenyl)-
581 pyridinecarbonyl]-amino} 395.17 1.94 LC 11_X 5,76
phenyl-butyric acid
(S){[6-(2-Chloro-phenyl)-
582 pyridinecarbonyl]-amino}m- 395.18 1.96 LC 11_X 0,16
tolyl-propionic acid
(R){[6-(2-Chloro-phenyl)-
583 pyridinecarbonyl]-amino} 395.29 1.81 LC 11_X >30.0
phenyl-butyric acid
(S){[6-(2-Fluoro-phenyl)-
584 pyridinecarbonyl]-amino}(4- 395.31 1.74 LC X 0,54
methoxy-phenyl)-propionic acid
3-(2-Chloro-phenyl)[(6-
585 phenoxy-pyridinecarbonyl)- 397.08 1.21 LC 11 8,67
amino]-propionic acid
(S){[6-(2-Chloro-phenyl)-
586 pyridinecarbonyl]-amino}(2- 399.13 1.92 LC 11_X 0,339
fluoro-phenyl)-propionic acid
(S){[6-(2-Chloro-phenyl)-
587 pyridinecarbonyl]-amino}(3- 399.15 1.92 LC 11_X 7,35
fluoro-phenyl)-propionic acid
(S){[6-(2-Chloro-phenyl)-
588 pyridinecarbonyl]-amino}(4- 399.23 4.49 LC 11_X 0,107
fluoro-phenyl)-propionic acid
3-(2-Chloro-phenyl){[6-(2-
589 fluoro-phenyl)-pyridine 399.26 1.8 LC X 4,89
carbonyl]-amino}-propionic acid
(S)(3-Chloro-phenyl){[6-(2-
590 fluoro-phenyl)-pyridine 399.26 1.83 LC 11_X 0,339
carbonyl]-amino}-propionic acid
(S)(4-Chloro-phenyl){[6-(2-
591 fluoro-phenyl)-pyridine 399.27 1.83 LC 11_X 0,322
carbonyl]-amino}-propionic acid
3-(2-Chloro-phenyl)[(1-ethyl-
3,6-dimethyl-1H-pyrazolo[3,4-
592 401.13 1.14 LC 11_2
b]pyridinecarbonyl)-amino]-
propionic acid
3-(2-Chloro-phenyl){[2-(2,2-
dimethyl-propionylamino)-
593 404.14 1.17 LC 11_2
pyridinecarbonyl]-amino}-
propionic acid
3-(2-Chloro-phenyl){[6-
(tetrahydro-pyranyloxy)-
594 405.1 1.14 LC 11_2
pyridinecarbonyl]-amino}-
propionic acid
3-(2-Chloro-phenyl){[6-(4-
595 methoxy-phenyl)-pyridine 409.3 1.27 LC 11_2 1,42
carbonyl]-amino}-propionic acid
3-(2-Chloro-phenyl){[6-(3-
596 methoxy-phenyl)-pyridine 411.1 1.27 LC 11_2 5,77
carbonyl]-amino}-propionic acid
3-(2-Chloro-phenyl){[6-(2-
597 methoxy-phenyl)-pyridine 411.1 1.27 LC 11_2 1,45
carbonyl]-amino}-propionic acid
3-[(6-Bromomethoxy-pyridine-
598 2-carbonyl)-amino](2-chloro- 411.18 1.2 LC 11_2 1,46
phenyl)-propionic acid
(S){[6-(2-Chloro-phenyl)-
599 pyridinecarbonyl]-amino}(4- 411.29 1.77 LC 11_X 2,83
methoxy-phenyl)-propionic acid
3-(2-Chloro-phenyl)[(6-
cyclopropyl-1,3-dimethyl-1H-
600 413.14 1.19 LC 11_2
pyrazolo[3,4-b]pyridine
carbonyl)-amino]-propionic acid
3-(2-Chloro-phenyl){[4-
601 (pyrimidinylsulfanyl)-pyridine 415.05 1.18 LC 11_2 3,85
carbonyl]-amino}-propionic acid
(S)(4-Chloro-phenyl){[6-(2-
602 chloro-phenyl)-pyridine 415.09 1.94 LC 11_X 0,0623
carbonyl]-amino}-propionic acid
(S)(3-Chloro-phenyl){[6-(2-
603 chloro-phenyl)-pyridine 415.12 1.98 LC 11_2 0,0803
carbonyl]-amino}-propionic acid
3-(2-Chloro-phenyl){[6-(2-
604 chloro-phenyl)-pyridine 415.25 1.83 LC_X 0,345
carbonyl]-amino}-propionic acid
(S)(2,4-Dichloro-phenyl){[6-
605 (2-fluoro-phenyl)-pyridine 433.24 1.9 LC 11_X 2,28
carbonyl]-amino}-propionic acid
(S)(2,3-Dichloro-phenyl){[6-
606 (2-fluoro-phenyl)-pyridine 433.25 1.87 LC 11_X 3,93
carbonyl]-amino}-propionic acid
(S){[6-(2-Fluoro-phenyl)-
pyridinecarbonyl]-amino}(2-
607 433.31 1.83 LC_X 0,88
trifluoromethyl-phenyl)-propionic
acid
(S){[6-(2-Fluoro-phenyl)-
pyridinecarbonyl]-amino}(4-
608 433.31 1.87 LC_X 6,27
trifluoromethyl-phenyl)-propionic
acid
(S){[6-(2-Fluoro-phenyl)-
pyridinecarbonyl]-amino}(3-
609 433.32 1.85 LC_X 0,902
trifluoromethyl-phenyl)-propionic
acid
(S){[6-(2-Chloro-phenyl)-
pyridinecarbonyl]-amino}
610 449.07 2.01 LC 11_X 2,32
(2,3-dichloro-phenyl)-propionic
acid
(S){[6-(2-Chloro-phenyl)-
pyridinecarbonyl]-amino}
611 449.09 2.05 LC 11_X 0,27
(2,4-dichloro-phenyl)-propionic
acid
(S){[6-(2-Chloro-phenyl)-
pyridinecarbonyl]-amino}(2-
612 449.13 1.98 LC 11_X 1,66
trifluoromethyl-phenyl)-propionic
acid
(S){[6-(2-Chloro-phenyl)-
pyridinecarbonyl]-amino}(4-
613 449.16 2.02 LC 11_X 0,406
trifluoromethyl-phenyl)-propionic
acid
(S){[6-(2-Chloro-phenyl)-
pyridinecarbonyl]-amino}(3-
614 449.16 2.0 LC 11_X 0,315
trifluoromethyl-phenyl)-propionic
acid
3-(2-Chloro-phenyl){[3-(4,6-
dimethoxy-pyrimidinyloxy)-
615 459.13 1.06 LC 11_2 3,58
pyridinecarbonyl]-amino}-
propionic acid
3-(2-Chloro-phenyl)[(6-phenyl-
2-piperidinyl-pyrimidine
616 carbonyl)-amino]-propionic acid; 465.21 5.02 LC 11_2 10,4
compound with trifluoro-acetic
acid
(S){[6-Bromo(3,3-dimethyl-
2-oxo-butoxy)-pyridine
617 477.03 1.25 LC 11 0,1568
carbonyl]-amino}o-tolyl-
propionic acid
(S){[5-(3,3-Dimethyloxo-
butoxy)phenyl-pyridine
618 474,31 1.19 LC 11
carbonyl]-amino}o-tolyl-
propionic acid
(S){[5-((S)Hydroxy-3,3-
dimethyl-butoxy)phenyl-
619 477.32 1.87 LC 11_X
pyridinecarbonyl]-amino}o-
tolyl-propionic acid
(S){[5-((R)Hydroxy-3,3-
dimethyl-butoxy)phenyl-
620 477.29 2.02 LC 11_X
pyridinecarbonyl]-amino}o-
tolyl-propionic acid
(1) Mass spectroscopic characterization; observed mass number of the ion [(M+H) ],
unless specified otherwise
(2) Cathepsin A inhibitory activity determined in the pharmacological test "Cathepsin
A inhibitory activity" described below.
Pharmacological tests
a) Cathepsin A inhibitory activity
Recombinant human cathepsin A (residues 29-480, with a C-terminal 10-His tag;
R&D Systems, # 1049-SE) was proteolytically activated with recombinant human
cathepsin L (R&D Systems, # 952-CY). Briefly, cathepsin A was incubated at 10
µg/ml with cathepsin L at 1 µg/ml in activation buffer (25 mM 2-(morpholinyl)-
ethanesulfonic acid (MES), pH 6.0, containing 5 mM dithiothreitol (DTT)) for 15 min
at 37 °C. Cathepsin L activity was then stopped by the addition of the cysteine
protease inhibitor E-64 (N-(trans-epoxysuccinyl)-L-leucineguanidinobutylamide;
Sigma-Aldrich, # E3132; dissolved in activation buffer/DMSO) to a final
concentration of 10 µM.
The activated cathepsin A was diluted in assay buffer (25 mM MES, pH 5.5,
containing 5 mM DTT) and mixed with the test compound (dissolved in assay buffer
containing (v/v) 3 % DMSO) or, in the control experiments, with the vehicle in a
multiple assay plate. After incubation for 15 min at room temperature, as substrate
then bradykinin carrying an N-terminal Bodipy FL (4,4-difluoro-5,7-dimethylbora-
3a,4a-diaza-s-indacenepropionyl) label (JPT Peptide Technologies GmbH;
dissolved in assay buffer) was added to the mixture. The final concentration of
cathepsin A was 833 ng/ml and the final concentration of labeled bradykinin 2 µM.
After incubation for 15 min at room temperature the reaction was stopped by the
addition of stop buffer (130 mM 2-(4-(2-hydroxy-ethyl)-piperazinyl)-ethanesulfonic
acid, pH 7.4, containing (v/v) 0.013 % Triton X-100, 0.13 % Coating Reagent 3
(Caliper Life Sciences), 6.5 % DMSO and 20 µM ebelactone B (Sigma, # E0886)).
Uncleaved substrate and product were then separated by a microfluidic capillary
electrophoresis on a LabChip 3000 Drug Discovery System (12-Sipper-Chip;
Caliper Life Sciences) and quantified by determination of the respective peak areas.
Substrate turnover was calculated by dividing product peak area by the sum of
substrate and product peak areas, and the enzyme activity and the inhibitory effect
of the test compound thus quantified. From the percentage of inhibition of cathepsin
A activity observed with the test compound at several concentrations, the inhibitory
concentration IC , i.e. the concentration which effects 50 % inhibition of enzyme
activity was, calculated. IC values of various example compounds are given in
Table 1 in µM.
B) In vivo antihypertrophic and renoprotective activity
The in vivo pharmacological activity of the compounds of the invention can be
investigated, for example, in the model of DOCA-salt sensitive rats with unilateral
nephrectomy. Briefly, in this model unilateral nephrectomy of the left kidney (UNX) is
performed on Sprague Dawley rats of 150 g to 200 g of body weight. After the
operation as well as at the beginning of each of the following weeks 30 mg/kg of
body weight of DOCA (desoxycorticosterone acetate) are administered to the rats
by subcutaneous injection. The nephrectomized rats treated with DOCA are
supplied with drinking water containing 1 % of sodium chloride (UNX/DOCA rats).
The UNX/DOCA rats develop high blood pressure, endothelial dysfunction,
myocardial hypertrophy and fibrosis as well as renal dysfunction. In the test group
(UNX/DOCA Test) and the placebo group (UNX/DOCA Placebo), which consist of
randomized UNX/DOCA rats, the rats are treated orally by gavage in two part
administrations at 6 a.m. and 6 p.m. with the daily dose of the test compound (for
example 10 mg/kg of body weight dissolved in vehicle) or with vehicle only,
respectively. In a control group (control), which consists of animals which have not
been subjected to UNX and DOCA administration, the animals receive normal
drinking water and are treated with vehicle only. After five weeks of treatment,
systolic blood pressure (SBP) and heart rate (HR) are measured non-invasively via
the tail cuff method. For determination of albuminuria and creatinine, 24 h urine is
collected on metabolic cages. Endothelial function is assessed in excised rings of
the thoracic aorta as described previously (W. Linz et al., JRAAS (Journal of the
renin-angiotensin-aldosterone system) 7 (2006), 155-161). As a measure of
myocardial hypertrophy and fibrosis, heart weight, left ventricular weight and the
relation of hydroxyproline and proline are determined in excised hearts.
Claims (14)
1. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a 5 physiologically acceptable solvate of any of them, wherein 10 A is chosen from the series consisting of C(R ) and N; D is chosen from the series consisting of C(R ) and N; E is chosen from the series consisting of C(R ) and N; L is chosen from the series consisting of C(R ) and N; where at least one and at most two of A, D, E or L is N; 71 72 73 G is chosen from the series consisting of R -O-C(O)-, R -N(R )-C(O)- and 20 tetrazolyl; R is chosen from the series consisting of hydrogen, halogen, (C -C )-alkyl, HO-, (C -C )-alkyl-O-, (C -C )-alkyl-S(O) - and NC-; 1 6 1 6 m 25 R is chosen from the series consisting of hydrogen, halogen, (C -C )-alkyl, (C -C )- 1 7 1 6 12 13 2, alkyl-O-, (C -C )-alkyl-CO-, (C -C )-alkyl-CO-HN-, -NR R , Het (C -C )-cycloalkyl- 1 6 1 6 3 7 C H - and Ar-C H -, wherein s is an integer chosen from the series consisting of 0, s 2s s 2s 1, 2 and 3; R is chosen from the series consisting of hydrogen, halogen, (C -C )-alkyl, (C -C )- 1 6 1 6 4 12 13 2 11 12 13 2 -, Het -(O) -, -NR R , Het , R -O-, R -N(R )-C(O)-O- and Het -C(O)- alkyl-S(O) O- and NC-, wherein s is an integer chosen from the series consisting of 0, 1, 2 and 5 3 and wherein t is an integer chosen from the series consisting of 0 and 1; R is chosen from the series consisting of hydrogen, halogen, (C -C )-alkyl, (C -C )- 1 6 1 6 12 13 2 alkyl-O-, HO-, NR R , Het ; 10 R is chosen from the series consisting hydrogen, halogen, (C -C )-alkyl, (C -C )- 1 6 1 6 12 13 2 alkyl-O-, (C -C )-alkyl-S(O) -, HO-, -NR R , Het , phenyl-C H -(O) -, wherein s is 1 6 m s 2s t an integer chosen from the series consisting of 0, 1, 2 and 3 and wherein t is an integer chosen from the series consisting of 0 and 1; 1 2 2 3 15 or R and R or R and R from pyridyl; or R and R are –C((C -C )-alkyl)=N-N((C -C )-alkyl)-; 1 3 1 3 or R and R are –NH-CH=N-; 1 2 3 4 10 with the proviso that one of R , R , R , R or R is a cyclic substituent; 11 14 R is chosen from the series consisting of hydrogen, R , (C -C )-cycloalkyl, Ar and Het ; 12 13 R and R are independently of each other chosen from the series consisting of 25 hydrogen and R ; R is (C -C )-alkyl which is optionally substituted by one or more identical or 1 10 different substituents chosen from the series consisting of halogen, HO-, R -O-, oxo, (C -C )-cycloalkyl, Ar, Het , Het , NC-, H N-C(O)-, (C -C )-alkyl-NH-C(O)-, 3 7 2 1 4 30 di((C -C )-alkyl)N-C(O)-, Het -C(O)-, (C -C )-alkyl-C(O)-NH- and (C -C )-alkyl- 1 4 1 4 1 4 S(O) -; R is (C -C )-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, HO- and (C -C )- alkyl-O-; 5 R is (C -C )-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, (C -C )-alkyl-O- and NC-; 30 31 32 R is chosen from the series consisting of R , (C -C )-cycloalkyl, R -C H - and 3 7 u 2u 10 Het -C H -, wherein u is an integer chosen from the series consisting of 0, 1, 2 and u 2u R is (C -C )-alkyl which is optionally substituted by one or more identical or 1 10 different substituents chosen from the series consisting of halogen, (C -C )- 15 cycloalkyl, HO-, (C -C )-alkyl-O-, (C -C )-alkyl-S(O) - and NC-; 1 6 1 6 m R is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and 20 sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, R , 1 6 3 7 33 33 HO-, (C -C )-alkyl-O-, R -O-, R -(C -C )-alkyl-O-, -O-CH -O-, -O-CF -O-, (C -C )- 1 6 1 4 2 2 1 6 alkyl-S(O) -, H N-S(O) -, (C -C )-alkyl-NH-S(O) -, di((C -C )-alkyl)N-S(O) -, H N-, m 2 2 1 4 2 1 4 2 2 25 (C -C )-alkyl-NH-, di((C -C )-alkyl)N-, Het , (C -C )-alkyl-C(O)-NH-, Ar-C(O)-NH-, 1 6 1 6 1 4 (C -C )-alkyl-S(O) -NH- and NC-; 1 4 2 R is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or 30 different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, HO-, 1 6 3 7 (C -C )-alkyl-O-, (C -C )-alkyl-S(O) -, H N-S(O) -, (C -C )-alkyl-NH-S(O) -, di((C - 1 6 1 6 m 2 2 1 4 2 1 )-alkyl)N-S(O) - and NC-; 5 R is chosen from the series consisting of hydrogen and (C -C )-alkyl; 30 40 or R and R together are (CH ) which is optionally substituted by one or more identical or different (C -C )-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5; R is chosen from the series consisting of hydrogen, (C -C )-alkyl, HO- and (C - 1 6 1 C )-alkyl-O-; R is chosen from the series consisting of hydrogen and (C -C )-alkyl; 50 60 or R and R together are (CH ) which is optionally substituted by one or more identical or different (C -C )-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5; 20 R is chosen from the series consisting of hydrogen and (C -C )-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (C -C )-alkyl-O- and (C -C )-alkyl-C(O)-O-; 1 6 1 6 R is chosen from the series consisting of hydrogen, (C -C )-alkyl, (C -C )- 1 6 3 6 25 cycloalkyl, –CH -(CH ) -(C -C )-cycloalkyl, Het and -(CH ) -Het , where alkyl or 2 2 b 3 6 2 b cycloalkyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, HOOC-, (C -C )-alkyl-O- and (C -C )-alkyl-C(O)-O-, NC-, N((C -C )-alkyl) and b is 0, 1 or 2; 1 6 1 4 2 R is chosen from the series consisting of hydrogen, (C -C )-alkyl; 30 or 72 73 R and R together with the nitrogen atom to which they are bonded form a saturated 4-membered to 7-membered monocyclic heterocycle, which contain optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C -C )-alkyl, HO- and (C -C )-alkyl-O-; Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon 10 atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C -C )-alkyl, HO-(C -C )-alkyl, Het , -(CH ) -Phenyl, (C -C )-alkyl-O-, (C -C )- 1 6 1 6 2 x 1 6 3 7 12 13 2 12 13 cycloalkyl-(CH ) -O-, -CF , -CO-(C -C )-alkyl, -NR R , Het , -CO-NR R , CO- 2 x 3 1 6 Het , (C -C )-alkyl-S(O) -, H N-S(O) - and NC-; 1 6 m 2 2 15 and wherein phenyl may be substituted by -CH=CH-CH=CH-, -O-CH -O-, -O-CH - CH -O-, -O-CF -O- or -N((C -C )-alkyl)-CH=CH-; 2 2 1 3 Het , independently of each other group Het , is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen 20 atom via which Het is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C -C )-alkyl, HO-, (C -C )-alkyl-O-, 1 4 1 4 oxo and NC-; Het is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents 30 chosen from the series consisting of halogen, (C -C )-alkyl, HO- and (C -C )-alkyl- 1 4 1 4 Het , independently of each other group Het , is a saturated 4-membered to 7- membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more 5 identical or different substituents chosen from the series consisting of fluorine, (C - C )-alkyl and oxo; Het , independently of each other group Het , is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises one to four ring 10 heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C -C )-alkyl, HO-, (C -C )-alkyl-O-, oxo and 1 4 1 4 NC-; 15 m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting 20 of fluorine and (C -C )-alkyl; wherein all alkyl, C H , C H , (CH ) and (CH ) groups, independently of each s 2s u 2u 2 x 2 y other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.
2. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein 71 72 73 30 G is chosen from the series consisting of R -O-C(O)- and R -N(R )-C(O)-; 30 32 R is R -C H -, wherein u is an integer chosen from the series consisting of 0 and u 2u R is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting 33 33 33 5 of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, R , HO-, (C -C )-alkyl-O-, R -O-, R - 1 6 3 7 1 6 (C -C )-alkyl-O-, -O-CH -O-, -O-CF -O-, (C -C )-alkyl-S(O) -, di((C -C )-alkyl)N- 1 4 2 2 1 6 m 1 4 S(O) -, H N-, di((C -C )-alkyl)N-, Het , (C -C )-alkyl-C(O)-NH-, Ar-C(O)-NH- and 2 2 1 6 1 4 NC-; 10 R is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, HO-, (C -C )-alkyl-O-, (C -C )-alkyl- 1 6 3 7 1 6 1 6 15 S(O) -, H N-S(O) -, di((C -C )-alkyl)N-S(O) - and NC-; m 2 2 1 4 2 R is hydrogen.
3. A compound of the formula I, in any of its stereoisomeric forms or a mixture of 20 stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1 or 2, wherein G is R -O-C(O)-; 30 32 R is R -C H -, wherein u is 0; u 2u 25 R is chosen from the series consisting of phenyl, wherein the phenyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, R , HO-, (C -C )-alkyl-O-, 1 6 3 7 1 6 33 33 R -O-, R -(C -C )-alkyl-O-, -O-CH -O-, -O-CF -O-, (C -C )-alkyl-S(O) -, di((C -C )- 1 4 2 2 1 6 m 1 4 alkyl)N-S(O) -, H N-, di((C -C )-alkyl)N-, Het , (C -C )-alkyl-C(O)-NH-, Ar-C(O)-NH- 2 2 1 6 1 4 30 and NC-; R is chosen from the series consisting of phenyl, wherein the phenyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C -C )-alkyl, (C -C )-cycloalkyl, HO-, (C -C )-alkyl-O-, (C - 1 6 3 7 1 6 1 C )-alkyl-S(O) -, H N-S(O) -, di((C -C )-alkyl)N-S(O) - and NC-; 6 m 2 2 1 4 2 is hydrogen.
4. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one of claims 1 to 3, wherein 10 R is hydrogen; R is hydrogen.
5. A compound of the formula I, in any of its stereoisomeric forms or a mixture of 15 stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one of claims 1 to 4, wherein formula I is selected from the series of subformulae I-1 to I-7 R10 R R 30 40 O G 40 N 60 R2 R1 I-1 I-2 30 30 R10 R10 40 40 60 60 50 50 R2 R2 I-4 I-5 R10 R R10 R N R3 R R R1 R2 I-6 I-7 .
6. A compound of the formula I-1, in any of its stereoisomeric forms or a mixture of 10 stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 5, wherein 15 R is Ar-C H -, wherein s is an integer chosen from the series consisting of 0; s 2s 3 11 R is chosen from the series consisting of hydrogen, halogen, R -O-, HO-, (C -C )- alkyl and (C -C )-alkyl-O-; preferred HO- and(C -C )-alkyl 1 6 1 6 R is hydrogen; R is hydrogen.
7. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 5 or 6, wherein 3 11 5 R is R -O-, wherein R11 is hydrogen or (C -C )-alkyl. 1 10
8. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a 10 physiologically acceptable solvate of any of them, as claimed in any one or more of claims 5 to 7, wherein R is -O-CH . 15
9. A compound of the formula I, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 8, chosen from (S)[(5-Methoxyphenyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid (S)(2,4-Dichloro-phenyl)[(5-methoxyphenyl-pyridinecarbonyl)-amino]- propionic acid (S){[3-(4,6-Dimethoxy-pyrimidinyloxy)-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[4-(Pyrimidinylsulfanyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S)[(6-Phenyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid (S)[(5-Phenyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid (S){[5-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[5-(2,3-Dichloro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[5-(2,3-Dimethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S)o-Tolyl[(6-m-tolyl-pyridinecarbonyl)-amino]-propionic acid (S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(2-Fluoro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(2,3-Difluoro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(2,5-Difluoro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(4-Fluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(2,3-Dimethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(5-Fluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(2-Methoxytrifluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(4-Chloromethoxy-phenyl)-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(2-Fluoromethoxy-phenyl)-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(2-Fluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(2-Fluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S)[(5-Methoxyphenyl-pyridinecarbonyl)-amino]p-tolyl-propionic acid (S)[(5-Methoxyo-tolyl-pyridinecarbonyl)-amino]p-tolyl-propionic acid (S){[5-Methoxy(2-trifluoromethyl-phenyl)-pyridinecarbonyl]-amino}p-tolyl- propionic acid (S){[6-(3-Fluoro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl- propionic acid (S){[5-Methoxy(2-methoxy-phenyl)-pyridinecarbonyl]-amino}p-tolyl- propionic acid (S){[6-(2-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl- propionic acid (S){[6-(2-Fluoro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl- propionic acid (S){[6-(2,4-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl- propionic acid (S){[6-(2,3-Dichloro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl- propionic acid (S){[6-(2-Chlorotrifluoromethyl-phenyl)methoxy-pyridinecarbonyl]- amino}p-tolyl-propionic acid (S){[6-(3-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2- fluoro-phenyl)-propionic acid (S){[6-(2-Chlorotrifluoromethyl-phenyl)methoxy-pyridinecarbonyl]- amino}(2-fluoro-phenyl)-propionic acid (S){[6-(2,3-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl- propionic acid (S){[6-(2,5-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl- propionic acid (S){[6-(2,5-Dichloro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl- propionic acid (S){[6-(3,5-Dimethyl-isoxazolyl)methoxy-pyridinecarbonyl]-amino}p- tolyl-propionic acid (S){[6-(4-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}p- tolyl-propionic acid (S){[6-(2,3-Dimethyl-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl- propionic acid (S)[(3,2'-Dimethoxy-[2,3']bipyridinylcarbonyl)-amino]p-tolyl-propionic acid (S){[6-(5-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}p- tolyl-propionic acid (S){[6-(4-Fluoromethoxy-phenyl)methoxy-pyridinecarbonyl]-amino}p- tolyl-propionic acid (S){[6-(5-Fluoromethoxy-phenyl)methoxy-pyridinecarbonyl]-amino}p- tolyl-propionic acid (S){[6-(2-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}p- tolyl-propionic acid (S){[6-(3-Chloromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}p- tolyl-propionic acid (S){[6-(3-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}p- tolyl-propionic acid (S){[6-(5-Chlorofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}p- tolyl-propionic acid (S)(2-Fluoro-phenyl)[(5-methoxyphenyl-pyridinecarbonyl)-amino]- propionic acid (S){[6-(2,4-Dichloro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro- phenyl)-propionic acid (S)(2-Fluoro-phenyl)[(5-methoxyo-tolyl-pyridinecarbonyl)-amino]- propionic acid (S)(2-Fluoro-phenyl){[5-methoxy(2-trifluoromethyl-phenyl)-pyridine carbonyl]-amino}-propionic acid (S)(2-Fluoro-phenyl){[5-methoxy(2-methoxy-phenyl)-pyridinecarbonyl]- amino}-propionic acid (S){[6-(2-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro- phenyl)-propionic acid (S)(2-Fluoro-phenyl){[6-(2-fluoro-phenyl)methoxy-pyridinecarbonyl]- amino}-propionic acid (S){[6-(2,4-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro- phenyl)-propionic acid (S){[6-(2,3-Dichloro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro- phenyl)-propionic acid (S){[6-(2,3-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro- phenyl)-propionic acid (S){[6-(2,5-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro- phenyl)-propionic acid (S){[6-(4-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2- fluoro-phenyl)-propionic acid (S){[6-(3,5-Dimethyl-isoxazolyl)methoxy-pyridinecarbonyl]-amino}(2- fluoro-phenyl)-propionic acid (S){[6-(2,3-Dimethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2-fluoro- phenyl)-propionic acid (S)[(3,2'-Dimethoxy-[2,3']bipyridinylcarbonyl)-amino](2-fluoro-phenyl)- propionic acid (S){[6-(5-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2- fluoro-phenyl)-propionic acid (S){[6-(4-Fluoromethoxy-phenyl)methoxy-pyridinecarbonyl]-amino}(2- fluoro-phenyl)-propionic acid (S){[6-(5-Fluoromethoxy-phenyl)methoxy-pyridinecarbonyl]-amino}(2- fluoro-phenyl)-propionic acid (S){[6-(2-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2- fluoro-phenyl)-propionic acid (S){[6-(3-Chloromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2- fluoro-phenyl)-propionic acid (S){[6-(5-Chlorofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2- fluoro-phenyl)-propionic acid (S){[6-(3-Chlorofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2- fluoro-phenyl)-propionic acid (S)(2-Fluoro-phenyl){[5-methoxy(2-methyl-furanyl)-pyridinecarbonyl]- amino}-propionic acid (S){[6-(2-Chloromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2- fluoro-phenyl)-propionic acid (S)(2-Chloro-phenyl)[(5-methoxyphenyl-pyridinecarbonyl)-amino]- propionic acid (S)(2-Chloro-phenyl){[6-(2,4-dichloro-phenyl)methoxy-pyridinecarbonyl]- amino}-propionic acid (S)(2-Chloro-phenyl){[6-(4-fluoro-phenyl)methoxy-pyridinecarbonyl]- amino}-propionic acid (S){[5-Methoxy(3-trifluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(2,4-Dichloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(4-Fluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(4-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S)[(5-Methoxyp-tolyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid (S){[6-(3-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[5-Methoxy(2-methoxy-phenyl)-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S)[(5-Methoxym-tolyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid (S){[6-(2-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(3,4-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(2,5-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(2,5-Dichloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(3,5-Dimethyl-isoxazolyl)methoxy-pyridinecarbonyl]-amino}o- tolyl-propionic acid (S){[6-(2,3-Dimethyl-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(2,4-Dimethyl-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(4-Fluoromethoxy-phenyl)methoxy-pyridinecarbonyl]-amino}o- tolyl-propionic acid (S){[6-(2-Chloromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}o- tolyl-propionic acid (S)(2-Chloro-phenyl)[(6-methoxyo-tolyl-pyridinecarbonyl)-amino]- propionic acid (S)(2-Chloro-phenyl){[5-methoxy(2-methoxy-phenyl)-pyridinecarbonyl]- amino}-propionic acid (S)(2-Chloro-phenyl)[(5-methoxym-tolyl-pyridinecarbonyl)-amino]- propionic acid (S)(2-Chloro-phenyl){[6-(2-chloro-phenyl)methoxy-pyridinecarbonyl]- amino}-propionic acid (S)(2-Chloro-phenyl){[6-(2-fluoro-phenyl)methoxy-pyridinecarbonyl]- amino}-propionic acid (S)(2-Chloro-phenyl){[6-(2,4-difluoro-phenyl)methoxy-pyridinecarbonyl]- amino}-propionic acid (S)(2-Chloro-phenyl){[6-(2,3-dichloro-phenyl)methoxy-pyridinecarbonyl]- amino}-propionic acid (S)(2-Chloro-phenyl){[6-(2,3-difluoro-phenyl)methoxy-pyridinecarbonyl]- amino}-propionic acid (S)(2-Chloro-phenyl){[6-(2,5-difluoro-phenyl)methoxy-pyridinecarbonyl]- amino}-propionic acid (S)(2-Chloro-phenyl){[6-(4-fluoromethyl-phenyl)methoxy-pyridine carbonyl]-amino}-propionic acid (S)(2-Chloro-phenyl){[6-(2,3-dimethyl-phenyl)methoxy-pyridinecarbonyl]- amino}-propionic acid (S)(2-Chloro-phenyl)[(3,2'-dimethoxy-[2,3']bipyridinylcarbonyl)-amino]- propionic acid (S)(2-Chloro-phenyl){[6-(5-fluoromethyl-phenyl)methoxy-pyridine carbonyl]-amino}-propionic acid (S)(2-Chloro-phenyl){[6-(4-fluoromethoxy-phenyl)methoxy-pyridine carbonyl]-amino}-propionic acid (S){[6-(4-Chloromethoxy-phenyl)methoxy-pyridinecarbonyl]-amino}(2- chloro-phenyl)-propionic acid (S)(2-Chloro-phenyl){[6-(5-fluoromethoxy-phenyl)methoxy-pyridine carbonyl]-amino}-propionic acid (S)(2-Chloro-phenyl){[6-(2-fluorotrifluoromethyl-phenyl)methoxy- pyridinecarbonyl]-amino}-propionic acid (S){[5-Methoxy(2-trifluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(2,4-Difluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(4-Fluoromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}o- tolyl-propionic acid (S)[(3,2'-Dimethoxy-[2,3']bipyridinylcarbonyl)-amino]o-tolyl-propionic acid (S)[(3'-Fluoromethoxy-[2,4']bipyridinylcarbonyl)-amino]o-tolyl-propionic acid (S){[5-Methoxy(2-methyl-furanyl)-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(4-Cyanofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o- tolyl-propionic acid (S)(2-Chloro-phenyl){[6-(2-fluoromethoxy-phenyl)methoxy-pyridine carbonyl]-amino}-propionic acid (S)(2-Chloro-phenyl){[6-(2-fluoromethyl-phenyl)methoxy-pyridine carbonyl]-amino}-propionic acid (S){[6-(3-Chloromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2- chloro-phenyl)-propionic acid (S)(2-Chloro-phenyl){[6-(3-fluoromethyl-phenyl)methoxy-pyridine carbonyl]-amino}-propionic acid (S){[6-(5-Chlorofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2- chloro-phenyl)-propionic acid (S)(2-Chloro-phenyl)[(3'-fluoromethoxy-[2,4']bipyridinylcarbonyl)-amino]- propionic acid (S)(2-Chloro-phenyl)[(5-methoxypyrazinyl-pyridinecarbonyl)-amino]- propionic acid (S){[6-(3-Chlorofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2- chloro-phenyl)-propionic acid (S)(2-Chloro-phenyl){[5-methoxy(2-methyl-furanyl)-pyridinecarbonyl]- amino}-propionic acid (S){[6-(2-Chlorofluoro-phenyl)methoxy-pyridinecarbonyl]-amino}(2- chloro-phenyl)-propionic acid (S){[6-(2-Chloromethyl-phenyl)methoxy-pyridinecarbonyl]-amino}(2- chloro-phenyl)-propionic acid (S){[6-(2-Fluoro-phenyl)-pyridinecarbonyl]-amino}phenyl-propionic acid (S)(3-Fluoro-phenyl){[6-(2-fluoro-phenyl)-pyridinecarbonyl]-amino}- propionic acid (S)(2-Fluoro-phenyl){[6-(2-fluoro-phenyl)-pyridinecarbonyl]-amino}- propionic acid (S)(4-Fluoro-phenyl){[6-(2-fluoro-phenyl)-pyridinecarbonyl]-amino}- propionic acid 3-(2-Chloro-phenyl)[(6-methoxy-quinolinecarbonyl)-amino]-propionic acid (S)[(6-Methoxy-biphenylcarbonyl)-amino]o-tolyl-propionic acid (S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}m-tolyl-propionic acid (S){[6-(2-Fluoro-phenyl)-pyridinecarbonyl]-amino}(4-methoxy-phenyl)- propionic acid (S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}(2-fluoro-phenyl)- propionic acid (S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}(4-fluoro-phenyl)- propionic acid (S)(3-Chloro-phenyl){[6-(2-fluoro-phenyl)-pyridinecarbonyl]-amino}- propionic acid (S)(4-Chloro-phenyl){[6-(2-fluoro-phenyl)-pyridinecarbonyl]-amino}- propionic acid (S)(4-Chloro-phenyl){[6-(2-chloro-phenyl)-pyridinecarbonyl]-amino}- propionic acid (S)(3-Chloro-phenyl){[6-(2-chloro-phenyl)-pyridinecarbonyl]-amino}- propionic acid 3-(2-Chloro-phenyl){[6-(2-chloro-phenyl)-pyridinecarbonyl]-amino}-propionic acid (S){[6-(2-Fluoro-phenyl)-pyridinecarbonyl]-amino}(3-trifluoromethyl-phenyl)- propionic acid (S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}(2,4-dichloro-phenyl)- propionic acid (S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}(4-trifluoromethyl- phenyl)-propionic acid (S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}(3-trifluoromethyl- phenyl)-propionic acid (S){[6-Bromo(3,3-dimethyloxo-butoxy)-pyridinecarbonyl]-amino}o- tolyl-propionic acid.
10. A compound of the formula I, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one of claims 1 to 8, chosen from (S)[(5-Methoxyphenyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid (S){[6-(2,3-Dimethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(2-Fluoro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(5-Fluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S)o-Tolyl[(6-m-tolyl-pyridinecarbonyl)-amino]-propionic acid (S)({6-[3-(1-Hydroxymethyl-ethyl)-phenyl]-pyridinecarbonyl}-amino)o- tolyl-propionic acid (S)(2,4-Dichloro-phenyl)[(5-methoxyphenyl-pyridinecarbonyl)-amino]- propionic acid (S)[(5-Phenyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid (S){[3-(4,6-Dimethoxy-pyrimidinyloxy)-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[4-(Pyrimidinylsulfanyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[5-(2,3-Dichloro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[5-(2,3-Dimethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[5-(2-Chloro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(2,3-Difluoro-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(2-Fluoromethoxy-phenyl)-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(2-Fluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl-propionic acid (S){[6-(2-Methoxytrifluoromethyl-phenyl)-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S)({5-Methoxy[3-(5-methyl-[1,3,4]oxadiazolyl)-phenyl]-pyridine carbonyl}-amino)o-tolyl-propionic acid (S)(2-Chloro-phenyl)[(5-methoxynaphthalenyl-pyridinecarbonyl)- amino]-propionic acid (S)(2-Chloro-phenyl)[(5-methoxypyrazinyl-pyridinecarbonyl)-amino]- propionic acid (S)(2-Chloro-phenyl)[(6-methoxynaphthalenyl-pyridinecarbonyl)- amino]-propionic acid (S)(2-Chloro-phenyl){[5-methoxy(2-methyl-furanyl)-pyridinecarbonyl]- amino}-propionic acid (S)(2-Chloro-phenyl){[6-(2,3-dimethyl-phenyl)methoxy-pyridinecarbonyl]- amino}-propionic acid (S)(2-Chloro-phenyl){[6-(2-chloro-phenyl)methoxy-pyridinecarbonyl]- amino}-propionic acid (S)(2-Fluoro-phenyl){[5-methoxy(1,3,5-trimethyl-1H-pyrazolyl)-pyridine- 2-carbonyl]-amino}-propionic acid (S)(2-Fluoro-phenyl){[5-methoxy(1-methyl-1H-indolyl)-pyridine carbonyl]-amino}-propionic acid (S)[(5-Methoxym-tolyl-pyridinecarbonyl)-amino]o-tolyl-propionic acid (S){[6-(2-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(3,5-Dimethyl-isoxazolyl)methoxy-pyridinecarbonyl]-amino}o- tolyl-propionic acid (S){[6-(4-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid (S){[6-(4-Chloro-phenyl)methoxy-pyridinecarbonyl]-amino}p-tolyl- propionic acid (S){[6-(5-Acetyl-thiophenyl)methoxy-pyridinecarbonyl]-amino}(2- chloro-phenyl)-propionic acid (S){[6-(2-Fluoro-phenyl)methoxy-pyridinecarbonyl]-amino}o-tolyl- propionic acid
11. A process for the preparation of a compound of the formula I or a physiologically acceptable salt thereof or a physiologically solvate of any of them as claimed in any one of claims 1 to 10, comprising reacting a compound of the formula II with a compound of the formula III, L 40 + 2 60 E 60 50 R J 50 D D R 10 30 40 50 60 wherein the groups A, D, E, L, G, R , R , R , R and R in the compounds of the 5 formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group J in the compound of the formula II is HO-, (C -C )-alkyl-O- or halogen. 10
12. A compound of the formula I as claimed in any one of claims 1 to 10 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for use as a pharmaceutical.
13. A pharmaceutical composition, which comprises at least one compound of the 15 formula I as claimed in any one of claims 1 to 10 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them and a pharmaceutically acceptable carrier.
14. Use of a compound of the formula I as claimed in any one of claims 1 to 10 or a 20 physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for the manufacture of a medicament for the treatment of heart failure, congestive heart failure, cardiomyopathy, myocardial infarction, left ventricular dysfunction, cardiac hypertrophy, valvular heart diseases, hypertension, atherosclerosis, peripheral arterial occlusive disease, restenosis, vasvular 25 permeability disorders, treatment of edema, thrombosis, rheumatoid arthritis, osteoarthritis, renal failure, cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, asthma, immunological diseases, diabetic complications, fibrotic diseases, pain, ischemia or reperfusion damage or neurodegenerative diseases, or for cardioprotection or renoprotection or as a diuretic (stand-alone treatment or in combination with established diuretics).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11305078 | 2011-01-26 | ||
EP11305078.5 | 2011-01-26 | ||
PCT/EP2012/051189 WO2012101197A1 (en) | 2011-01-26 | 2012-01-26 | Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ613672A NZ613672A (en) | 2015-04-24 |
NZ613672B2 true NZ613672B2 (en) | 2015-07-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9120783B2 (en) | Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | |
RU2561126C2 (en) | Oxygen-substituted derivatives of 3-heteroaroylaminopropionic acids and their application as pharmaceutical substances | |
US9751858B2 (en) | 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | |
RU2617843C2 (en) | Substituted derivatives of 3-thiazolaminepropionic acid and their use as pharmaceuticals | |
JP5957468B2 (en) | Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | |
NZ613672B2 (en) | Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | |
US9199947B2 (en) | Biaryl-propionic acid derivatives and their use as pharmaceuticals |